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ABSTRACT 
The objective of this research is to investigate the role of ultrasound-guided foam 
sclerotherapy (UGFS) in the treatment of chronic venous disease (CVD). 
UGFS was found to be a safe and effective treatment for both primary and recurrent 
great saphenous vein (GSV) and small saphenous vein (SSV) incompetence, 
assessed by occlusion of treated veins on duplex ultrasound (DUS), and by 
disappearance of visible varicose veins (VV) on clinical examination. There was 
some evidence that healing of chronic venous ulcers (CVU) may be improved by 
UGFS when combined with compression bandaging. 
When compared with patients undergoing superficial venous surgery (SVS), UGFS 
was associated with significantly less pain, bruising and analgesia requirement, and 
a quicker return to work and driving.  
Significant improvements in both generic physical and disease-specific health-related 
quality of life (HRQL) were observed following UGFS, and were sustained for 12 
months after treatment. UGFS significantly improved lower limb physical symptoms 
(pain, itching, restlessness, swelling, heaviness, cramp and tingling), cosmetic 
appearance, and provided life-style benefits in the majority of patients. Furthermore, 
the great majority of patients who expected such benefits had their expectations met 
or exceeded. 
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CHAPTER 1. INTRODUCTION 
1.1 Classification of chronic venous disease 
Chronic venous disease (CVD) can affect either the deep or superficial venous 
systems, resulting in a wide range of clinical conditions: varicose veins (VV), chronic 
venous insufficiency (CVI), and chronic venous ulceration (CVU). Many classification 
systems have been developed for CVD, but the most widely used, and the one I have 
used throughout this Thesis, is the CEAP classification (Table 1.1). (Eklof et al., 
2004)  
There are four parts to the classification: clinical severity (C), aetiology (E), 
anatomical distribution (A) and pathophysiology (P). The clinical classification ranges 
in severity from C0 where there are no palpable or visible signs of venous disease to 
C6 where there is active CVU present; this is suffixed by ‘s’ or ‘a’ according to 
whether the limb is symptomatic or asymptomatic. Aetiology can be congenital (Ec), 
primary (Ep) or secondary (Es). Anatomical distribution, which is determined by 
imaging, can be superficial (As), deep (Ad), or from the perforating veins (Ap), or a 
combination. The pathophysiology of the disease may be reflux (Pr) or obstruction 
(Po). In this Thesis I am concerned with the management of patients with 
symptomatic, CEAP clinical grades C2-6 CVD, all of primary aetiology, all with 
superficial venous reflux (SVR) with or without deep venous reflux (DVR), and all with 
reflux rather than obstruction. VV without evidence of skin changes of CVI 
(pigmentation, eczema, lipodermatosclerosis) will at times be referred to as 
‘uncomplicated VV’ (C2-3) and those with skin changes of CVI as ‘complicated VV’ 
(C4-6).  
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Table 1.1 Basic CEAP classification 
 
Classification 
 
 
 
Clinical classification 
C0 
C1 
C2 
C3 
C4a 
C4b 
C5 
C6 
S 
 
 
A 
 
A(E)tiologic classification 
Ec 
Ep 
Es 
En 
 
Anatomic classification 
As 
Ap 
Ad 
An 
 
Pathophysiologic 
classification 
Pr 
Po 
Pr,o 
Pn 
 
 
 
No visible or palpable signs of venous disease 
Telangiectases or reticular veins 
Varicose veins 
Oedema 
Pigmentation or eczema 
Lipodermatosclerosis or atrophie blanche 
Healed venous ulcer 
Active venous ulcer 
Symptomatic, including ache, pain, tightness, skin irritation, 
heaviness, and muscle cramps, and other complaints 
attributable to venous dysfunction 
Asymptomatic  
 
 
Congenital 
Primary 
Secondary (post-thrombotic) 
No venous cause identified 
 
 
Superficial veins 
Perforator veins 
Deep veins 
No venous location identified 
 
 
 
Reflux 
Obstruction 
Reflux and obstruction 
No venous pathophysiology identifiable 
 
1.2 Reasons for seeking treatment 
When assessing a patient for treatment, it is important to establish what has 
prompted the patient to seek medical attention for their CVD. For example, many 
patients with asymptomatic and uncomplicated VV may be simply concerned about 
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their future risk of ulceration and thrombosis and may be reassured. Others are 
primarily concerned about the appearance of their legs, while some wish to have 
physical symptoms such as aching and itching relieved. Yet others seek treatment for 
the skin complications of CVI. Failure to understand, and therefore meet, the 
patient’s expectations are likely to be an important cause of dissatisfaction, complaint 
and even medico-legal action. (Jackson and Kroenke, 2001; Kravitz, 2001; Campbell 
and France, 2002) 
 
1.2.1 Appearance 
Many patients who seek treatment for their VV are concerned about the appearance 
of their legs and related ‘lifestyle’ issues, but these may not be their only, or even 
their predominant concerns. Most patients are aware that they are unlikely to get 
treatment for VV for cosmetic indications within a publicly-funded health system such 
as the National Health Service (NHS), (especially at a time when significant 
reductions on healthcare spending are being sought), and thus may invent, or at 
least inflate, concerns about physical symptoms. 
 
1.2.2 Lower limb symptoms 
A wide range of lower limb symptoms have been ascribed to CVD: most commonly 
pain, heaviness, swelling, itching, restlessness and cramps. Symptoms tend to be 
less troublesome in the mornings, increase over the course of the day or with 
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prolonged periods of standing and are often ameliorated by the use of support 
hosiery.  
Clinical experience indicates that there are large numbers of people with significant 
CVD who are asymptomatic, while other patients with apparently trivial disease seem 
to be greatly troubled by their legs. This often poor relationship between the 
symptoms of CVD, the signs on clinical examination, and the results of 
investigations, has been noted in a number of clinical and population-based studies. 
(Bradbury et al., 1999; Bradbury et al., 2000) These observations lead to the 
assumption that some patients with uncomplicated VV with marked symptoms, who 
may currently be denied treatment on the NHS in some geographical areas of the 
United Kingdom (UK), have a lot to gain from treatment in terms of improvement in 
both symptoms and possibly health-related quality of life (HRQL), and this is an area 
ripe for study.  
 
1.2.3 Skin complications of chronic venous insufficiency 
There is some evidence that eradicating SVR may improve, or at least prevent 
progression of, the skin changes of CVI. The mainstay of treatment for CVU is 
elastic, multi-layer graduated bandaging followed by knee-length European class II 
compression hosiery. (Fletcher et al., 1997; Palfreyman et al., 1998; Cullum et al., 
2001) In terms of CVU management however, it is widely agreed that eradication of 
SVR, traditionally by superficial venous surgery (SVS), is effective in reducing 
recurrence following ulcer healing, but does not significantly accelerate ulcer healing 
itself. (Barwell et al., 2004) Only one study has found improved CVU healing rates 
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following SVS, but this was only true in patients with isolated saphenous reflux. 
(Scriven et al., 1998) 
 
1.3 Current treatment of superficial venous reflux 
The perfect treatment for VV would rapidly and permanently abolish all sources of 
SVR, relieve all physical symptoms, significantly improve the appearance of the leg, 
be complication-free, allow a fast (immediate) return to normal activities, be 
inexpensive, and be widely available and applicable to affected patients. (Beale and 
Gough, 2005) Such treatment does not and probably will never exist, but well aware 
of the shortcomings of SVS, clinicians have devoted considerable energies to the 
development of minimally-invasive alternatives, such as radiofrequency ablation 
(RFA), endovenous laser ablation (EVLA) and ultrasound-guided foam sclerotherapy 
(UGFS). 
 
1.3.1 Superficial venous surgery 
SVS that aims to remove visible VV and correct axial superficial and perforator (deep 
to superficial) incompetence has been considered the ‘gold standard’ for many 
decades. In patients with great saphenous vein (GSV) incompetence, the sapheno-
femoral junction (SFJ) is ligated and the GSV is stripped out from the groin to the 
knee. Recurrence is much less likely when the GSV is adequately stripped. 
(Dwerryhouse et al., 1999; MacKenzie et al., 2002b) In patients with small 
saphenous vein (SSV) incompetence the sapheno-popliteal junction (SPJ) is ligated. 
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Many surgeons do not strip the SSV, often because of fear of damage to the sural 
nerve, but may remove a short portion of the proximal vein. (Sam et al., 2004b; 
Winterborn et al., 2004) Any remaining varices are removed through several tiny stab 
incisions (avulsions). In the UK, SVS is usually performed under general anaesthesia 
and many people take at least two weeks away from work. 
In most patients SVS results in relief of symptoms and improvement in both generic 
and disease-specific HRQL. (O’Shaughnessy et al., 1989; Baker et al., 1995; Smith 
et al., 1999; MacKenzie et al., 2002a; MacKenzie et al., 2002b; Sam et al., 2004a) 
However, around one quarter of patients are dissatisfied with their treatment at five to 
ten year follow-up. (O’Shaughnessy et al., 1989; Davies et al., 1995) Recurrence is 
common with reflux demonstrated on duplex ultrasound (DUS) in 13-29% of patients 
at two to five years, (Jones et al., 1996; Dwerryhouse et al., 1999; Turton et al., 1999; 
Van Rij et al., 2003) and clinical recurrence in up to 37% of patients. (Dwerryhouse et 
al., 1999; Jones et al., 1996) SVS is also one of the most common areas for litigation 
in the UK and, although usually considered fairly minor surgery, carries with it risks of 
wound infection or haematoma, thrombo-embolism and cutaneous nerve injury. 
(Corder et al., 1991; Hayden and Holdsworth, 2001; Sam et al., 2004b; Van Rij et al., 
2004) 
 
1.3.2 Radiofrequency ablation 
RFA was developed as an ‘office-based’ procedure as an alternative to SVS with the 
aims of reducing post-operative pain and bruising, avoiding the need for an incision 
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in the groin, allowing earlier return to mobility and thus to work, and delivering a 
better cosmetic result.  
The VNUS Closure® system was introduced in 1998 by VNUS Medical technologies 
(California, USA; now owned by Covidien) for ablation of the GSV using a 
radiofrequency current, and more recently Celon AG (Berlin, Germany) have 
introduced RFITT® (radiofrequency-induced thermo-therapy; now owned by 
Olympus). RFA is usually performed using local (tumescent) anaesthesia. The 
treated vein is obliterated by a combination of denaturation of collagen fibres in the 
vein wall and thrombus formation. (Subramonia and Lees, 2007)  
Early results show complete occlusion of treated veins in over 90% of cases, and 85-
100% occlusion at two-year follow-up. (Weiss and Weiss, 2002; Lurie et al., 2003; 
Pichot et al., 2004; Lurie et al., 2005; Merchant et al., 2005) Reported complications 
include paraesthesia, skin burns, haematomas and phlebitis, with symptomatic deep 
vein thrombosis (DVT) occurring in around 1% of patients undergoing RFA. (Weiss 
and Weiss, 2002; Merchant et al., 2002; Lurie et al., 2003) 
Limitations of RFA are that the ablation catheters cannot be passed along tortuous 
superficial veins and the manufacturers suggest that treatment is limited to veins of 
<12mm diameter, meaning that up to 50% of patients are unsuitable for this 
technique. (Rautio et al., 2002) Also, RFA only replaces the ligation and stripping 
parts of SVS, and thus additional treatment, usually avulsions or UGFS, are required 
in the majority of patients to treat residual varicosities. (Merchant et al., 2005; Mundy 
et al., 2005)  
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1.3.3 Endovenous laser ablation 
EVLA was first introduced in 1999 by Diomed (Cambridge, UK) and aims to ablate 
the GSV using a diode laser. EVLA is also performed using tumescent anaesthesia. 
As the laser is fired heat is generated in the blood around the tip and steam bubbles 
are produced and it is the action of these steam bubbles, and direct action of the 
laser on the vein wall, that causes the damage (collagen contraction and endothelial 
destruction) resulting in venous occlusion. (Proebstle et al., 2002) 
Reported early occlusion rates are at least 90%, and persistent occlusion at up to two 
years is found in 90-100% in uncontrolled studies. (Navarro et al., 2001; Min et al., 
2003; Proebstle et al., 2003b) The main complications are bruising and 
thrombophlebitis, although skin burns and paraesthesia also occur. DVT is rare after 
EVLA. Limitations are similar to those of RFA except treatment does not need to be 
limited to veins <12mm in diameter. As with RFA, EVLA only treats the GSV so 
additional treatment is often required (30-40%) for visible varicosities. There are 
many different laser systems on the market now with little evidence to guide clinicians 
as to which is best.    
 
1.3.4 Sclerotherapy 
Sclerotherapy has been in use for treating VV for over 150 years, but was 
popularised by Fegan in 1963. (Tisi and Beverley, 2004) However, high recurrence 
rates of over 50% in patients with SFJ or SPJ incompetence has lead to liquid 
sclerotherapy being reserved in the UK for the treatment of superficial varicosities 
without any identifiable saphenous reflux or for residual VV after SVS. (Hobbs, 1974; 
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Galland et al., 1998) The idea of using sclerosant in the form of a foam, rather than 
liquid, has been around for more than 70 years. Foam has been shown in a 
randomized controlled trial (RCT) to be significantly more effective than liquid in 
treating saphenous reflux, (Hamel-Desnos et al.,2003) and over the last few years 
UK vascular surgeons have begun to embrace UGFS, performed on an outpatient 
basis under local anaesthesia, as an alternative to SVS for truncal VV. In this Thesis 
I shall concentrate on this modality of treatment.  
 
1.4 Ultrasound-guided foam sclerotherapy 
1.4.1 Mechanism of action and choice of sclerosant 
Sclerotherapy is the introduction of a substance into the lumen of a vessel with the 
intention of causing thrombosis and, subsequently, fibrosis. Sclerosing solutions 
produce endothelial damage that evolves to fibrosis, with the extent of damage to the 
blood vessel wall determining the effectiveness of the solution. Destruction of the 
endothelium exposes subendothelial collagen fibres initiating platelet aggregation 
and adherence and activating the intrinsic coagulation pathway. The inflammatory 
reaction at the vessel wall and the organization of the resultant thrombus result in 
fibrosis, causing obliteration of the vessel lumen. Excessive thrombosis causes 
discomfort and also can allow recanalisation of the vessel and compression 
bandaging is usually employed in an attempt to minimize this. (Sadick, 2000) 
Sclerosants can be classified into three groups according to the mechanism by which 
they cause endothelial damage, with the ideal sclerosant being painless to inject and 
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free of any adverse effects. Detergent sclerosants include polidocanol, sodium 
tetradecyl sulphate (STS), and sodium morrhuate and they cause endothelial 
damage by altering the surface tension around the endothelial cell, allowing rapid 
overhydration (maceration). Osmotic agents, including hypertonic saline, produce 
damage by dehydration of the endothelial cell. The final category is the chemical 
irritants, such as chromate glycerine and polyiodinated iodide, which act as 
corrosives. (Sadick, 2000) 
The most commonly used sclerosants in the treatment of VV are STS and 
polidocanol. STS is a long-chain fatty acid salt and is painless to inject, but can 
cause extravasation necrosis. It is usually used in concentrations of 1% to 3% to treat 
large VV and it produces maceration of the endothelium within one second of 
exposure. Polidocanol is a urethane anaesthetic agent which is also painless to inject 
and has a minimal risk of causing extravasation necrosis compared with other 
sclerosants. It is usually used in concentrations of 0.5% to 3%.  
The use of foamed sclerosant has several important benefits over liquid sclerosant: it 
displaces blood preventing dilution and inactivation of the sclerosant, it has a much 
larger surface area incurring a greater sclerosing ability, it is possible to manipulate 
the foam once it has been injected to ‘steer’ the sclerosant in the correct direction, it 
has a greater volume and therefore fills more of the vein, and it is visible on DUS.  
Sclerosing foam is a mixture of a physiologic gas and a detergent sclerosing solution, 
but within this definition foams can differ dramatically from one another. Physiologic 
gases are those which are either readily absorbed by the blood or can pass rapidly 
across pulmonary gas exchange membranes, including oxygen, carbon dioxide, 
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nitrous oxide and helium. A microfoam is one comprising bubbles which are smaller 
than 250 microns, allowing a larger surface area and better contact with the 
endothelium. Debate continues around the ideal technique for producing and 
administering the most effective foam.   
 
1.4.2 History and development of foam preparation techniques 
A comprehensive article reviewing the history of sclerosing foams has recently been 
published and is summarized here. (Wollman, 2004) McAusland first described the 
use of ‘froth’ that he prepared by shaking a bottle containing sodium morrhuate for 
the treatment of telangiectasia in 1939. Two modifications of the technique were 
described in 1944. The first by Orbach, who described the ‘air block’ technique, 
where a volume of air (no more than 3ml) was injected into the vein ahead of the 
sclerosant. The theory being that the air would displace the blood in the vein allowing 
increased contact of the sclerosant with the vein wall. It was later shown by Stemmer 
et al. in 1970 that the ‘air block’ technique was only reliable in veins of diameter up to 
4mm. Also in 1944, Foote described the technique of mixing ethanolamine oleate 
with air to form an air/liquid dispersion for injecting telangiectasia. This so-called 
‘agitation technique’ is no longer in use. In 1949 Sigg described a ‘foam block’ 
technique, where he injected foam instead of air, followed by liquid sclerosant. He 
found that foamed sclerosant was less rapidly washed away than air.   
Orbach published a further paper in 1950 describing the use of a foam which he 
created by ‘vigorously shaking’ a syringe containing air and sclerosant to produce a 
froth and injected after an ‘air block’. He found a four-fold increase in efficacy when 
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compared with liquid sclerosant. Ree was the first doctor in 1953 to describe the use 
of a pure foam technique without the use of an ‘air block’.  
In 1956 Fluckiger discussed many important properties of foam and suggested 
another technique, the ‘aspiration technique’ in order to produce a fine-bubbled foam. 
This involved aspiration of the sclerosant and air simultaneously into a syringe 
through a narrow lumen injection needle. He also described the technique of 
‘retrograde injection’ whereby the sclerosant is injected proximally into the 
saphenous vein with the leg held in an elevated position. Fluckiger went on in 1962 
to describe another technique for foam preparation by pumping sclerosant and air 
backwards and forwards between the drug vial and a syringe, a technique that was 
later modernized by Frullini in 2000 by adding an adaptor between the bottle and the 
seal. 
Mayer and Brucke described a double-plunger syringe specifically for the production 
of sclerosant foam in 1957. This device has an inner plunger with several tiny holes 
which is moved rapidly backwards and forwards to mix sclerosant and air within the 
syringe while the external plunger is held in a fixed position. 
Gillesberger described a low-pressure technique in 1969, which was based on the 
creation of a negative pressure in a glass syringe. Monfreux later modified this in 
1997, but a consistent problem with the two techniques is the inability to produce a 
standard ratio between air and sclerosant, thus producing foam with different 
qualities each time.  
In 1986 Grigg introduced a new technique based on turbulent flow between two 
syringes connected by a plastic infusion tube, allowing the sclerosant and air to be 
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pumped back and forth. This technique was known as the ‘Irvine technique’ after the 
laboratory where the technique was demonstrated and is a precursor of Tessari’s 
technique and the double-syringe system. 
Cabrera described his ‘rotating brush technique’ in 1995 where foam was agitated 
using a high-speed rotating brush. Another addition was the use of carbon dioxide 
rather than air as a carrier gas. He also suggested a high volume technique intending 
to completely fill the venous lumen with foam; this has been associated with high 
incidence of DVT and is no longer recommended. 
In 1999 Mingo introduced the ‘foam medical system’ which generates foam by the 
introduction of gases from a cylinder and passes the mixture through a fine nozzle.  
Currently Tessari’s ‘Tourbillon technique’, introduced in 2000, is the most commonly 
used technique of foam production and, as mentioned, is based on the ‘Irvine 
technique’ but with the use of a three-way tap instead of connection tubing. 
Sclerosant and air mixture is pumped forwards and backwards approximately 20 
times. The liquid to air ratio varies from 1:3 to 1:4. By varying the size of the passage 
of the three-way tap it is possible to create higher turbulence and thus smaller, more 
stable, bubbles. Foam produced in this way is stable for approximately two minutes. 
A similar technique, the ‘double-syringe system’ was introduced in 2001 and instead 
of the three-way tap, uses an adaptor to connect the syringes and a 0.2-micron filter.  
Clearly there are many ways of creating foam and therefore comparisons of efficacy 
from the literature are somewhat complicated. This is not helped by the many ways of 
administering the foam in use. 
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1.4.3 Variations in technique for administration 
1.4.3.1 Cannulation and injection 
Several different techniques of delivering the foam to the vein have been described 
and none to date has been proven to be better than the others. 
Cabrera described direct cannulation of the saphenous trunk to be treated under 
DUS guidance. He then injected foam until it completed filled the vein along with its 
tributaries. Any tributaries that remained unfilled were injected using a butterfly 
needle. (Cabrera et al., 2000) 
In France, the direct puncture technique is favoured, whereby the saphenous trunk is 
injected using a needle and syringe. (Hamel-Desnos et al., 2003) The entire length of 
the incompetent trunk and its tributaries is treated by several injections, often carried 
out over a number of sessions. While the direct puncture technique is simple to 
perform it can be risky, particularly in the popliteal fossa due to the proximity of 
several arteries to the SSV. Intra-arterial injection of sclerosant can result in 
extensive skin loss. (Biegeleisen et al., 1993; Bergan et al., 2001)   
An alternative method is to indirectly fill the saphenous trunk via a major tributary 
often by placing a butterfly needle into the tributary. It is thought that indirectly filling 
the saphenous trunks in this manner will be less effective than direct injection as the 
foam is likely to mix with blood when filling the vein, producing more thrombosis 
rather than endothelial injury, making permanent sclerosis less likely. 
In terms of volume of foam to be injected, a wide range of maximum suggested 
volumes have been reported. One group has used volumes of up to 40ml, (Cabrera 
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et al., 2004) whereas others used a maximum of 2.5ml. (Hamel-Desnos et al., 2003) 
A consensus document suggested that 6-8ml of foam per session is the maximum 
appropriate amount, (Breu and Guggenbichler, 2004) and this has since been 
increased to 12ml in 2006. (Breu et al., 2008)  
 
1.4.3.2 Bandaging and compression 
It is conventional to apply some form of compression following UGFS although there 
is little scientific evidence to support this practice. Examining the published literature, 
some groups have used stockings alone, (Tessari et al., 2001) others used a 
combination of bandages and stockings, often changed to stockings alone after a few 
days (Cabrera et al., 2000; Frullini and Cavezzi, 2002; Barrett et al., 2004; Yamaki et 
al., 2004) but Hamel-Desnos and colleagues used no stockings and no bandaging at 
all in their patients. (Hamel-Desnos et al., 2003) The usual duration of compression, 
when used, was two to three weeks.  
 
1.4.4 Patient selection 
Deep venous occlusion, severe peripheral arterial disease and extreme obesity are 
absolute contraindications to UGFS (they are also contraindications to SVS). Virtually 
all primary and recurrent VV are suitable, given sufficient operator expertise and 
experience, in contrast to the techniques requiring passage of a catheter (RFA and 
EVLT). Warfarin does not need to be stopped.  
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Other adverse patient factors to be considered are extreme frailty, severe comorbidity 
including cardiovascular, respiratory or malignant conditions, and those patients who 
are ‘needle-phobic’ or who request treatment under general anaesthesia. Very thin 
patients and those with very large varices may be left with palpable and visible lumps 
or skin pigmentation and are less suitable for treatment.  
 
1.4.5 Evidence for efficacy and safety 
The many different techniques of foam production and administration outlined above, 
along with the fact that many authors do not comment on their techniques, make 
interpretation of the available literature difficult.  
Cabrera et al. published their findings in 2000 of the outcome of 500 GSV treated 
with a foam made from 1-3% polidocanol and carbon dioxide using an undisclosed 
technique, and administered by direct cannulation of the GSV in the thigh. At three 
years they found that 81% of GSV were obliterated and 96.5% of superficial 
branches were obliterated. This required one session of sclerotherapy in 86% of 
patients, two in 11% and three sessions in 3% of patients. They found no serious 
complications and no DVT in their series. (Cabrera et al., 2000)  
In 2001, Tessari et al. presented their results of their pilot study using Tessari’s 
technique to create the foam. Twenty-four patients with saphenous or recurrent 
varices were treated within a group of 77 patients, with 1-3% STS. A maximum of 8ml 
foam was used and one to four treatments were required. At one month they found 
that ‘almost 100% were obliterated’. They reported two patients with transient 
scotomas and one case of thrombophlebitis. (Tessari et al., 2001) 
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Frullini and Cavezzi reported their results of a comparison of the Monfreux and 
Tessari techniques of generating foam from Italy in 2002. They treated 167 ‘medium 
or large’ veins with a mean of 1.8 sessions of up to 4ml of STS or polidocanol foam 
made using the Monfreux technique; and a further 170 ‘medium or large’ veins using 
a mean of 1.8 sessions injecting a mean of 2.7ml STS foam made using the Tessari 
technique. In the Monfreux group, immediate success was found in 88.1%, with five 
episodes of transient visual disturbance, one partially occlusive popliteal DVT and 
four episodes of skin necrosis. In the Tessari group they found immediate success in 
93.3%, with one episode of visual disturbance, two partially occlusive popliteal DVT 
and two episodes of skin necrosis. (Frullini and Cavezzi, 2002) 
In 2003, Hamel-Desnos et al. reported the outcome of an RCT comparing liquid and 
foamed 3% polidocanol. They created their foam using the double-syringe system 
and used direct puncture to treat GSV 4-8mm in diameter. In the foam group, 84% of 
the 45 patients had no residual reflux at three weeks; compared with 40% of the 
liquid group. They reported no episodes of skin necrosis in either group. At six 
months there were two recanalizations in the foam group, and six in the liquid group. 
(Hamel-Desnos et al., 2003) 
Barrett et al. published their findings from New Zealand in 2004. They treated 99 
saphenous veins (79 GSV) with a diameter of less than 10mm and 17 (14 GSV) with 
a diameter of more than 10mm. They used 3% STS foam, generated by Tessari’s 
technique with 1-2.5% polidocanol for branches. In the <10mm group, a mean of 2.2 
treatments was required (follow-up treatments were only allowed up to three months). 
At two years, 92% of visible varicosities were successfully treated, 69% had complete 
sclerosis, and 97% had no reflux. In the >10mm group, a mean of 2.8 treatments 
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were required. At two years, 94% of visible varicosities were successfully treated, 
77% had complete sclerosis, and 88% had no reflux. Of the whole group, 86% 
showed an improvement in their symptoms, and 100% felt their treatment had been 
successful. Phlebitis occurred in less than 5%, there were no major DVT or 
pulmonary embolism (PE), but there were six ‘minor’ DVT; five in a gastrocnemius 
vein and one in a posterior tibial vein. (Barrett et al., 2004)  
Also in 2004, Yamaki et al. published their results from Japan. They treated 77 GSV 
with 1% and 3% polidocanol. Foam was used to treat 37 and liquid in the remaining 
40 (not randomized). Foam was prepared using Tessari’s technique and only one 
injection was given, although the volume injected is unclear. At 12 months they found 
vein occlusion in 68% of those treated with foam, compared with 18% of those 
treated with liquid. Recurrent VV were present in 8% of the foam group, and 25% of 
the liquid group. They do not comment on their complications of treatment. (Yamaki 
et al., 2004)  
Cabrera et al. also reported on the outcome of 151 patients with CVU from Spain in 
2004. They used their polidocanol and carbon dioxide microfoam created using a 
patented technique (Varisolve®, BTG International Ltd., London, UK). They treated 
either saphenous veins or incompetent perforators and used 20-30ml of foam to treat 
saphenous trunks, and 1-4ml to treat perforators. A mean of 3.6 treatments was 
required (range 1-17). They found complete ulcer healing in 86% of patients at six 
months, and a 6.3% recurrence rate at two years (70% of the original cohort was 
reviewed at two years). They reported no DVT, two episodes of transient visual 
disturbance, two episodes of dry cough lasting for less than one minute, and 10% 
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had thrombophlebitis. Skin pigmentation was seen in 20% but this had resolved in 
90% of cases by six months. (Cabrera et al., 2004)  
Since the commencement of our own studies towards the end of 2004, several other 
authors have published their findings on the efficacy and safety of UGFS. These are 
included in the Discussion sections of the various clinical chapters where 
appropriate.  
 
1.5 Outcome assessment in venous disease 
Traditional measures of outcome from surgical procedures including morbidity and 
mortality are less useful in the assessment of interventions for CVD, which is chronic 
and not life- or limb-threatening, as they give little information about the patient’s 
experience of the disease. (McDaniel et al., 2000) Extended outcome assessment, 
including measures of technical success, clinical status, functional status, satisfaction 
and cost, enables us to achieve a more complete understanding of the effectiveness 
of different interventions, allows health-care providers and patients to make better 
decisions, and also allows us to deliver the most appropriate, cost-effective and 
medically-effective care. (McDaniel et al., 2000)  
 
1.5.1 Technical success 
Technical success following interventions for VV is usually measured by DUS. DUS 
is non-invasive, safe and reliable and is ideal for multiple assessments over time. 
Colour images of specific veins and the blood flow within them is provided by 
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combining real-time ultrasound imaging with pulsed Doppler information. When 
combined with the Doppler spectrum analysis, information about the patency of veins 
and the presence and duration of any reflux is gained. 
Technical and anatomical success can be defined as occlusion of the treated 
saphenous trunk, determined by a lack of compressibility and the absence of any 
flow, or absence of the treated vein following SVS. Unfortunately, many published 
studies on outcome following minimally invasive treatment for VV use different 
definitions of technical success, thus making comparison difficult. The majority of 
these studies have also concentrated on primary GSVV; little has been published on 
either the treatment of recurrent VV after previous SVS or on the treatment of SSVV. 
 
1.5.2 Clinical status 
In the setting of CVD, measures of clinical status include those that quantify the 
outcomes that are meaningful to the patient. These include the safety of the 
procedure, relief of the presenting symptoms, healing of CVU and time to recurrence, 
and improvement in appearance. 
 
1.5.2.1 Improvement in symptoms 
A number of methods can be used to assess improvement in symptoms following 
intervention. Objective measures of certain symptoms (such as a pain scale) can be 
used over time to show improvement, patients can be asked to rate the improvement 
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in their symptoms, or a validated measure of symptom status (such as the disease-
specific HRQL measures detailed below) can be used.  
The most important thing when assessing improvement in symptoms is the pre-
operative assessment and determining whether the patient’s lower limb symptoms 
are likely to be due to their CVD. The symptoms that are often ascribed to CVD are 
fairly non-specific and are found in up to 50% of the adult population, (Bradbury et 
al., 1999) and the relationship between symptoms and objective evidence of CVD is 
weak. (Bradbury et al., 1999; Bradbury et al., 2000) Little work has been done 
examining the improvement in symptoms as an outcome of minimally invasive 
techniques; indeed only one group have looked at symptom improvement after 
UGFS. (Barrett et al., 2004)  
 
1.5.2.2 Disappearance of VV and ulcer healing 
No measures of determining improvement in appearance have been validated in 
patients with VV. It is important to differentiate between true VV (dilated, tortuous 
subcutaneous veins) and other types of visible superficial veins including reticular 
veins and telangiectasia. Reticular veins are dilated and tortuous subcutaneous veins 
that do not belong to the main saphenous trunk or its major tributaries. These veins 
are visible below the skin, sometimes even when normal. They typically become 
dilated in response to back pressure from truncal varices or an incompetent 
perforating vein, however, in certain patients no obvious source can be found, even 
on careful clinical and DUS examination. Telangiectasia, also known as hyphenweb 
or spider veins, are dilated intradermal venules that can occur in association with 
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trunk or reticular varices or in isolation. It is also important to differentiate between VV 
that are residual (still present after initial treatment) and those that are recurrent 
(initially disappeared after treatment, but now returned). The position of the VV must 
also be considered as those arising from reflux in a different saphenous trunk are 
representative of progression of disease, rather than recurrence.  
CVU healing can be defined as complete re-epithelialisation of the leg, and ulcer 
recurrence as any loss of skin continuity below the knee. Studies have found that 
ulcer recurrence rates are significantly lower after SVS, but that ulcer healing was 
unaffected. (Barwell et al., 2004) The results of one study suggest that CVU healing 
may be accelerated after UGFS, but this relationship requires further examination. 
(Cabrera et al., 2004)   
 
1.5.3 Functional status (Health-related quality of life) 
HRQL is a multidimensional concept that incorporates general health, physical and 
psychological functioning, physical symptoms and the ability to interact socially. 
(Skevington and Tucker, 1999) Measuring HRQL is a comprehensive way to assess 
the effect of VV on patients, and whether interventions produce improvement. (Smith 
et al., 1999) Valuable information is gained on the patient-perceived burden of 
illness. HRQL is measured using structured questionnaires (also known as 
instruments) which have been developed in a scientifically rigorous manner adhering 
to specific psychometric properties. The questionnaire must be ‘valid’ and should 
measure what is intended; it must be ‘reliable’ and should give consistent results 
when repeated; it should be ‘responsive’ and should detect change in the condition of 
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interest; and it should be ‘acceptable’ by being easy to understand and complete. 
(McDaniel et al., 2000)  
 It is important when assessing HRQL to use both generic and disease-specific 
instruments. Generic instruments allow comparison of health status across groups by 
assessing the dimensions of HRQL that are common to all patients, but may be 
insensitive to some clinically important changes. Disease-specific instruments allow a 
more detailed and clinically relevant health assessment of the particular condition of 
interest. (McDaniel et al., 2000)  
Both disease-specific and generic HRQL improve following SVS for VV, (Baker et al., 
1995; Smith et al., 1999; Durkin et al., 2001; MacKenzie et al., 2002a; MacKenzie et 
al., 2002b; Sam et al., 2004a) and more recently this has been shown to hold true for 
EVLA and RFA. (Rautio et al., 2002; Lurie et al., 2003) At the time of commencing 
the studies included in this Thesis the effects of UGFS on HRQL are unknown.  
 
1.5.3.1 Generic health-related quality of life 
The Short Form-36 (SF36) from the Medical Outcomes Survey is the most common 
generic HRQL measure used to demonstrate improvement after SVS. (Baker et al., 
1995; Smith et al., 1999, Durkin et al., 2001; MacKenzie et al., 2002a; MacKenzie et 
al., 2002b; Sam et al., 2004a) It consists of 36 questions assessing eight health 
status domains, and also provides two summary scores; the physical component 
summary score (PCS) which represents what a person can do, and the mental 
component summary score (MCS) which represents how a person feels. The SF36 
has been widely used in many languages in many different clinical conditions and 
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‘norms’ have been created to allow comparisons with the general population. 
(Bowling et al, 1999) The mean PCS and MCS of the general population are 50 with 
a standard deviation of 10: the higher the score, the better the HRQL. 
The Short Form-12 (SF12, Appendix 1) is a fully-validated adaptation of the SF36. It 
consists of 12 questions (developed from a subset of the original SF36 questions) 
also giving two summary scores, the PCS and MCS, and is faster and easier to 
complete and has been shown to give results comparable to those of the SF36. 
(Jenkinson et al., 1997; Hurst et al., 1998; Ware et al., 2002) The SF12 is scored 
using published regression weights and scoring rules, in particular, if any SF12 
question is unanswered, the SF12 summary scores are recorded as missing. (Ware 
et al., 2002)  
 
1.5.3.2 Venous disease-specific health-related quality of life 
A variety of venous disease-specific HRQL measures have been developed and 
validated. The most commonly used is the Aberdeen Varicose Vein Symptom 
Severity Score (AVSS, Appendix 2). (Garratt et al., 1993; Garratt et al., 1996; Smith 
et al., 1999; MacKenzie et al., 2002a; MacKenzie et al., 2002b) The AVSS comprises 
13 questions about leg symptoms and signs, and a diagram where the patient can 
draw their VV. After weighting, it provides a final score between 0 and 100; a higher 
score denotes more symptoms and so a poorer disease-specific HRQL. Other 
validated measures include the VEINES-QOL/Sym and Chronic Venous Insufficiency 
Questionnaire (CIVIQ) questionnaires. (Launois et al., 1996; Lamping et al., 2003) 
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1.5.4 Satisfaction 
Patient satisfaction is the least well standardized measure of extended outcome 
assessment. Satisfaction depends on addressing the main complaint of the patient 
and as such it is important to realize the patient’s expectations prior to commencing 
treatment.  Little has been published on the expectations of patients undergoing 
treatment for VV, but up to 20% of patients have expressed dissatisfaction with SVS. 
(Davies et al., 1995; Ray, 2005; Scurr and Scurr, 2005)  
 
1.5.5 Cost 
Methods of measuring cost depend on the perspective of measurement. From the 
patient’s perspective, time lost from normal activities would be most important, but for 
the health-care provider the direct costs of providing treatment are most important. 
Cost calculations are frequently omitted from early attempts to measure extended 
outcomes because of their complexity. (McDaniel et al., 2000) Adverse outcomes 
from SVS can have a significant impact on the young and economically active 
population undergoing treatment for VV, and thus minimally invasive techniques 
which are associated with less morbidity and consequently a quicker return to normal 
activities and to work will be beneficial.  
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CHAPTER 2. THE EFFICACY OF ULTRASOUND-GUIDED 
FOAM SCLEROTHERAPY FOR CHRONIC VENOUS 
DISEASE 
SVS is still considered by many to be the ‘gold standard’ treatment for VV. In order to 
be considered a useful treatment for VV, UGFS should therefore be at least as 
effective as SVS. Traditional objective measures of success of any intervention for 
VV include the technical (anatomical) success of the procedure, and the clinical 
success as judged by the disappearance of visible VV and, where appropriate, 
healing of CVU. 
In this Chapter I assess the effectiveness of UGFS in terms of technical and clinical 
success in the treatment of both GSVV and SSVV. In addition I assess the effect of 
UGFS on healing of CVU.  
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2.1 Duplex ultrasound and clinical outcomes following 
ultrasound-guided foam sclerotherapy of symptomatic 
primary great saphenous varicose veins 
The data contained within this Chapter were 
 presented (poster) at the West Midlands Surgical Society in Birmingham, UK 
in November 2008 
 presented (poster) at the International Surgical Congress of the Association of 
Surgeons of Great Britain and Ireland in Glasgow, UK in May 2009 
 published in the European Journal of Vascular and Endovascular Surgery in 
October 2010 (Darvall et al., 2010a) 
 
2.1.1 Introduction 
SVS comprising ligation of the SFJ, stripping of the above-knee GSV (AK-GSV) and 
multiple stab avulsions remains the preferred treatment for symptomatic GSVV 
among UK vascular surgeons. Although such surgery improves lower limb 
symptoms, venous haemodynamics and HRQL, (Smith et al., 1999; MacKenzie et al., 
2002a; MacKenzie et al., 2002b; Sam et al., 2004a) it can be associated with a 
significant incidence of troubling and sometimes serious complications, morbidity, 
delayed return to work, as well as medico-legal activity. (Tennant and Ruckley, 1997; 
Corder et al., 1991; Sam et al., 2004a; Subramonia and Lees, 2005; Wood et al., 
2005; Beale and Gough, 2005; Ray, 2005) Furthermore, previous studies of surgical 
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GSV stripping have reported a significant primary technical failure and recurrence 
rate. (MacKenzie et al., 2002b) Thus, despite best attempts to strip the GSV, post-
operative DUS not infrequently reveals reflux in residual (remnant) GSV segments in 
the thigh. Furthermore, most surgeons are reluctant to strip the GSV below the knee 
for fear of causing saphenous nerve injury. Such residual disease in the AK- and BK-
GSV is a well-recognised cause of clinically significant recurrent disease.  
Minimally invasive techniques, such as UGFS, offer significant advantages over SVS 
although durability, and specifically late recanalisation, remains incompletely defined. 
The aim of this study, therefore, is to describe DUS and clinical outcomes 12 months 
following UGFS of symptomatic primary GSVV.  
 
2.1.2 Methods 
2.1.2.1 Patients 
Following local ethical committee approval and after obtaining written informed 
consent, consecutive patients undergoing UGFS for symptomatic primary GSVV 
between November 2004 and May 2007 were invited to take part in the study. All 
patients were NHS patients referred to the Heart of England NHS Foundation Trust 
(HEFT) by their general practitioners. All patients were assessed in a consultant-led 
NHS outpatient clinic by one of two consultant surgeons (Professor AW Bradbury 
and Mr DJ Adam) prior to enrolment in the study. 
To be considered suitable for inclusion patients had to have symptomatic venous 
disease (i.e. treatment was not offered for cosmetic indications), to have significant 
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reflux (>0.5s) in the GSV confirmed on DUS, and to be willing to undergo UGFS. 
Patients who had had previous SVS for GSVV on the same leg were excluded from 
the study. Patients with absent pedal pulses or an ankle-brachial pressure index 
(ABPI) of <0.8 were excluded, as were those with post-thrombotic deep venous 
occlusion. 
  
2.1.2.2 Pre-treatment assessment 
Patients were examined and the severity of venous disease according to the CEAP 
clinical classification was determined (Table 1.1). (Eklof et al, 2004) All patients had 
either visible varicosities (C2 or C3) or skin complications (C4, C5 or C6).  
All patients underwent DUS at their initial outpatient clinic appointment to identify 
sites of SVR and DVR. All DUS examinations were performed in a standard manner. 
Patients were examined standing with their weight on the contralateral limb and the 
leg to be examined slightly bent with the heel on the floor to relax the calf muscle 
while maintaining stability, with a Sonosite Micromaxx® (Sonosite Ltd, Hitchin, Herts, 
UK) fitted with a 10-MHz transducer. The following venous segments were insonated: 
proximal and distal superficial femoral vein; above- and below-knee popliteal vein; 
SFJ and SPJ; the whole length of the GSV, SSV and anterior accessory saphenous 
vein (AASV). All veins were assessed for patency and compressibility. Reflux was 
induced with a manual calf squeeze and was considered pathological when it 
exceeded 0.5 seconds. 
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2.1.2.3 UGFS treatment 
All UGFS treatments were performed on an outpatient basis in a treatment room, and 
took less than 30 minutes. Patients with bilateral VV had only one leg treated at a 
time (usually worst leg first); the second leg was treated at least four weeks later. 
Immediately before treatment the incompetent truncal veins and superficial varices 
were marked on the skin using DUS (Figure 2.1).  
 
Figure 2.1 Pre-treatment skin marking 
 
 
The patient then reclined in the supine position for cannulation of the GSV. 
Peripheral intravenous catheters (OptivaTM; Medex Medical, Rossendale, UK) were 
inserted under direct ultrasonographic guidance (Figure 2.2). According to the size 
and depth of the target vein, 18-22G cannulae (green, pink or blue) were used. Once 
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all cannulae were secured, the leg was elevated (to empty the veins) for injection of 
the foam (Figure 2.3). All cannulae were flushed with normal saline to ensure that 
they were not dislodged during the changes in leg position.  
 
Figure 2.2 Ultrasound-guided cannulation of the GSV 
 
 
Sclerosant foam was prepared by Tessari’s method using two 2ml syringes 
connected by a three-way tap and a 5 micron filter (B Braun Medical, Sheffield, UK), 
and comprised 0.5ml of 3% STS (Fibrovein®; STD Pharmaceuticals, Hereford, UK) 
and 2ml of air (Figure 2.4). Foam was injected in 2ml aliquots, and its distribution 
and resultant venous spasm observed by DUS. At least 30 seconds was left between 
injecting each aliquot of foam. After each injection patients were asked to dorsi- and 
plantar-flex their ankle several times to clear any foam that might have entered the 
deep venous system.  
32 
 
Figure 2.3 Elevation of the leg prior to foam injection 
 
 
Figure 2.4 Tessari’s method of foam preparation 
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When all the trunk and tributary veins and the varices were in spasm, and filled with 
foam, the cannulae were removed and compression was applied with the leg still 
elevated. 
A roll of Velband® (Johnson and Johnson Medical, Ascot, UK) was applied directly 
along the line of the previously marked saphenous trunk and superficial varices 
(Figure 2.5), and retained using Pehahaft® cohesive bandage (Hartmann, 
Heidenheim, Germany) (Figure 2.5). The bandage was then secured with 
Medipore® (3M Company, USA) 100mm wide adhesive tape. This regimen produced 
direct compression over the treated truncal veins.  
 
Figure 2.5 Post-treatment bandaging 
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A thigh-length European (RAL) class II compression stocking (Credelast®; 
Credenhill, Ilkeston, UK) was applied over the bandage (Figure 2.6). The bandaging 
was left intact for five to ten days, depending on the size of the veins, after which it 
was removed and the class II stocking worn alone for a further three weeks.  
After the procedure patients were required to walk for around 10 minutes and then it 
was suggested that they walk for at least five minutes during every waking hour while 
the bandages were in situ. Patients were told to take analgesia as required, to return 
to driving when they felt able to perform an emergency stop and to return to work 
when they felt comfortable. Patients were given a contact telephone number to use if 
they experienced severe discomfort or had any other concerns following treatment.  
 
Figure 2.6 Thigh-length compression stocking applied over bandage 
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Patients with residual or recurrent VV at any follow-up appointment were offered 
further treatment, either by direct injection of 1% polidocanol liquid (Sclerovein®, 
Resinag AG, Zurich, Switzerland) or 0.5% or 1% STS foam into the varicosities, or if 
saphenous truncal reflux was present by repeating UGFS with 3% STS (Fibrovein®) 
as outlined above. 
 
2.1.2.4 Outcome measures and follow-up 
The chosen outcome measures were complete occlusion of, and abolition of reflux in, 
the GSV on DUS (defined as technical success), and the complete absence of any 
visible VV (defined as clinical success). All patients were seen at one, six and 12 
months after treatment in a dedicated research clinic. At the first visit the patients 
were also asked whether they had had any complications following their treatment. 
Patients were specifically asked about visual disturbance, headache, and possible 
nerve problems in the treated leg. 
Repeat DUS was performed at each follow-up visit as per the pre-treatment DUS 
(described in Section 2.1.2.2). In addition, occlusion of the treated saphenous trunk 
was assessed by a lack of compressibility and the absence of any flow. Complete 
occlusion was defined as occlusion over the entire length of the GSV to the SFJ. 
Recanalisation was defined as the presence of flow in either an antegrade or 
retrograde direction in a previously occluded AK or below-knee (BK) GSV. 
Recanalisation was considered complete if over 50% of the length of vein had 
recanalised. Where recanalisation was found, the presence or absence of recurrent 
reflux was determined. 
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Patients with residual reflux or recanalisation at any follow-up appointment were 
offered further treatment by repeating foam sclerotherapy with 3% STS as outlined 
above. 
At each follow-up appointment treated limbs were also examined to determine the 
presence of any visible trunk VV. The presence of reticular veins only was not 
recorded as clinical failure of treatment. The distribution (GSV, AASV, or SSV) of any 
residual or recurrent VV was recorded.  
 
2.1.3 Results 
2.1.3.1 Patients and treatments 
The characteristics of the 278 patients (344 legs) undergoing UGFS for primary 
GSVV are shown in Table 2.1.  
One, two, three and four cannulae were used in 123, 202, 18, and one treatments 
respectively. The median volume of 3% STS foam used at each treatment was 10 
(range 2-16) ml. 
Three patients complained of visual disturbance shortly after their injections which 
consisted of blurring of vision and in all cases lasted for less than 10 minutes. There 
was no DVT observed in this group of patients either clinically or on follow-up DUS. 
There were no reported cases of PE. There were no other complications.  
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Table 2.1 Patient and disease characteristics 
 
Parameter 
 
 
 
No. of patients 
No. of legs 
 
Age: median (range) in years 
 
Sex 
   Male 
   Female 
 
CEAP clinical grade 
   C2 
   C3 
   C4 
   C5 
   C6 
 
A(E)tiology 
   Primary (Ep) 
   Secondary (Es) 
 
Anatomical patterns of venous reflux 
   Superficial and deep (Asd) 
   Superficial only (As) 
      Primary GSV above and below-knee 
      Primary GSV above-knee only 
      Primary GSV below-knee only 
 
Pathophysiological classification 
   Reflux (Pr) 
   Obstruction (Po) 
 
278 
344 
 
57 (21-89) 
 
 
103 (37.1) 
175 (62.9) 
 
 
213 (61.9) 
24 (7.0) 
72 (20.9) 
14 (4.1) 
21 (6.1) 
 
 
344 (100) 
0 (0) 
 
 
10 (2.9) 
334 (97.1) 
297 (86.3) 
36 (10.5) 
11 (3.2) 
 
 
344 (100) 
0 (0) 
Figures in parentheses are percentages unless otherwise specified 
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2.1.3.2 Treatment of the AK-GSV 
Complete eradication of reflux in the AK-GSV was achieved in 323/333 (97.0%) legs 
after one, and in a further 6/333 (1.8%) legs after two treatment sessions (course of 
primary treatment) (Figure 2.7). In four legs (1.2%) complete eradication of reflux in 
the AK-GSV was not achieved by one treatment session but these patients, despite 
residual reflux in the AK-GSV, were content with the clinical result and declined 
further treatment sessions. 
In the 329 legs in whom the primary course of UGFS achieved complete eradication 
of the reflux in the AK-GSV, recanalisation was observed in 7/295 (2.4%) legs at 6 
months and 18/286 (6.3%) legs at 12 months (Figure 2.7). 34 legs were not seen at 
6 months; 43 at 12 months. 
At 6 months this AK-GSV recanalisation was partial (<50%) without reflux in one leg 
and partial with reflux in six legs. Of these seven legs, four underwent one session of 
repeat UGFS which resulted in successful complete eradication of AK-GSV reflux, 
and three patients were content with the clinical result and declined further treatment. 
At 12 months this AK-GSV recanalisation was partial without reflux in two legs, partial 
with reflux in 13 legs, and complete (>50%) with reflux in three legs. Of these 18 legs, 
eight underwent one session of repeat UGFS which resulted in successful complete 
eradication of AK-GSV reflux, and ten were content with the clinical result and 
declined further treatment. 
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Figure 2.7 Eradication of reflux and recanalisation in the AK-GSV after UGFS for 
primary GSVV  
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2.1.3.3 Treatment of the BK-GSV 
Complete eradication of reflux in the BK-GSV was achieved in 294/308 (95.5%) legs 
after one, and in a further 10/308 (3.2%) legs after two treatment sessions (course of 
primary treatment) (Figure 2.8). In four legs (1.3%), complete eradication of reflux in 
the BK-GSV was not achieved by one treatment session but these patients, despite 
residual reflux in the BK-GSV, were content with the clinical result and declined 
further treatment sessions. 
In the 304 legs in whom the primary course of UGFS achieved complete eradication 
of the reflux in the BK-GSV, recanalisation was observed in 4/272 (1.5%) legs at 6 
months and 23/259 (8.9%) legs at 12 months (Figure 2.8). 32 legs were not seen at 
6 months; 45 at 12 months.  
At 6 months this BK-GSV recanalisation was complete with reflux in all four legs. Of 
these four legs, three underwent one session of repeat UGFS which resulted in 
successful complete eradication of BK-GSV reflux, and one patient was content with 
the clinical result and declined further treatment. 
At 12 months this BK-GSV recanalisation was partial without reflux in one leg, partial 
with reflux in seven legs, and complete with reflux in 15 legs. Of these 23 legs, 12 
underwent one session of repeat UGFS which resulted in successful complete 
eradication of BK-GSV reflux, and for the remaining 11 legs the patient was content 
with the clinical result and declined further treatment. 
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Figure 2.8 Eradication of reflux and recanalisation in the BK-GSV after UGFS for 
primary GSVV  
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2.1.3.4 Clinical success 
There were no visible VV in 304 legs (88.4%) after one treatment, and in 316 legs 
(91.9%) after two treatment sessions (course of primary treatment) to eradicate GSV 
reflux. Six legs had residual GSV reflux in association with residual VV after one 
session, but the patients were happy with the results and did not want further 
treatment. In 22 legs, there were still some residual visible VV after successful 
eradication of GSV reflux with just one session of treatment. For six of these legs, no 
further treatment was requested by the patient; and a single session of foam 
injections directly into the visible varicosities successfully treated the residual VV in 
the remaining 16 legs, giving a total of 332 legs (96.5%) with no visible VV after a 
maximum of two treatment sessions. 
By 12 months, 273/311 (87.8%) still had no visible VV after their primary course of 
treatment (33 were lost to follow-up or had residual untreated VV). Six legs had 
recurrent VV in association with recanalisation at 6 months, and 19 had recurrent VV 
in association with recanalisation at 12 months. Fifteen of these 25 had further 
successful UGFS treatment resulting in both eradication of the reflux and 
disappearance of their recurrent VV; the remainder were happy with the clinical 
results. Ten legs had a few recurrent VV at 12 months but no recanalisation or reflux 
and only two of these wanted further treatment; three had VV secondary to new 
reflux in the SSV. 
 
2.1.4 Discussion 
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The main findings of this study are that a single session of UGFS eradicates reflux in 
the AK- and BK-GSV in over 95% of patients with symptomatic primary GSV; 
recanalisation at 12 months is low (9% in the BK-GSV; 6% in the AK-GSV) and, 
when it does occur and leads to clinically significant varices, is easily treated with 
further UGFS. 
Although still the preferred treatment among UK vascular surgeons, (Winterborn and 
Corbett, 2008) it is widely recognised that residual and recurrent GSV reflux are 
common after SVS for primary GSVV. MacKenzie et al. reviewed 66 patients two 
years after SFJ ligation and attempted GSV stripping in the thigh and found that 62% 
had AK and 69% had BK truncal reflux on DUS. (MacKenzie et al., 2002b) An RCT 
reported by Dwerryhouse et al. found that failure to strip the GSV was associated 
with an unacceptably high rate of recurrence. (Dwerryhouse et al., 1999). Van Rij and 
colleagues prospectively followed up 92 patients (127 limbs) after GSV surgery. (van 
Rij et al., 2003) and found that two weeks after SVS 1/100 SFJ ligations had clearly 
failed, with DUS demonstrating an intact SFJ. Clinical recurrence (defined as 
recurrent VV) in all limbs was progressive, present in 13.7% (17/124) at three 
months, 31.6% (36/114) at one year, and 51.7% (60/116) limbs after three years. Of 
100 SFJ that were adequately ligated, 23 demonstrated recurrent reflux at three 
years, with most of the recurrences present by one year. 
 Although the primary aim of the current work is not to compare UGFS with the other 
currently available minimally invasive techniques, nevertheless, it is important and 
useful to place the current findings in context. During the study period and over the 
last few years there have been a number of RCTs comparing EVLA and, less 
44 
 
commonly, RFA with SVS; several meta-analyses and systematic reviews have been 
published.  
Van den Bos et al. published a meta-analysis comparing SVS, RFA, EVLA and 
UGFS. (van den Bos et al., 2009) They included 72 studies, 13 SVS, 19 RFA, 30 
EVLA and 10 UGFS. Only 9 were RCTs, 49 were prospective clinical series and the 
remaining 14 were retrospective case series. They only included studies that used 
DUS as the outcome measure with a total of 12320 limbs and an average follow-up 
of 32.2 months. Anatomic success rates of SVS were 80.4% at three months, 
reducing to 75.7% at five years; for RFA they were 88.8% at three months and 79.9% 
at five years; for EVLA they were 92.9% at three months and 95.4% at five years; 
and for UGFS they were 82.1% at three months reducing to 73.5% at five years. 
After adjusting for duration of follow-up they found that compared with SVS, UGFS 
and RFA were as effective, and EVLA significantly more effective. (van den Bos et 
al., 2009)  
Both EVLA and RFA are also considered to be as effective as SVS for the treatment 
of primary GSV incompetence in terms of early recanalisation rates, and mid-term 
recurrence of visible VV. Following EVLA recanalisation rates of 0-9% at 1-2 years 
have been reported, (Min et al., 2003; Mundy et al., 2005; Theivacumar et al., 2009b, 
Christenson et al., 2010; Pronk et al., 2010) although one RCT comparing EVLA and 
RFA found recanalisation rates of 22% (7/32) and 26% (9/34) respectively 6 months 
after treatment. (Goode et al., 2010) Other studies found recanalisation in 0-19% of 
patients treated with RFA at 1 year. (Merchant et al., 2002; Merchant et al., 2005; 
Nicolini et al., 2005) 
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Recurrent visible VV have been reported in 6-26% of EVLA-treated limbs, 
(Theivacumar et al., 2009b; Disselhoff et al., 2009; Rasmussen et al., 2010; Pronk et 
al., 2010) and in 0-21% of RFA-treated limbs at 1-2 year follow-up. (Merchant et al., 
2002; Merchant et al., 2005; Nicolini et al., 2005; Luebke and Brunkwall, 2008)  In the 
RCTs comparing EVLA with SVS, there were no significant differences found in 
technical and clinical outcomes between the two groups. (Theivacumar et al., 2009b; 
Rasmussen et al., 2010; Christenson et al., 2010; Pronk et al., 2010) 
Since commencing the studies included in this Thesis, several other groups have 
published their outcomes from UGFS.  However, the majority of the available data 
regarding UGFS still comes from clinical series rather than RCTs. Two systematic 
reviews found occlusion rates of 84% and 87% (Luebke and Brunkwall, 2008; Jia et 
al., 2007) and recurrence of visible VV in 11% and 14% (Luebke and Brunkwall, 
2008; Jia et al., 2007). The results from this study are superior to those published for 
UGFS and comparable with those reported with EVLA and RFA.  
The effectiveness of SVS for GSV incompetence is also limited by the reluctance to 
strip the BK-GSV based on fear of damaging the saphenous nerve. (Sam et al., 
2004b) Dwerryhouse et al. found that even in the legs that had undergone stripping 
to knee level, a quarter had incompetence in the residual BK-GSV at five years. They 
questioned the importance of this however, as many had no visible VV. 
(Dwerryhouse et al., 1999) Van Neer et al. prospectively followed 74 limbs that had 
undergone SFJ ligation and GSV strip to knee level for primary GSV incompetence. 
They reported BK-GSV reflux in 81% before SVS, 84% at six months, and 91% at 
two years, with visible VV in the BK-GSV in 16% at six months and 22% at two years, 
although they did not perform any stab avulsions which may explain the higher 
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incidence compared with other studies. (van Neer  et al., 2009) They also found that 
there was a tendency to worsening of the clinical signs and symptoms between six 
months and two years after SVS. 
Persistent reflux in the BK-GSV may lead to venous hypertension and thus to the 
signs and symptoms of CVD as evidenced by a smaller improvement in AVSS post-
treatment in patients with residual BK-GSV reflux after EVLA. (Theivacumar et al., 
2009a) In limbs undergoing AK-GSV EVLA without concomitant treatment to the BK-
GSV, Theivacumar et al. reported that significant BK-GSV reflux was present in 
15/23 (52%) at six weeks. (Theivacumar et al., 2009b) In their RCT they found that 
BK-GSV reflux was abolished in 23/23 (100%) limbs that underwent EVLA from mid-
calf to groin (BK-EVLA) and that this was associated with significantly less additional 
sclerotherapy requirements (17% vs. 61%). Improvement in AVSS, pain scores and 
satisfaction were comparable in both groups, and importantly BK-EVLA was not 
associated with saphenous nerve injury. However, the authors comment that only 
70% (67/95) limbs with primary BK-GSV reflux were suitable for BK-EVLA from mid-
calf to groin because of BK-GSV tortuosity. (Theivacumar et al., 2009b) 
By contrast, as is clearly demonstrated here, patients can be offered a primary 
course of UGFS treatment until all AK- and BK-GSV reflux has been eradicated. In 
most cases this requires only one treatment session using a modest volume of foam 
and is associated with a very low incidence of side-effects and complications. 
Furthermore, if recurrent reflux develops as a result of recanalisation it can be very 
simply and effectively treated, usually by a further single injection of foam.  
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One problem with UGFS is that the technique itself remains far from standardised 
and many variations on the basic theme exist. Despite seven years elapsing since 
commencing this study, there remains little consensus regarding techniques for foam 
preparation and delivery, and post-treatment compression making comparison and 
generalisation of the results achieved difficult. (Myers and Roberts, 2009; Cavezzi 
and Tessari, 2009; Coleridge Smith, 2009) There is further evidence from RCTs and 
a systematic review that UGFS is more effective in both the short and long-term than 
liquid sclerotherapy, (Wright et al., 2006b; Rabe et al., 2008; Ouvry et al., 2008; 
Hamel-Desnos and Allaert, 2009) and that 3% polidocanol foam is no more effective 
than 1%. (Hamel-Desnos et al., 2007; Blaise et al., 2010)  
There have been two recent RCTs looking at bandaging and compression after 
UGFS. One group compared bandaging for 24 hours with bandaging for five days, 
both followed by a thromboembolus deterrent (TED) stocking for the remainder of 
two weeks. (O’Hare et al., 2010) They found no advantage in prolonged wearing of 
the compression bandages in terms of incidence of phlebitis, skin discolouration and 
post-procedural pain, improvement in HRQL and 6-week target vein occlusion rates. 
(O’Hare et al., 2010) The other study compared the use of compression stockings 
(15-20mmHg) worn during the day for three weeks with no compression at all. 
(Hamel-Desnos et al., 2010) They found no difference in occlusion of treated veins, 
side-effects (thrombophlebitis, inflammation, pain and pigmentation), satisfaction 
scores and HRQL improvement between the two groups.  
It is clear that further controlled studies are required to determine optimum technique. 
We have honed our technique over the last ten years and it continues to develop and 
we think improve. For example, present data on eradication of GSV reflux appear 
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materially superior to those reported in a multicentre prospective trial of Varisolve® 
1% polidocanol microfoam. (Wright et al., 2006b) EVLA and RFA technology is also 
evolving to improve the balance between desired and undesired effects. (Enzler and 
van den Bos, 2010)  
In conclusion, the present study adds further evidence that UGFS is a safe and 
clinically effective treatment for primary GSVV. A primary course of UGFS comprising 
one and infrequently two treatment sessions, leads to complete eradication of GSV 
reflux in virtually 100% of cases. Recanalisation at 12 months in this study is superior 
to that reported after SVS and similar to that observed following other minimally 
invasive techniques.   
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2.2 Duplex ultrasound and clinical outcomes following 
ultrasound-guided foam sclerotherapy of symptomatic 
recurrent great saphenous varicose veins 
The data contained within this Chapter were 
 presented at the Venous Forum Spring Meeting at the Royal Society of 
Medicine, London, UK in April 2011 
 published in the European Journal of Vascular and Endovascular Surgery in 
July 2011 (Darvall et al., 2011) 
 
2.2.1 Introduction 
Residual and/or recurrent GSV reflux is disappointingly common after SVS. For many 
years, authors have reported that around 20% of patients undergoing SVS for GSVV 
have been operated previously for GSVV in the same leg. (Bradbury et al., 1993; 
Negus, 1993) In our current UGFS practice we find that figure to be 21% suggesting 
that there has been little improvement in surgical outcomes in recent times. 
Recurrence after GSVV surgery may be due to 
1. Residual VV often because of failure to adequately strip a refluxing AK or BK-
GSV at the first operation, (MacKenzie et al., 2002b) 
2. True recurrence, often referred to as neovascularisation. (Jones et al., 1996) 
This can occur at the previously dissected SFJ or stripping track, or 
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3. Progression of disease, for example the development of new reflux in the 
AASV in the thigh. 
All three pathologies often co-exist in the same patient and can be difficult to 
distinguish. 
Redo GSVV surgery typically comprises re-exploration of the SFJ, stripping of the 
AK-GSV and multiple phlebectomies. Such surgery can be technically demanding 
and associated with a higher incidence of significant complications and re-recurrence 
than first time GSVV surgery. (Gibbs et al., 1999; Hayden and Holdsworth, 2001) 
Furthermore, reflux in the BK-GSV is similarly difficult to treat with further SVS. 
Although the role of EVLA, RFA and UGFS in treating primary GSVV is becoming 
established, their effectiveness in the treatment of recurrent GSVV is less well 
defined. (Navarro et al., 2001; Merchant et al., 2002; Rautio et al., 2002; Weiss and 
Weiss, 2002; Lurie et al., 2003; Min et al., 2003; Proebstle et al., 2003b; Beale and 
Gough, 2005) 
The aim of the present study, therefore, is to describe DUS and clinical outcomes 12 
months following UGFS of symptomatic recurrent GSVV. 
 
2.2.2 Methods 
2.2.2.1 Patients 
Following local ethical committee approval and after obtaining written informed 
consent, consecutive patients undergoing UGFS for symptomatic recurrent GSVV 
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between November 2004 and May 2007 were invited to take part in the study (as per 
Section 2.1.2.1). 
Recurrence was defined as previous SVS to the GSV in the same leg on at least one 
previous occasion. Specifically, all patients had undergone attempted SFJ ligation 
and multiple phlebectomies, with or without attempted stripping of the GSV; in most 
cases this was to the level of the knee only. 
To be considered suitable for UGFS patients had to have symptomatic, CEAP C2-6 
venous disease (i.e. treatment was not offered for cosmetic indications) and 
significant (> 0.5seconds) reflux in a segment of residual above and/or below knee 
GSV on DUS. Patients with absent pedal pulses or an ankle brachial pressure index 
< 0.8 were excluded as were those with post-thrombotic deep venous occlusion. 
 
2.2.2.2 Pre-treatment assessment 
Patients were examined and the severity of venous disease according to the CEAP 
clinical classification was determined (Table 1.1).  
DUS was performed, as described in Section 2.1.2.2, at the initial clinic attendance 
in order to identify sites of superficial, deep and communicating venous reflux. 
 
2.2.2.3 UGFS treatment 
UGFS treatment was performed as described in Section 2.1.2.3. 
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2.2.2.4 Outcome measures and follow-up 
The chosen outcome measures were complete occlusion of, and abolition of reflux in, 
the GSV on DUS (defined as technical success) and the complete absence of any 
visible VV (defined as clinical success).  
Patients were followed up at 1, 6 and 12 months as described in Section 2.1.2.4 with 
DUS and clinical examination.  
 
2.2.3 Results 
2.2.3.1 Patients and treatments 
The characteristics of the 73 patients (91 legs) undergoing UGFS for recurrent GSVV 
are shown in Table 2.2. In 88 legs there was reflux in the AK-GSV, of which 77 also 
exhibited reflux in the BK-GSV; isolated BK-GSV reflux was observed in only 3 legs. 
Despite a previous SFJ dissection as evidenced by a previous scar, in 27 legs there 
was an apparently intact and incompetent SFJ refluxing into an incompetent residual 
AK-GSV. In 34 legs the SFJ appeared to have been (at least partially) ligated and 
there was collateral reflux into an incompetent residual AK-GSV through tributaries 
and/or neovascularisation. In the remaining 30 legs the SFJ had been satisfactorily 
ligated and the proximal (usually 5-10cm) AK-GSV removed but there was reflux in 
the AK and/or BK-GSV trunk below this point as a result of perforator incompetence. 
One, two, and three cannulae were used to introduce the foam in 36, 43, and 12 
treatments respectively. The median volume of 3% STS foam used at each treatment 
was 8 (range 4-14) ml. 
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Table 2.2  Patient and disease characteristics 
 
Parameter 
 
 
 
 
No. of patients 
No. of legs 
 
Age: median (range) in years 
 
Sex 
   Male 
   Female 
 
CEAP clinical grade 
   C2 
   C3 
   C4 
   C5 
   C6 
 
A(E)tiology 
   Primary (EP) 
   Secondary (ES) 
 
Anatomical patterns of venous reflux 
   Superficial and deep (ASD) 
   Superficial only (AS) 
      Recurrent GSV above and below-knee 
      Recurrent GSV above-knee only 
      Recurrent GSV below-knee only 
 
Pathophysiological classification 
   Reflux (PR) 
   Obstruction (PO) 
 
73 
91 
 
58 (32-86) 
 
 
24 (33) 
49 (67) 
 
 
54 (59) 
4 (4.5) 
21 (23) 
8 (9) 
4 (4.5) 
 
 
91 (100) 
0 (0) 
 
 
5 (5.5) 
86 (94.5) 
77 (84.5) 
11 (12) 
3 (3.5) 
 
 
91 (100) 
0 (0) 
Figures in parentheses are percentages unless otherwise specified 
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There was no clinical or DUS evidence of DVT or PE, no visual disturbance, nor any 
other complications or side effects. 
 
2.2.3.2 Treatment of the AK-GSV 
Complete eradication of AK-GSV reflux was achieved in all 88 legs; 86 (98%) legs 
after one treatment and in a further two legs after a second (course of primary 
treatment) (Figure 2.9). 
Recanalisation was observed in 0/79 (0%) scanned legs at 6 months and 7/78 (9%) 
scanned legs at 12 months (Figure 2.9). Nine and ten legs were not scanned at 6 
and 12 months respectively because the patients defaulted from follow-up.  
At 12 months this AK-GSV recanalisation was partial (<50% length) with reflux in four 
legs, and complete (>50%) with reflux in three legs. Of these seven legs, four 
underwent one session of repeat UGFS which resulted in successful complete 
eradication of AK-GSV reflux, and three were content with the clinical result and 
declined further treatment. 
 
2.2.3.3 Treatment of the BK-GSV 
Complete eradication of reflux in the BK-GSV was achieved in 77 (96.5%) legs; 74 
(93%) legs after one, and in a further three (3.5%) legs after a second, treatment 
session (course of primary treatment) (Figure 2.10). 
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Figure 2.9 Eradication of reflux and recanalisation in the AK-GSV after UGFS for 
recurrent GSVV  
 
Legs with recurrent AK-GSV reflux 
undergoing UGFS 
88 legs (100%) 
Legs with recurrent AK-GSV reflux in whom 
reflux was completely eradicated by: 
1 treatment = 86 legs (98%) 
2 treatments = 88 legs (100%) 
9 legs not 
scanned 
at 6m 
After primary treatment NO AK-
GSV recanalisation at 6m 
79 legs (100%) 
10 legs not 
scanned at 12m 
After primary treatment NO 
AK-GSV recanalisation at 12m 
71 legs (91%)  
After primary treatment AK-
GSV recanalisation 
PRESENT at 12m 
7 legs (9%) 
No further 
treatment 
3 legs 
Further 
treatment 
4 legs 
After re-treatment AK-GSV 
reflux eradicated after 12m 
4 legs (100%) 
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In three legs (3.5%), complete eradication of reflux in the BK-GSV was not achieved 
after a single treatment session but these patients, despite residual reflux in the BK-
GSV, were content with the clinical result and declined further treatment sessions. 
In the 77 legs in whom the primary course of UGFS achieved complete eradication of 
the reflux in the BK-GSV, recanalisation was observed in 1/69 (1.5%) scanned legs 
at 6 months and 8/68 (12%) scanned legs at 12 months (Figure 2.10). Eight and 12 
legs were not scanned at 6 and12 months respectively. 
At 6 months this BK-GSV recanalisation was complete (> 50%) with reflux in the 
single leg, but the patient was content with the clinical result and declined further 
treatment. 
At 12 months this BK-GSV recanalisation was partial (<50%) with reflux in three legs, 
and complete with reflux in five legs. Of these eight legs, three underwent one 
session of repeat UGFS which resulted in successful complete eradication of BK-
GSV reflux, and for the remaining five legs the patient was content with the clinical 
result and declined further treatment.  
 
2.2.3.4 Clinical success 
There were no visible VV in 78 legs (86%) after one treatment, and in 83 legs (91%) 
after two treatment sessions (course of primary treatment) to eradicate GSV reflux. 
Two patients had a few residual VV in association with residual reflux after one 
treatment but were happy with their results and declined further treatment.  
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Figure 2.10 Eradication of reflux and recanalisation in the BK-GSV after UGFS for 
recurrent GSVV  
 
Legs with recurrent BK-GSV 
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No further 
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After retreatment BK-GSV reflux 
completely eradicated after 12m 
3 legs (100%) 
After primary treatment 
BK-GSV recanalisation 
PRESENT at 6m 
1 legs (1.5%) 
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3 legs (3.5%) 
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In six legs, there were still some residual visible VV after successful eradication of 
GSV reflux with two treatment sessions. A single session of foam injections directly 
into the visible varicosities successfully treated the VV in all six legs. 
By 12 months, 68/78 (87%) still had no visible VV after their primary course of 
treatment (11 were lost to follow-up; 2 had residual untreated VV). One leg had 
recurrent VV in association with recanalisation at 6 months (but declined further 
treatment), and seven legs had recurrent VV in association with recanalisation at 12 
months. Four of these seven had further successful UGFS treatment resulting in both 
eradication of the reflux and disappearance of their recurrent VV; the remainder were 
happy with the clinical result. Three legs had a few recurrent VV at 12 months but no 
recanalisation or reflux, and none wanted further treatment. 
 
2.2.4 Discussion 
Many observers have reported disappointing results with redo SVS for residual and 
recurrent GSVV; and most surgeons would probably prefer not to do such surgery if 
an effective alternative could be found. (Gibbs et al., 1999; Hayden and Holdsworth, 
2001) 
Intuitively, therefore, it is in the treatment of recurrent VV that one might imagine that 
the new endovenous techniques would have their greatest appeal to patients and 
surgeons alike.  But, somewhat surprisingly, data on the effectiveness of EVLA, RFA 
and UGFS for recurrent GSVV are relatively limited when compared to primary 
disease. (Rautio et al., 2002; Lurie et al., 2003; Beale and Gough, 2005; Hinchcliffe et 
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al., 2006; Pannier and Rabe, 2006; Rasmussen et al., 2007; Vasquez et al., 2007; 
Darwood et al., 2008) 
Fassiadis et al. reported on the use of RFA in 18 legs with recurrent GSV. (Fassiadis 
et al., 2002) Fifteen legs had neovascularization connecting with a residual GSV, two 
had an incompetent thigh perforator, and one had a refluxing anterior thigh branch 
reconnecting with the GSV. They found occlusion of all 18 GSV at one month; and in 
16/16 followed up to 12 months. One-third had temporary sensory disturbances. All 
returned to daily activities within three days.  
Hinchcliffe et al. randomized 16 patients with bilateral recurrent GSVV to have one 
leg treated with RFA and the other with SVS comprising a lateral approach to the 
SFJ and GSV strip to the knee. (Hinchcliffe et al., 2006) All limbs had previously 
been treated with SFJ ligation and had an incompetent SFJ and reflux in the GSV on 
DUS. Prior to randomization they found that 70% of patients had a persistent and 
incompetent GSV suitable for treatment with RFA. GSV were considered unsuitable if 
excessively tortuous, or <3 or >12mm in diameter. The patients were followed up to 
12 months and they found complete occlusion in 13/16 GSV treated with RFA, and 
complete GSV stripping in 14/16 legs treated with SVS. RFA was significantly quicker 
to perform and associated with less pain and bruising.  
van Groenendael et al. retrospectively compared outcomes in 149 patients that 
underwent SVS and 67 patients that underwent EVLA for recurrent GSVV. (van 
Groenendael et al., 2009) All limbs had a recurrent SFJ and had reflux in a part of the 
GSV. In the surgically-treated group 87% had had previous GSV stripping, and in the 
EVLA group 57% had had stripping. All had had previous SFJ disconnection. All 
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treatments were deemed successful immediately after treatment and in the 46% 
(69%) legs scanned 8 weeks after EVLA, all treated veins remained occluded. At a 
median follow-up of 13.5 months 26% of SVS patients had ‘clinical recurrence’ 
(although a definition for this is not given in the paper and repeat DUS was not 
performed), compared with 12% in the EVLA group at a median follow-up of 15 
months. However, after adjusting for length of follow-up this difference was not 
statistically significant. They also found less post-treatment pain in the SVS group, 
but more analgesia usage. Wound infection occurred in 8% of the SVS group. They 
conclude that ‘if anatomically suitable’ EVLA is a good treatment alternative for 
recurrent GSVV, however, they also point out that only 31% of patients with recurrent 
GSVV were suitable for EVLA. Various reasons were given for unsuitability: 37% 
tortuosity of the GSV, 8% GSV diameter <4mm, 4% presence of thrombophlebitis, 
51% other reasons including veins too branched or superficial and too many 
connections with the deep venous system. This finding was confirmed recently in a 
study that found that only 44/113 (38.9%) of legs with recurrent GSV reflux were 
suitable for treatment with EVLA or RFA. (Goode et al., 2009) 
Four groups have looked at UGFS for recurrent GSVV. Kakkos et al. presented 
immediate results of 45 legs with recurrent GSVV treated with UGFS (3% STS foam). 
(Kakkos et al., 2006) Twenty-eight had groin reflux, five perforator vein, and the 
remainder had isolated GSV remnant reflux. A single injection of 6ml was adequate 
in 58% of legs; 11% needed three or more treatment sessions. However, complete 
elimination of reflux at the end of treatment was only achieved in 39/45 (87%) legs. 
Follow-up was only for three weeks.  
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Darke et al. treated 18 legs with recurrent GSVV with UGFS (3% polidocanol foam). 
(Darke and Baker, 2006) All had persistent or reconstituted GSV trunks in continuity 
with superficial varicosities and usually with the femoral vein in the groin. Legs were 
assessed clinically and with DUS after six weeks. Ten legs had complete occlusion 
after one treatment; a further five had complete occlusion after two treatments. The 
three remaining legs had partial occlusion (either GSV still open but varicosities all 
closed, or less than complete GSV occlusion but patient satisfied) after one, two or 
three treatments.  
Coleridge Smith reported his experience with using UGFS (mostly 3% STS foam) for 
267 recurrent GSVV in 2006. (Coleridge Smith, 2006) Further information about the 
type of recurrence was not given. One hundred and six legs (40%) were reviewed at 
least six months (mean 11 months) following treatment. The GSV was occluded in 
98/106 (92.5%); better than the 86% occlusion rate seen in primary GSV.  
O’Hare et al. reviewed 32 legs six months after UGFS (3% STS foam) for recurrent 
VV. (O’Hare et al., 2008a) They found occlusion of treated veins on DUS at six 
months in 23/32 (72%), and 28/32 (88%) were satisfied with the results of treatment. 
Unfortunately, this represented less than 50% of their treated cohort and they gave 
no further information regarding the type of recurrence treated. They also included 
some patients treated for SSV rather than GSV recurrence.  
In conclusion, the present study adds further evidence that UGFS is a safe and 
clinically effective treatment for recurrent GSVV. A primary course of UGFS, 
comprising one and infrequently two treatment sessions, leads to complete 
eradication of GSV reflux in virtually 100% of cases. Recanalisation at 12 months is 
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superior to that reported after SVS and similar to that observed following other 
minimally invasive techniques. Recanalisation is easily and successfully treated with 
a further single UGFS treatment. 
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2.3 Duplex ultrasound and clinical outcomes following 
ultrasound-guided foam sclerotherapy of symptomatic small 
saphenous varicose veins 
The data contained within this Chapter were 
 presented (poster) at the West Midlands Surgical Society in Birmingham, UK 
in May 2009 
 published in the British Journal of Surgery in November 2009 (Darvall et al., 
2009).  
 
2.3.1 Introduction 
Approximately 20% of patients presenting with VV have SSVV. (Engelhorn et al., 
2005) The literature indicates that the surgical approach to SSVV remains 
contentious, (Winterborn et al., 2004) and that the outcomes are often suboptimal. 
The SSV and SPJ are subject to considerable anatomical variation, and surgery is 
often difficult, ineffective and associated with complications, including paraesthesia, 
and high recurrence rates. (Tong et al., 1996; Rashid et al., 2002; van Rij et al., 
2003, Sam et al., 2004b) Most studies examining the safety and efficacy of minimally 
invasive alternatives to SVS have focused on GSVV, and their role in the treatment 
of SSVV remains incompletely defined. EVLA and RFA are currently used to treat 
SSVV with high success rates, but they are not suitable for all patients, often require 
additional stab avulsion or UGFS, and can be associated with complications such as 
paraesthesia. (Proebstle et al., 2003a; Merchant et al., 2005) 
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The aim of the present study, therefore, is to describe DUS and clinical outcomes 12 
months following UGFS for symptomatic SSVV. 
 
2.3.2 Methods 
2.3.2.1 Patients 
Following local ethical committee approval and obtaining written informed consent, 
consecutive patients undergoing UGFS for symptomatic SSVV between November 
2004 and May 2007 were invited to take part in the study (as per Section 2.1.2.1).  
To be considered suitable for UGFS patients had to have symptomatic, CEAP C2-6 
venous disease (i.e. treatment was not offered for cosmetic indications) and 
significant (>0.5 seconds) reflux in the SSV on DUS. Patients with absent pedal 
pulses or an ABPI <0.8 were excluded, as were those with post-thrombotic deep 
venous occlusion. 
 
2.3.2.2 Pre-treatment assessment 
Patients were examined and the severity of venous disease according to the CEAP 
clinical classification was determined (Table 1.1). 
DUS was performed, as described in Section 2.1.2.2, at the initial clinic attendance 
in order to identify sites of superficial, deep and communicating venous reflux. 
During the study period all patients presenting to the study team with SSVV were 
offered UGFS and SVS, and all chose UGFS. 
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2.3.2.3 UGFS treatment 
UGFS treatment was performed as described in Section 2.1.2.3, except the SSV 
was cannulated with the patient reclining in the prone position rather than supine. 
 
2.3.2.4 Outcome measures and follow-up 
The chosen outcome measures were complete occlusion of, and abolition of reflux in, 
the SSV on DUS (defined as technical success) and the complete absence of any 
visible VV (defined as clinical success). 
Patients were followed-up at one, six and 12 months as described in Section 2.1.2.4 
with DUS and clinical examination. Complete occlusion in the SSV was defined as 
occlusion over the entire length of the treated SSV up to the first meeting with a deep 
vein, usually the popliteal vein, but sometimes a gastrocnemius vein. 
 
2.3.3 Results 
2.3.3.1 Patients and treatments 
Table 2.3 summarizes the baseline characteristics for each of the 92 legs (86 
patients); 60 legs had UGFS for isolated SSVV and the remaining 32 also underwent 
UGFS for co-existing GSVV at the same treatment session. In the 60 legs 
undergoing treatment for SSVV alone, a single cannula was used in 58 legs, and two 
cannulae in the other two. The median volume of foam used was 6 (range 2-8) ml.  
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Table 2.3  Patient and disease characteristics 
 
Parameter 
 
 
 
 
No. of patients 
No. of legs 
 
Age: median (IQR) in years 
 
Sex 
   Male 
   Female 
 
CEAP clinical grade 
   C2 
   C3 
   C4 
   C5 
   C6 
 
A(E)tiology 
   Primary (Ep) 
   Secondary (Es) 
 
Anatomical patterns of venous reflux 
   Deep (Ad) 
   Superficial only (As) 
      Primary SSV alone 
      Recurrent SSV alone 
      Primary SSV and primary GSV 
      Primary SSV and recurrent GSV 
      Recurrent SSV and primary GSV 
 
Pathophysiological classification 
   Reflux (Pr) 
   Obstruction (Po) 
 
86 
92 
 
57 (47-66) 
 
 
28 (33) 
58 (67) 
 
 
62 (67) 
10 (11) 
14 (15) 
6 (6) 
0 (0) 
 
 
92 (100) 
0 (0) 
 
 
0 (0) 
92 (100) 
47 (51) 
13 (14) 
22 (24) 
9 (10) 
1 (1) 
 
 
92 (100) 
0 (0) 
Figures in parentheses are percentages unless otherwise specified 
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In the 32 legs undergoing simultaneous treatment for GSV incompetence a median 
of 2 (range 2-4) cannulae were used, with a median volume of 10 (range 6-16) ml of 
foam. 
There was one symptomatic popliteal vein thrombosis that was detected four days 
after treatment and remained localized to the area of the SPJ. After six months of 
treatment with warfarin this patient was found to have mild (new) popliteal vein 
incompetence; the SSV remained occluded, there were no visible VV and the patient 
was asymptomatic. There were no other complications or adverse side-effects and, in 
particular, no visual/neurological symptoms nor symptoms of nerve injury in the 
treated leg.  
 
2.3.3.2 Technical success 
At one and six months, the technical success rates (complete SSV occlusion without 
reflux) were 100% and 91% (84/92 legs) respectively (Figure 2.11). At six months, 
seven patients had SSV that had partially recanalised and exhibited reflux, and one 
patient had reflux at the SPJ into a tributary while the SSV remained occluded. Of 
these eight technical failures, six had some associated visible VV (clinical failure) but 
only three patients wanted further treatment (the others were happy with the 
outcome) and in all cases this was technically and clinically successful. Thus 
including the three patients who had a second treatment the technical success rate at 
12 months was 91% (84/92). None of the 14 patients undergoing UGFS for recurrent 
SSVV following previous SVS experienced a technical failure out to 12 months.  
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Figure 2.11 Eradication of reflux and recanalisation in the SSV after UGFS 
 
 
 
 
  
Legs with SSV reflux 
undergoing UGFS 
92 legs (100%) 
Legs with SSV reflux in whom 
reflux was completely eradicated 
by: 
1 treatment = 92 legs (100%) 
After primary treatment 
NO SSV recanalisation at 
6m 
84 legs (91%) 
After primary 
treatment NO 
SSV 
recanalisation at 
12m 
81 legs (88%)  
After primary 
treatment SSV 
recanalisation 
PRESENT at 
12m 
3 legs (3%) 
Further treatment 
3 legs 
All SSV reflux 
completely eradicated 
after retreatment (after 
12m) 
After primary treatment 
SSV recanalisation 
PRESENT at 6m 
8 legs (9%) 
No further 
treatment 
5 legs 
Further treatment 
3 legs 
All SSV reflux 
completely 
eradicated after 
retreatment (at 
12m) 
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2.3.3.3 Clinical success 
At one month, four legs (4%) had some visible VV present. The SSV was occluded 
without reflux in all of these patients. Two patients wanted and underwent tidy-up 
injections of these tributaries and reticular veins at this stage.  
At six months, nine legs (10%) had some visible VV and in six cases this was due to 
recanalisation of the main SSV or a tributary. In the remaining three legs, the VV 
were due to new GSV incompetence. Six of these legs underwent further UGFS at 
between six and twelve months. At 12 months, six legs (7%) had visible VV (clinical 
success rate 93%). Three were associated with SSV recanalisation that was present 
at six months; there were two further SSV recanalisations, and one patient had VV in 
association with an incompetent below-knee perforating vein. 
 
2.3.3.4 Missing data 
All 86 patients attended one-month follow-up. Three patients did not attend follow-up 
at six months, but when seen at one and 12 months they had complete technical and 
clinical success and so have been assumed to have had successful treatment at six 
months. Two patients did not attend follow-up at 12 months, but when seen at six 
months and subsequently at two years they had complete technical and clinical 
success, so are assumed to have had treatment success at 12 months. A further two 
patients did not attend 12-month follow-up, but when seen at six months they had 
recanalisation of the SSV and recurrent visible VV for which they did not want any 
additional treatment. These were included in the 12-month analysis as treatment 
failures so as not to underestimate the recurrence rate at 12 months. 
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2.3.4 Discussion 
The main finding of this study in terms of treatment of the SSV, is that UGFS is a 
safe, technically (91%) and clinically (93%) effective treatment for SSVV out to 12 
months. In 89/92 limbs a single treatment was sufficient. The only complication in the 
current study was a short, occlusive popliteal vein DVT that resolved following six 
months of warfarin.  This patient had no identifiable risk factors for DVT and the 
reason for the thrombosis in this particular patient remains unclear.  In particular 
there were no cases of transient visual disturbance or other central neurology or 
features of nerve injury in the treated leg. 
By contrast, the literature indicates that the surgical approach to SSVV remains 
challenging and that outcomes are often disappointing in terms of recurrence and a 
high incidence of significant complications. (Tong et al., 1996; Rashid et al., 2002; 
van Rij et al., 2003, Sam et al., 2004b; Winterborn et al., 2004; Allegra et al., 2007; 
O’Donnell and Iafrati, 2007; Winterborn and Corbett, 2008; O’Hare et al., 2008b) 
Popliteal fossa anatomy is highly variable and potentially treacherous. Despite pre-
operative duplex marking, SVS is often technically inadequate with an intact SPJ 
being reported in 24-47% patients at six weeks (Table 2.4). (Rashid et al., 2002; van 
Rij et al., 2003; O’Hare et al., 2008b; Ikponmwosa et al., 2010) In one recent 
prospective multicentre observational study paraesthesia was present in 27% of 
limbs at six weeks, and in the majority this persisted to 12 months. (O’Hare et al., 
2008b) Two studies reported visible recurrent VV in 26% and 30% of patients at one 
and five years respectively. (Allegra et al., 2007; O’Hare et al., 2008b) 
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Table 2.4  Published outcomes from SVS, EVLA, RFA and UGFS of the SSV 
 
Name and year 
 
 
n 
 
Follow-up 
 
No reflux 
 
No visible VV 
 
DVT 
 
Paraesthesia 
 
SVS 
Rashid et al., 2002 
 
Van Rij et al., 2003 
 
 
Allegra et al., 2007 
 
O’Hare et al., 2008b 
 
 
Ikponmwosa et al., 2010 
 
 
EVLA 
Proebstle et al., 2003a 
 
 
Ravi et al., 2006 
 
 
Gibson et al., 2007 
 
 
 
Thievacumar et al., 2007 
 
 
 
 
Park et al., 2008 
 
 
 
Huisman et al., 2009 
 
Kontothanassis et al., 2009 
 
 
Desmyttere et al., 2010 
 
 
 
Doganci et al., 2011 
 
 
 
RFA 
Merchant et al., 2005 
 
 
 
UGFS 
Darke and Baker, 2006 
 
Coleridge Smith, 2006 
 
Myers et al., 2007 
 
 
 
59 
 
33 
 
 
132 
 
234 
 
 
90 
 
 
 
41 
 
 
101 
 
 
210 
 
 
 
68 
 
 
 
 
96 
 
 
 
169 
 
229 
 
 
147 
 
 
 
68 
 
 
 
 
52 
 
 
 
 
28 
 
263 
 
177 
 
 
6wk 
 
2wk 
5y 
 
5y 
 
6wk 
1y 
 
6wk 
 
 
 
1m 
6m 
 
2wk 
3y 
 
3d 
6wk 
4m 
 
6wk 
3m 
6m 
 
 
1m 
1y 
3y 
 
3m 
 
1wk 
1y 
 
1wk 
1y 
3y 
 
1wk 
6m 
 
 
 
1wk 
6m 
 
 
 
6wk 
 
6m+ 
 
3y 
 
 
 
31/59 (53) 
 
25/33 (76) 
12/33 (36) 
 
 - 
 
123/230 (53) 
 82/203 (40) 
 
51/90 (57) 
 
 
 
- 
37/39 (95) 
 
92/101 (91) 
34/37 (92) 
 
210/210 (100) 
- 
121/126 (96) 
 
68/68 (100) 
68/68 (100) 
48/48 (100) 
 
 
89/93 (96) 
77/77 (100) 
55/55 (100) 
 
148/150 (98) 
 
227/229 (99) 
147/154 (95) 
 
147/147 (100) 
114/117 (97) 
30/30 (100) 
 
68/68 (100) 
68/68 (100) 
 
 
 
- 
- 
 
 
 
27/27 (100) 
 
116/141 (83) 
 
(36) 
 
 
- 
 
- 
- 
 
93/132 (70) 
 
201/226 (89) 
151/204 (74) 
 
- 
 
 
 
- 
- 
 
- 
- 
 
- 
143/200 (71) 
-  
 
56/68 (82) 
- 
- 
 
 
- 
- 
- 
 
- 
 
- 
- 
 
- 
117/117 (100) 
30/30 (100) 
 
- 
- 
 
 
 
- 
- 
 
 
 
- 
 
132/141 (94) 
 
- 
 
 
2/59 (3) 
 
- 
- 
 
- 
 
0 
- 
 
0 
 
 
 
1/37 (3) 
- 
 
0 
- 
 
12/210 (6) 
- 
- 
 
0 
- 
- 
 
 
0 
- 
- 
 
0/150 (0) 
 
3/229 (1) 
- 
 
0 
- 
- 
 
0 
- 
 
 
 
- 
- 
 
 
 
- 
 
- 
 
- 
 
 
- 
 
- 
- 
 
- 
 
62/230 (27) 
46/204 (23) 
 
8 (9) 
 
 
 
4/37 (11) 
- 
 
- 
- 
 
- 
3/200 (2) 
- 
 
3/68 (4) 
- 
0/48 (0) 
 
 
4/95 (4) 
0/77 (0) 
- 
 
2/150 (1) 
 
5/229 (2) 
0/154 (0) 
 
58/147 (40) 
0 
- 
 
7/68 (10) 
0/68 (0) 
 
 
 
(9) 
(10) 
 
 
 
- 
 
0 
 
- 
Figures in parentheses are percentages 
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More recently EVLA and RFA have been used to reduce morbidity, allow faster 
return to normal activities, and to be at least as effective as traditional SVS. Early 
occlusion rates following EVLA to the SSV range from 91 to 100% (Table 2.4), (Ravi 
et al., 2006; Gibson et al., 2007; Theivacumar et al., 2007; Park et al., 2008; 
Huisman et al., 2009; Kontothanassis et al., 2009; Desmyttere et al., 2010; Doganci 
et al., 2011) and the limited data available suggest this is sustained to six months 
(95-100%) (Proebstle et al., 2003a; Gibson et al., 2007; Theivacumar et al., 2007; 
Park et al., 2008; Kontothanassis et al., 2009; Desmyttere et al., 2010; Doganci et al., 
2011) and even to three years (92-100%). (Ravi et al., 2006; Park et al., 2008; 
Desmyttere et al., 2010) Two studies reported an absence of visible VV in 71% and 
82% of patients at six weeks after EVLA, (Gibson et al., 2007; Theivacumar et al., 
2007) and one study found no recurrence of visible SSVV at 1 or 3 years. 
(Desmyttere et al., 2010) Early paraesthesia rates range from 0 to 40%, (Proebstle et 
al., 2003a; Gibson et al., 2007; Theivacumar et al., 2007; Park et al., 2008; Huisman 
et al., 2009; Kontothanassis et al., 2009; Desmyttere et al., 2010; Doganci et al., 
2011) all of which resolved by six month follow-up.  
The vast majority of studies of RFA for VV have concentrated on GSV treatment. 
Merchant et al. treated 52 SSV with RFA, however they combined duplex and clinical 
outcomes for both GSV and SSV. (Merchant et al., 2005) They found paraesthesia in 
9% of limbs in which the SSV had been treated at 1 week, and 10% at 6 months 
(Table 2.4). 
Three other groups have also published their results on UGFS outcomes for SSV 
treatment since this study began (Table 2.4). Darke and Baker found a 100% 
occlusion rate at six weeks in 27 limbs, but they did not look at longer term results 
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and half of the patients only had direct injections into varicosities as the distal SSV 
trunks were small and competent. (Darke and Baker, 2006) Coleridge Smith found 
SSV occlusion in 83% of limbs followed up for longer than six months, but 
unfortunately those attending follow-up only represented less than 60% of the treated 
cohort. (Coleridge Smith, 2006) In contrast with these reports and the current study, 
Myers et al. found a worse outcome in SSV UGFS compared with GSV UGFS; only 
36% occlusion at three years, although some patients were treated with liquid 
sclerosant only, some had tributary rather than truncal injections, and various types 
and concentrations of sclerosant were used. (Myers et al., 2007) Paraesthesia is not 
a documented complication of UGFS, and the incidence of DVT is fairly similar (0-
5%) with all modes of treatment (Table 2.4). (Van Rij et al., 2004) 
The occlusion rates seen in the current study after UGFS are better than those seen 
in the literature after conventional SVS. (Table 2.4) Paraesthesia rates are also 
lower. The results of the current study are similar to those found with EVLA, although 
the medium to long-term recanalisation rate is probably slightly higher with UGFS, 
however, subsequent UGFS is no more technically difficult than the initial procedure 
and is usually effective. It is also important to remember that anatomical failure does 
not necessarily result in clinical recurrence.  
EVLA and RFA only replace the ‘stripping’ part of SVS and in addition the remaining 
tributary varicosities often have to be treated either by sclerotherapy or phlebectomy, 
thereby increasing treatment time and costs. (Merchant et al., 2005; Mundy et al., 
2005; Pannier and Rabe, 2006; Darwood et al., 2008) EVLA also requires a >10cm 
relatively straight segment of SSV immediately distal to the SPJ and the absence of 
severe varicosities arising within 5cm of the SPJ. (Theivacumar et al., 2007) Indeed, 
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only 70% of consecutive patients with SSV incompetence were suitable for EVLA in 
one study. (Theivacumar et al., 2007) For UGFS no such requirements are 
necessary with the only limiting factor being the experience of the operator. Indeed in 
the current study, no patients were turned down for UGFS for symptomatic SSV 
incompetence.  
In this study, 14 patients were treated for recurrent SSVV after previous SSV 
surgery, and none of these had developed a recurrence by 12 months. UGFS would 
be particularly suitable for recurrent SSVV where the anatomical requirements for 
EVLA may not be met, and SVS is more technically demanding and associated with 
higher complication rates. 
Patient attendance at clinical and duplex follow-up in this study was very good with 
100%, 97% and 95% of patients attending follow-up at 1, 6 and 12 months 
respectively. This is unusually high for patients undergoing treatment for VV, but may 
in part be explained by the fact that patients were attending a dedicated research 
clinic and were not kept waiting, and also that follow-up was often arranged at a time 
to suit them. The patients may also have been more motivated to attend as they 
knew they were undergoing a new treatment of which the long-term outcomes were 
uncertain, and they were getting closer follow-up than is usually available on the 
NHS. No financial assistance or incentives were given.  
In conclusion, UGFS is an effective treatment for SSV incompetence in terms of 
occlusion of the treated vein and abolition of reflux and the disappearance of visible 
VV. Longer term follow-up is required to determine the durability of UGFS, although 
repeat treatments are quick, easy, effective and well-tolerated.  
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2.4 Ultrasound-guided foam sclerotherapy for the treatment of 
chronic venous ulceration: a preliminary study 
The data contained within this Chapter were 
 presented (poster) at the West Midlands Surgical Society in Birmingham, UK 
in May 2009 
 published in the European Journal of Vascular and Endovascular Surgery in 
May 2009 (Darvall et al., 2009c).  
 
2.4.1 Introduction 
Approximately 1% of Europeans will develop CVU during their life time; the point 
prevalence of open ulceration is estimated at 0.1%. (Nelzen et al., 1996; Margolis et 
al., 2002; Ruckley et al., 2002) CVU has a significant adverse impact on HRQL and 
the condition consumes significant health care resources. (Phillips et al.,1994; 
Ruckley, 1997; Kurz et al., 1999) 
The treatment of CVU remains controversial and outcomes are often disappointing, 
especially in the presence of DVR.  However, one RCT (ESCHAR) comparing 
compression alone with compression plus SVS in patients with SVR and CVU found 
that, although there appeared to be no difference in healing rates, recurrence rates 
were significantly lower in the SVS group. (Barwell et al., 2004) Only one group has 
published data to suggest that UGFS in patients with CVU and SVR may be an 
effective and attractive alternative to SVS in this often elderly and frail population. 
76 
 
(Cabrera et al., 2004) However, the study was retrospective and did not include DUS 
follow-up to assess residual or recurrent reflux and its relationship with CVU healing.  
The aim of this study, therefore, is to describe prospectively the rate of CVU healing 
and recurrence during the 12 months following UGFS of SVR, and also to assess the 
relationship between healing, recurrence and the pattern and severity of post-
intervention venous reflux as determined by serial DUS. 
 
2.4.2 Methods 
2.4.2.1 Patients 
Following local ethical committee approval and obtaining written informed consent, 
consecutive patients undergoing UGFS in addition to compression bandaging as part 
of their treatment for open (CEAP clinical grade 6) CVU between June 2005 and May 
2007 were invited to take part in the study (as per Section 2.1.2.1). 
To be considered suitable for inclusion patients had to have open (CEAP C6) CVU, 
and significant reflux (>0.5s) in the GSV or SSV confirmed on DUS. Patients without 
SVR, those with an ABPI <0.8 or post-thrombotic deep venous occlusion, and those 
in whom the ulcer had healed prior to UGFS treatment were excluded. 
  
2.4.2.2 Pre-treatment assessment 
Patients were examined and the severity of venous disease according to the CEAP 
clinical classification was determined (Table 1.1).  
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DUS was performed, as described in Section 2.1.2.2, at the initial clinic attendance 
in order to identify sites of superficial, deep and communicating venous reflux. At this 
appointment, an ulcer history was also taken and the ABPI was measured. 
  
2.4.2.3 Management of CVU while awaiting UGFS treatment 
Patients were put on the waiting list for UGFS (approximately four to six weeks) and 
the ulcerated limb was placed into multilayer compression bandaging, using Profore® 
or ProGuide® (Smith and Nephew, Hull, UK) delivering 40 mmHg at the ankle, while 
awaiting treatment. 
 
2.4.2.4 UGFS treatment 
UGFS treatment was performed as described in Section 2.1.2.3, with the following 
modifications.  
As previously described, a roll of Velband® was applied directly along the treated 
saphenous trunk and was retained on the thigh using Pehahaft® cohesive bandage. 
Below-knee multilayer compression bandaging was applied using Profore® or 
ProGuide®, and a thigh-length class II compression stocking (with the foot/lower leg 
portion removed) was applied over the top. The thigh bandaging was left in place for 
seven to ten days when the patient was reviewed in clinic, at which time the 
bandaging was removed and the class II stocking worn (along with the below-knee 
multilayer compression bandaging) for a further three weeks. Compression 
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bandaging was changed by the district nurse as necessary according to the amount 
of exudate.    
 
2.4.2.5 Outcome measures and follow-up 
The chosen outcome measures were ulcer healing and complete occlusion of, and 
abolition of reflux in, the treated saphenous trunks on DUS. 
Patients were followed up at 7-10 days and one, six and 12 months as described in 
Section 2.1.2.4 with DUS and clinical examination. At the first visit the bandages 
were removed and DUS was performed specifically to look for DVT. 
Ulcer healing was defined as complete re-epithelialisation of the leg, and ulcer 
recurrence as any loss of skin continuity below the knee.  
After ulcer healing was achieved patients wore below-knee class II stockings (Medi, 
Hereford, UK) and patients were advised to wear these during the daytime. 
 
2.4.3 Results 
2.4.3.1 Patients 
Twenty-seven patients (28 limbs) of median age 69 (interquartile range [IQR] 54-79) 
years with open CVU of primary aetiology (CEAP C6, EP) were treated between June 
2005 and May 2007. Demographic data, ulcer history, and pre-UGFS findings on 
DUS are shown in Table 2.5. ABPI was normal (>0.8) in all limbs. SVR alone (AS) 
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was present in 20 limbs and eight limbs had mixed SVR and DVR (ASD); all limbs had 
reflux (PR) rather than obstruction.  
 
Table 2.5  Ulcer pre-treatment data 
  
Demographics 
 
  
Ulcer characteristics 
  
Refluxing segments on duplex† 
 
Patient 
 
 
Gender 
 
Age 
  
Site 
 
Duration 
 
Compression‡ 
  
DV 
 
GSV 
 
SSV 
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27-R 
27-L 
 
F 
M 
F 
M 
M 
F 
F 
F 
M 
F 
F 
F 
M 
M 
F 
F 
M 
F 
M 
M 
M 
F 
F 
M 
M 
F 
F 
F 
 
87 
86 
67 
22 
58 
53 
74 
56 
79 
70 
56 
89 
68 
62 
55 
80 
52 
38 
86 
49 
79 
75 
81 
51 
70 
79 
54 
54 
  
Lateral 
Medial 
Medial 
Medial 
Medial 
Medial 
Lateral 
Medial 
Medial 
Medial 
Medial 
Medial 
Medial 
Medial 
Lateral 
Lateral 
Medial 
Medial 
Medial 
Lateral 
Medial 
Lateral 
Medial 
Medial 
Medial 
Medial 
Lateral 
Lateral 
 
10y 
12m 
6m 
2y 
9m 
9m 
4m 
9y 
4y 
6m 
4y 
3m 
12m 
12m 
2y 
12m 
6m 
7m 
40y 
12m 
20m 
4m 
8m 
12m 
12m 
3m 
12m 
12m 
 
+ 
+ 
- 
- 
- 
+ 
+ 
+ 
- 
- 
+ 
- 
+ 
- 
+ 
+ 
- 
- 
+ 
- 
- 
- 
- 
+ 
+ 
- 
- 
- 
  
+ 
+ 
- 
- 
- 
- 
- 
- 
- 
+ 
+ 
- 
+ 
- 
- 
- 
- 
- 
- 
- 
- 
+ 
- 
- 
+ 
+ 
- 
- 
 
- 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
 
+ 
- 
- 
- 
- 
- 
- 
- 
- 
+ 
- 
- 
- 
- 
- 
- 
- 
- 
 -  
- 
- 
- 
- 
- 
- 
+ 
- 
- 
 
† + = reflux present; - = no reflux. DV = deep veins (superficial femoral and or popliteal vein); ‡ + = 
compression bandaging used to treat current ulcer; - = no compression tried 
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Four patients had a previous history of DVT; this was multiple in two patients and 
they consequently were on lifelong warfarin, one with a target INR of 4.5, the other 
3.5. Two other patients were on warfarin for atrial fibrillation with target INR of 2-3. 
Median ulcer duration (IQR) was 12 (6-23) months.  
There were no symptomatic DVT in any of the treated limbs, neither was there 
evidence of DVT on DUS at seven-ten days or one, six or 12 month follow-up. There 
were no episodes of visual disturbance or other neurological symptoms, no 
cutaneous ulceration at cannulation sites, or paraesthesia. 
 
2.4.3.2 Ulcer healing 
At one and six months after treatment with a median of 8ml foam (range 2-14ml), 22 
ulcers (79%) and 27 ulcers (96%) respectively had healed completely (Table 2.6, 
Figure 2.12). Although the patients were not seen personally by the investigators at 
hospital between one and six months, all were reported by community carers to have 
healed their ulcers within three months of treatment. One patient whose ulcer had not 
healed at one month died soon after from carcinomatosis and was, therefore, 
excluded from further analysis. At 12 months, 25 ulcers (93%) remained healed and 
two ulcers had recurred (7%). Both patients who had recurrence at 12 months had 
stopped wearing their compression stockings, and both also had DVR prior to (and 
after) treatment.  
 
2.4.3.3 Treated vein occlusion 
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Total occlusion of all treated veins at one month was observed in 22 of 28 limbs 
(Table 2.6, Figure 2.12).  
 
Table 2.6 Ulcer treatment and follow-up data 
  
Treatment data 
  
Ulcers completely healed at 
follow-up† 
 
  
All treated venous segments occluded 
on follow-up duplex scan‡ 
 
 
Patient 
 
 
No. of 
cannulae 
 
 
Volume of 
foam (ml) 
  
1m 
 
6m 
 
12m 
  
1m 
 
6m 
 
12m 
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27-R 
27-L 
 
1 
1 
1 
2 
1 
2 
3 
2 
2 
2 
2 
1 
2 
2 
1 
2 
1 
2 
1 
1 
2 
1 
1 
3 
2 
4 
2 
1 
 
2 
12 
8 
12 
8 
10 
8 
12 
8 
8 
8 
8 
10 
10 
8 
8 
8 
10 
4 
8 
12 
3 
8 
10 
8 
14 
10 
6 
  
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
+ 
+ 
- 
+ 
+ 
+ 
+ 
+ 
- 
+ 
- 
+ 
- 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
 
+ 
+ 
- 
+ 
+ 
+ 
+ 
+ 
+ 
  
+ 
- 
+ 
+ 
+ 
+ 
+ 
+ 
- 
+ 
- 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
 
+ 
- 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
 
- 
+ 
+ 
- 
+ 
+ 
- 
+ 
+ 
 
+ 
- 
- 
- 
+ 
+ 
+ 
+ 
+ 
+ 
- 
+ 
+ 
+ 
- 
+ 
+ 
+ 
 
- 
+ 
+ 
- 
+ 
+ 
- 
+ 
+ 
† + = completely healed; - = not healed; left blank = lost to follow-up (died). 
‡ + = all treated venous segments occluded and no residual reflux; - = some reflux present; left blank 
= lost to follow up (died) 
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Two patients had had unsuccessful treatment: one refused further treatment (patient 
19) and the other had repeat UGFS although the ulcer was already healed (patient 
18). Three patients had residual BK-GSV reflux only with an occluded GSV in the 
thigh (patients 2, 9 and 20). All of these patients’ ulcers had healed by one month 
and only one wanted further treatment (patient 9) for residual visible VV. The 
remaining one patient (patient 11) only had occlusion of her proximal GSV after the 
first treatment with many remaining VV and distal reflux. Her previously almost 
circumferential ulcer however was much improved and she did not want further 
injections. 
 
Figure 2.12 Ulcer healing rates and treated vein occlusion rates after UGFS 
 
 
 
At six month follow-up 22 of 27 limbs (patient 19 lost to follow-up) had total occlusion 
of all treated veins. Patients 2 and 20 still had residual BK-GSV reflux and patient 11 
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still only had occlusion of the proximal GSV. The remaining two patients had had 
recanalisation of their BK-GSV with recurrent reflux (patients 23 and 26). In both 
patients the ulcers remain healed and they only had a few VV so no further treatment 
was wanted. 
At 12 months, 19 of 27 limbs had total occlusion of all treated veins. The situation for 
patients 2 and 20 (residual BK-GSV reflux) and patients 23 and 26 (recurrent BK-
GSV reflux) remained unchanged. Patients 3, 4 and 15 had recanalisation of the 
majority of their GSV with recurrent reflux at 12 months follow-up. However, their 
ulcers remained healed and they had few visible VV and remained asymptomatic, so 
they elected to have no further treatment at this stage. Finally, patient 11 had a 
recurrence of her ulcer between 6 and 12 months and continued to have distal reflux 
and many VV amenable to treatment with UGFS. However, the ulcers are intermittent 
and her symptoms are much improved so she continues to decline further treatment. 
 
2.4.4 Discussion 
The main findings of the present study are that following UGFS combined with 
compression, 27 of 28 (96%) CVU healed within three months, and at 12 months 
only two ulcers had recurred.  
The outcomes reported here appear superior to those reported from other studies 
using compression alone with no attempt made to eradicate SVR (healing 68-83% at 
six months, recurrence 26-28% at 12 months). (Bello et al., 1999; Barwell et al., 
2000; Ghauri et al., 2000)  
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The importance of eradicating SVR was clearly demonstrated in the ESCHAR study, 
an RCT of 500 patients comparing CVU healing and recurrence rates with 
compression bandaging alone, and following SVS combined with compression. 
(Barwell et al., 2004) Healing rates at six months were 65% in both groups, and 
approached 80% by 12 months. (Barwell et al., 2004) Recurrence rates, however, 
were significantly lower in patients undergoing SVS, 15% versus 34% at a median 
follow-up of 14 months (range 10-23 months). (Barwell et al., 2004) Longer term 
follow-up from the same study found CVU healing rates at three years of 89% in the 
compression only group, and 93% in the SVS and compression group (P = .73, log 
rank test); and CVU recurrence rates at four years of 56% in the compression only 
group, and 31% for the SVS and compression group (P < .01). (Gohel et al., 2007)  
The CVU outcomes reported here after UGFS appear to be at least as good as those 
reported after SVS in the ESCHAR study (n=216), although the numbers in the 
studies are very different.  This suggests that UGFS may be an attractive alternative 
to SVS in this group of patients who are often elderly, frail and refuse (or are refused) 
operative intervention; further supporting this is the lack of side-effects found in this 
clinical series and the successful treatment of four patients anticoagulated with 
warfarin.  Four other groups have thus far looked at the effect of UGFS on CVU 
healing and have also reported promising results. 
In 2004, Cabrera et al. reported a retrospective study of 116 consecutive patients 
with 151 CVU of median duration (range) 62 (1-480) months treated over a ten-year 
period with 0.27% to 1% polidocanol CO2 microfoam. Almost 30% of their patients 
had DVR and 20 had undergone previous SVS (unspecified). Unlike the present 
study where only two of the 28 treated limbs required two sessions of UGFS, their 
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patients underwent repeated treatment sessions (median 3.6, range 1-17) until all 
identifiable SVR was eliminated. At six months, Cabrera reported an 82.8% healing 
rate (96/116) with a median time to healing of 2.7 months; seven patients were never 
healed, one patient was lost to follow-up and there were recurrences in ten patients 
(9%). In a multivariate analysis they found that both long CVU duration and the 
presence of DVR were adverse prognostic factors; the latter appears to be the case 
in the present series too. Beyond six months, follow-up rates were really too low to 
undertake proper analysis of longer term healing and recurrence rates; and repeated 
post-intervention DUS scans to assess the success of their treatment were not 
undertaken. However, the authors reasonably concluded on the basis of their short 
term results that microfoam treatment of CVU was promising and worthy of further 
study. (Cabrera et al., 2001; Cabrera et al., 2004) 
In 2006, Bergan et al. described their experience of 50 limbs with active CVU. 
Twenty-two were treated with compression bandaging alone, 13 failed compression 
therapy and went on to have UGFS, and a further 15 were treated promptly with 
UGFS. (Bergan et al., 2006) Polidocanol foam was used in strengths of 1-3%, and 
the usual volume used was 8ml. At six weeks follow-up they found complete CVU 
healing in 45% of the compression only group, and 100% of the patients who had 
had UGFS. (Bergan et al., 2006)  
Hertzman et al. performed UGFS of incompetent GSV using 3% polidocanol in 13 
legs with CVU (9 patients). At one week follow-up, they reported healing of two ulcers 
and improvements in another nine. (Hertzman and Owens, 2007) O’Hare and 
Earnshaw randomized 22 patients to compression bandaging alone and 18 patients 
to compression bandaging with additional UGFS using 3% STS. (O’Hare and 
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Earnshaw, 2010) They reported healing in 17/20 (85%) of the compression group, 
and 12/13 (92%) of the additional UGFS group at 24 weeks. Unfortunately the study 
failed to recruit and randomize the 170 patients required for formal comparison. 
It has been suggested that this observed increased efficacy of UGFS over SVS in 
CVU healing could be due to the fact that the foamed sclerosant can act directly on 
the microcirculation (the end point of venous hypertension), rather than indirectly by 
superficial venous stripping. (Pascarella et al., 2006; Hertzman et al., 2007) 
Also, GSV stripping is usually carried out to knee level only due to the risk of damage 
to the saphenous nerve below the knee, (Morrison and Dalsing, 2003) with 44-91% 
of patients having reflux in the BK-GSV at two-year follow-up. (MacKenzie et al., 
2002b; MacKenzie et al., 2004; Blomgren et al., 2005; van Neer et al., 2009) Kulkarni 
et al., however, concluded that residual reflux after SVS is not the most important 
predictor of CVU recurrence, and although the hazard ratio of developing CVU 
recurrence by three years was 2.5 in those with residual BK-GSV reflux, this did not 
reach statistical significance. (Kulkarni et al., 2007) No other group has considered 
the effect of technically ‘successful’ treatment (i.e. occlusion of all treated veins on 
duplex) on CVU healing and recurrence. In the current study, of the three patients 
who still had residual reflux in the thigh GSV at one month, only one ulcer had 
healed. Five limbs have had some recurrence of reflux by 12 months but in none of 
these limbs have the ulcers recurred. It will be interesting to see whether these 
patients go on to develop recurrent CVU and hence whether it would be useful to 
treat these asymptomatic ‘recurrences’ to prevent this. Of the two patients with 
recurrent CVU, both have DVR and one continued to have significant SVR also.  
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The small number of patients is an inherent weakness in the study, but as a 
preliminary study it demonstrates the potential of UGFS as an adjunct to healing 
CVU. The results must be interpreted with caution due to the fact that only 12 of 28 
limbs had been treated by compression prior to assessment for treatment. This is 
slightly offset by the observation that none of the ulcers healed in the interval 
between placement on the waiting list for treatment and attending for UGFS (usually 
four to six weeks), during which time all limbs were treated with multilayer graduated 
compression bandaging. Another obvious limitation is that this study is not an RCT. 
Although all patients are offered a choice between SVS and UGFS as appropriate, in 
our practice patients rarely choose a surgical option.  The striking differences we 
have observed over the last few years between the outcomes following UGFS and 
SVS have removed our ‘grey area of clinical equipoise’ and we therefore feel it 
inappropriate for us to randomise patients between the two treatments. Even if we 
did wish to do that type of study, it is clear that the great majority of our patients 
would simply refuse randomisation. In these particular patients, this problem of 
recruitment and suitability for treatment has been demonstrated in the published 
RCTs. (Howard et al., 2008; O’Hare and Earnshaw, 2010) 
In summary, our preliminary data add further weight to the contention that eradication 
of SVR by means of UGFS improves CVU outcomes when compared to compression 
alone.  In this regard, UGFS appears to be at least as effective as SVS as a means 
of dealing with SVR and does, therefore, appear the more attractive option in this 
elderly patient population. As is probably to be expected, patients with DVR do not 
respond as well to treatment with UGFS but this is also true of SVS and compression 
alone. Furthermore, the novel follow-up duplex data presented here does suggest 
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long-term healing following UGFS probably requires careful follow-up and, if required, 
further sessions of UGFS to make sure that SVR remains completely eradicated.   
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CHAPTER 3. THE SAFETY AND ACCEPTABILITY OF 
ULTRASOUND-GUIDED FOAM SCLEROTHERAPY 
As well as being effective, the ideal treatment for VV should be free from 
complications and allow a quick return to work and normal activities. While SVS is the 
traditional gold standard for the treatment of VV, it is not complication-free and can 
be associated with a prolonged recovery. UGFS, to be considered a useful 
alternative, should be associated with less morbidity and a quicker recovery. 
In this Chapter I compare the safety and acceptability of UGFS compared with SVS 
in terms of post-procedural morbidity and time taken to return to normal activities. 
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3.1 Recovery and return to normal activities after ultrasound-
guided foam sclerotherapy compared with conventional 
surgery for varicose veins 
The data contained within this Chapter were 
 presented (poster) at the International Surgical Congress of the Association of 
Surgeons of Great Britain and Ireland in Glasgow, UK in May 2009 
 published in the British Journal of Surgery in November 2009 (Darvall et al., 
2009a).  
 
3.1.1 Introduction 
Surgical treatment of VV improves physical symptoms, generic and disease-specific 
HRQL, and venous haemodynamics. (Smith et al., 1999; MacKenzie et al., 2002a; 
MacKenzie et al., 2002b; Sam et al., 2004a) However, it is also widely accepted that 
such surgery can be associated with a significant incidence of complications, 
morbidity, and delayed return to normal activities and to work. (Sam et al., 2004b; 
van Rij et al., 2004; Beale and Gough, 2005; Subramonia and Lees, 2005; Wood et 
al., 2005)  
Apart from being unpleasant for some patients and a rich source of medicolegal 
activity, (Tennant and Ruckley, 1997; Ray, 2005) adverse outcomes after SVS can 
have a significant financial impact in this predominantly young and economically 
active patient population. Minimally invasive techniques may have advantages over 
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traditional SVS that include less morbidity and quicker return to normal activities. 
(Beale and Gough, 2005) 
The aim of this study, therefore, is to determine early morbidity, analgesia use, and 
time taken to return to driving and work following UGFS, and to compare these 
findings with those in a contemporaneous series of similar patients undergoing SVS. 
 
3.1.2 Methods 
3.1.2.1 Patients 
Local ethical committee approval and written informed consent was obtained from all 
patients. Questionnaires were posted to 391 consecutive patients who had UGFS 
between November 2004 and May 2007, and 94 consecutive patients who had 
conventional SVS between October 2007 and March 2008. All patients were treated 
at HEFT but under the care of separate surgical teams. All patients were referred by 
their general practitioners to NHS outpatient clinics, and were assessed in a 
consultant-led vascular outpatient clinic. 
To be considered for treatment patients had to have symptomatic, CEAP C2-6 venous 
disease (i.e. treatment was not offered for cosmetic indications) and significant 
(>0.5s) reflux in either the GSV or SSV. 
 
3.1.2.2 Pre-treatment assessment 
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Patients were examined and the severity of venous disease according to the CEAP 
clinical classification was determined (Table 1.1). 
DUS was performed, as described in Section 2.1.2.2, at the initial clinic attendance 
in order to identify sites of superficial, deep and communicating venous reflux.  
 
3.1.2.3 UGFS treatment 
UGFS treatment was performed as described in Section 2.1.2.3. In patients with 
bilateral VV only one leg was treated at a time (worst leg first); the second leg was 
treated at least four weeks later. UGFS patients were told to take analgesia as 
required, to return to driving when they felt able to perform an emergency stop, and 
to return to work when they felt comfortable. It was suggested to patients who had 
had their right leg treated that they wait until the bandaging was removed to 
commence driving as it may prove difficult to perform an emergency stop. 
 
3.1.2.4 Surgical treatment 
All SVS was performed on inpatients, usually without an overnight stay, under 
general anaesthesia. Patients with bilateral VV usually had both legs treated at the 
same time. Primary GSV incompetence was treated by SFJ ligation, stripping of the 
GSV to knee level and multiple stab phlebectomies. Recurrent GSV varices were 
treated by re-exploration at the groin, and phlebectomies with stripping of any GSV 
remnant, as appropriate. SSV incompetence was treated by SPJ ligation (marked 
immediately before operation by DUS), removal of the proximal 10cm of the SSV via 
93 
 
the popliteal incision, and phlebectomies. No surgeon performed stripping of the 
SSV.  
Limbs were bandaged after SVS with Velband® and Elastocrepe® (Smith and 
Nephew Healthcare, London, UK). Bandaging was replaced after 24 hours with thigh-
length antiembolism stockings (TED®; Kendall Healthcare Products, Mansfield, MA) 
worn for a further two weeks. No specific restrictions were suggested to patients. 
They were advised to take analgesia as required, to return to driving when they felt 
able to perform an emergency stop, and to return to work when they felt comfortable.  
 
3.1.2.5 Questionnaires and outcome measures 
Questionnaires (Appendix 3 and 4) were sent to all patients four weeks after 
treatment. No reminders were sent. Separate questionnaires were sent for each 
treated leg. Patients were asked to grade the amount of pain, bruising, itching and 
lumpiness they had following UGFS or SVS. Possible responses were ‘an awful lot’, 
‘a lot’, ‘quite a bit’, ‘a little’ or ‘none’. ‘An awful lot’ and ‘a lot’ were grouped together, 
as were ‘a little’ and ‘none’ for analysis. Patients were also asked: ‘For how many 
days after your foam injections/varicose vein surgery did you take painkilling tablets?’ 
Possible responses were: ‘none at all’, ‘same day only’, ‘1-2 days’, ‘2-4 days’, ‘5-7 
days’, ‘7-14 days’ and ‘more than 14 days’. The final questions were: ‘How long after 
your foam injections/varicose vein surgery did you return to work/driving?’ Possible 
responses were: ‘I don’t go out to work/drive’, ‘same day’, ‘next day’, ‘2-7 days’, ‘7-14 
days’ and ‘more than 14 days’. 
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3.1.2.6 Statistical analysis 
Statistical analysis was performed using the Statistical Package for the Social 
Sciences (SPSS) version 17.0 software (SPSS Inc., Chicago, IL, USA). The chi-
squared test (Χ2, with Yates’ correction where appropriate) was used to compare 
proportions between the two groups. Analysis of return to work and driving, and 
analgesia use was undertaken for the group as a whole, and then again after 
exclusion of patients who had bilateral SVS. 
 
3.1.3 Results 
3.1.3.1 Patients and treatments 
The response rates were 84.9% (332 patients, 418 limbs) in the UGFS group and 
56% (53 patients, 70 limbs) in the SVS group. There were no significant differences 
between the groups in terms of age, sex, proportion with bilateral or recurrent VV, or 
extent of SVR treated (Table 3.1).  
In the SVS group, four legs had primary SPJ ligation and phlebectomies; four legs 
had primary combined SFJ and SPJ ligation, GSV stripping and phlebectomies; four 
legs had groin exploration for recurrence and phlebectomies without GSV stripping; 
and 58 limbs had SFJ ligation, GSV stripping and phlebectomies (nine recurrent). In 
the UGFS group, 341 had GSV treatment (90 recurrent) with additional AASV 
treatment in 22; 55 has SSV treatment (ten recurrent); and 22 had both GSV and 
SSV treatment (nine recurrent). 
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Table 3.1 Demographic data of patients with VV treated by UGFS or SVS 
  
UGFS 
 
 
SVS 
 
 
 
P 
 
No. of patients 
 
No. of legs 
 
Age: median (IQR) in years 
 
Male sex† 
 
Bilateral† 
 
Recurrent‡ 
 
GSV‡ 
 
CEAP C2 or C3‡ 
 
 
332 
 
418 
 
58 (46-66) 
 
111 (33.4) 
 
87 (26.2) 
 
109 (26.1) 
 
363 (86.8) 
 
296 (70.8) 
 
53 
 
70 
 
53 (42-64) 
 
20 (38) 
 
17 (32) 
 
13 (19) 
 
66 (94) 
 
57 (81) 
  
 
 
 
 
.162 
 
.540 
 
.350 
 
.085 
 
.120 
 
.066 
P values from chi-squared test, except age where MWU test was used 
Values in parentheses are percentages of patients† or legs‡ unless otherwise specified 
 
 
3.1.3.2 Complications of UGFS 
One symptomatic popliteal vein thrombosis was detected four days after UGFS, 
localized to the area of the SPJ. This was treated with warfarin for six months, at 
which point the patient was asymptomatic but had mild DVR. Three patients 
complained of visual disturbance following foam injections, consisting of blurred 
vision that lasted for less than 10 minutes. There were no other complications or 
adverse effects and, in particular, no other neurological symptoms or symptoms of 
nerve injury in the treated leg. Complications after SVS were not recorded. 
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Figure 3.1 Bruising following treatment 
 
UGFS n=418; SVS n=70 
Presence of significant bruising: UGFS versus SVS, 7.2% versus 44%, P < .0001, χ2 
 
 
 
Figure 3.2 Pain following treatment 
 
UGFS n=418; SVS n=70 
Presence of significant pain: UGFS versus SVS, 5.5% versus 17%, P = .001, χ2 
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3.1.3.3 Questionnaire results 
Significant bruising (44% after SVS versus 7.2% after UGFS; P < .0001) (Figure 3.1) 
and pain (17% versus 5.5%; P = .001) (Figure 3.2) were significantly more common 
after SVS. There was no difference in terms of itching (SVS 10%, UGFS 8.4%) or 
lumpiness (SVS 9%, UGFS 7.4%).  
 
Figure 3.3 Duration of analgesia usage following treatment 
 
UGFS n=418; SVS (all patients) n=53; SVS (unilateral only) n=36 
No analgesia at all: 
    UGFS versus SVS (all patients), 70.8% versus 23%, P < .0001, χ2 
    UGFS versus SVS (unilateral only), 70.8% versus 26%, P < .0001 
Analgesia usage for >1 week:  
  UGFS versus SVS (all patients), 4.1% versus 30%, P < .0001 
  UGFS versus SVS (unilateral only), 4.1% versus 29%, P < .0001 
 
After UGFS, 70.8% of patients required no analgesia compared with 24% after SVS 
(P < .0001). After one week only 4.1% were still using analgesia compared with 30% 
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after SVS (P < .0001). These differences persisted when patients undergoing 
bilateral SVS were excluded from the analysis (Figure 3.3).  
After UGFS, 47.7% of patients resumed driving within four days compared with 25% 
after SVS (P = .014) (Figure 3.4). After UGFS, 43.2% of patients returned to work 
within 24 hours, but none after SVS (P < .0001). Respective proportions after one 
week were 77.4% and 23% (P < .0001) (Figure 3.5). These differences in resuming 
driving and returning to work persisted when patients undergoing bilateral SVS were 
excluded from the analysis.  
 
Figure 3.4 Time taken to return to driving following treatment 
 
UGFS n=304 (114 non-drivers); SVS (all) n=32 (21 non-drivers); SVS (unilateral) n=26 (10 
non-drivers) 
Returned to driving within 4 days:  
  UGFS versus SVS (all), 47.7% versus 25%, P = .014, χ2 
  UGFS versus SVS (unilateral), 47.7% versus 27%, P = .041 
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Figure 3.5 Time taken to return to work following treatment 
 
UGFS n=234; SVS (all patients) n=35; SVS (unilateral only) n=23 
Returned to work within 24 hours:  
  UGFS versus SVS (all patients), 43.2% versus 0%, P < .0001, χ2 
  UGFS versus SVS (unilateral only), 43.2% versus 0%, P < .0001 
Returned to work within 1 week: 
  UGFS versus SVS (all patients), 77.4% versus 23%, P < .0001 
  UGFS versus SVS (unilateral only), 77.4% versus 30%, P < .0001 
 
 
3.1.4 Discussion 
The main finding of this study is that when compared with conventional SVS, UGFS 
is associated with significantly less bruising, pain and analgesia requirement, and 
time off work and driving. UGFS is well-tolerated and safe, with only one DVT and 
three instances of self-limiting blurred vision after treatment. 
Bruising after SVS has been reported in 25-53% of limbs which is similar to the 
incidence found in the current study. (Lurie et al., 2003; Subramonia and Lees, 2005) 
The incidence of bruising of 13-27% after RFA (Lurie et al., 2003; Vasquez et al., 
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2007) and 11-15% after EVLA (Rasmussen et al., 2007; Christenson et al., 2010), 
while significantly less than after SVS, are still higher than the 7% rate of bruising 
after UGFS in the current study. 
The levels of pain and analgesia use reported here after SVS are similar to those 
reported by others. (Nelzen, 2000; Shamiyeh et al., 2003; Biswas et al., 2007). Pain 
and tenderness have been found in several studies to be less common following RFA 
when compared with SVS (Rautio et al., 2002; Lurie et al., 2003; Hinchcliffe et al., 
2006; Subramonia and Lees, 2010), being present in one study in 10% of RFA 
patients and 25% of SVS patients (Lurie et al., 2003). RFA patients also required less 
analgesia than patients having SVS (Rautio et al., 2002; Subramonia and Lees, 
2010). In recently published RCTs, RFA has been found to be associated with 
significantly less pain and post-operative analgesia use than EVLA. (Goode et al., 
2010; Shepherd et al., 2010a) After EVLA pain along the treated vein is reported in 
up to 50% of patients during the first week (Pannier and Rabe, 2006). However, 
results from the RCTs are somewhat inconsistent with two such studies finding no 
difference between EVLA and SVS in terms of pain scores and analgesia 
requirement (Rasmussen et al., 2007; Christenson et al., 2010); one finding in favour 
of EVLA (Carradice et al., 2011); and another in favour of SVS. (Pronk et al., 2010) In 
the current study we found significant pain in only 6% of patients undergoing UGFS 
and only 4% continued to require analgesia one week after treatment. 
In the present study, return to work and driving was significantly quicker after UGFS 
than after SVS and appeared similar to, or perhaps better than, that reported after 
other minimally invasive treatments. The median time to return to work after SVS has 
been reported at between four and 21 days (Bountouroglou et al., 2006; Wright et al., 
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2006a; Darwood et al., 2009; Subramonia and Lees, 2010; Pronk et al., 2010; 
Carradice et al., 2011). In one study, 10% of SVS patients took between six and 12 
weeks to return to work (Biswas et al., 2007). Patients who had experienced minor 
complications, such as wound infection or haematoma, took even longer. (Wright et 
al., 2006a) Two studies found return to driving after SVS at a median of seven days, 
(Darwood et al., 2009; Subramonia and Lees, 2010) and median time to return to 
normal activities varies from 7-14 days. (Bountouroglou et al., 2006; Subramonia and 
Lees, 2010; Christenson et al., 2010; Carradice et al., 2011). Bilateral SVS had no 
effect on return to work and physical activity in one study (Shamiyeh et al., 2003), a 
finding supported by the current study, but in another those patients undergoing 
bilateral SVS took longer to return to work. (Darwood et al., 2009)  
It has been suggested that, for the procedure to be cost-effective, patients 
undergoing RFA must return to work 3.2 days earlier than those having SVS. (Rautio 
et al., 2002) Reported median return to work following RFA ranges from 1.4 to 10 
days (Rautio et al., 2002; Lurie et al., 2003; Beale and Gough, 2005, Subramonia 
and Lees, 2010), and RCTs found a significantly faster return to normal activities, 
driving and to work in patients undergoing RFA compared with SVS (Lurie et al., 
2003; Subramonia and Lees, 2010). Again the situation with EVLA is less clear; two 
RCTs comparing RFA and EVLA found no differences in time to return to normal 
activities and to work between the groups, (Goode et al., 2010; Shepherd et al., 
2010a) and three found no difference between EVLA and SVS; (Rasmussen et al., 
2007; Pronk et al., 2010; Christenson et al., 2010) whereas others found recovery to 
be significantly quicker after EVLA compared with SVS. (Ravi et al., 2006; 
Theivacumar et al., 2007; Darwood et al., 2008; Carradice et al., 2011) In a 
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comparative trial, patients returned to normal activities a median of two days after 
UGFS, compared with 13 days after SVS (Wright et al., 2006b). 
As mentioned in the Introduction (Section 1.5.5), return to work and normal activities 
can be used as a marker of cost-effectiveness from a societal perspective. A recent 
study has examined the cost-effectiveness of the available treatments for VV from 
the perspective of the NHS, (Gohel et al., 2010) and found that day-case SVS or 
EVLA and RFA performed as an outpatient are likely to be cost-effective treatment 
strategies for patients with primary unilateral GSV reflux, but UGFS despite low initial 
costs was not cost-effective. This conclusion regarding UGFS was based, however, 
on only one half of the results of a single RCT (Wright et al., 2006b) which found 
UGFS to be less effective in occluding the GSV than SVS (63% versus 86%); 
however in the same study when the UGFS was administered by sclerotherapists the 
GSV occlusion rate was 94% at three months. The authors of the cost-effectiveness 
study state that UGFS would be cost-effective if the probability of GSV occlusion 
three months after UGFS was the same as that for SVS. (Gohel et al., 2010) We 
have found this to be true; however there are no further published data from an RCT 
as yet. A large Health Technology Assessment-funded multicentre RCT comparing 
SVS, EVLA, and UGFS (Comparison of Laser, Surgery and foam Sclerotherapy, 
CLASS study) is currently recruiting.  
In addition, we found UGFS to be a safe procedure. Complications after UGFS can 
be divided into local (skin necrosis or ulceration, thrombophlebitis and skin 
pigmentation) and systemic complications (anaphylaxis, DVT and PE, chest 
symptoms, and neurological symptoms). (Guex, 2009) In our recently published 
prospective series (1221 procedures in 976 legs including the patients in this study), 
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we have observed no cases of skin necrosis or ulceration, significant 
thrombophlebitis in around 5% of cases, and skin pigmentation in around 20% at 1 
month which had disappeared in virtually all patients by 12 months. (Bradbury et al., 
2010) These figures are similar to those found in the literature. (Jia et al., 2007)  
Anaphylaxis is a recognized complication of liquid sclerotherapy but in a recent 
systematic review of UGFS no cases of anaphylaxis were found. (Jia et al., 2007) 
There is however a single case report in the literature following UGFS. (Scurr et al., 
2007) DVT following UGFS remains rare usually occurring in less than 1% of cases 
as is found in this study. (Jia et al., 2007; Myers et al., 2007; Gillet et al., 2009) One 
study found that injecting more than 10 ml of foam into a limb resulted in a greater 
than three-fold increased risk of DVT, (Myers and Jolley, 2008) thus a consensus 
document now recommends the maximum appropriate amount of foam to be used 
per session is 10ml. (Breu et al., 2008) Hamel-Desnos et al. have treated 105 
patients with known thrombophilia without a single incidence of DVT or PE. (Hamel-
Desnos et al., 2009) 
Prior to undertaking this research the systemic complications of transient visual 
disturbance, headache and migraine, and chest symptoms including dry cough had 
been reported in less than 1% of patients as outlined previously in Section 1.4.5. 
(Guex et al., 2005; Jia et al., 2007) and this is similar to the findings of the current 
study. Shortly after the commencement of the studies reported in this Thesis, a case 
report by Forlee et al. on the occurrence of an ischaemic stroke shortly following 
UGFS led to intense renewed debate regarding the safety of UGFS. (Forlee et al., 
2006) Following this there have been six other reports of transient neurological 
events in patients following UGFS, (Hanisch et al., 2004; Bush et al., 2008; Hartmann 
104 
 
et al., 2009; Hahn et al., 2010; Picard et al., 2010) although this is not unique to 
UGFS, with cerebral infarcts also being reported following both SVS and EVLA. 
(Harzheim et al., 2000; Caggiati and Franceschini, 2010) All of the patients were 
found on investigation to have a patent foramen ovale (PFO). PFO has been 
previously reported to exist in 26-40% of the general population, (Meier and Lock, 
2003; Homma and Sacco, 2005; Rush and Wright, 2008) but more recently this 
proportion has been shown to be much greater in patients with symptomatic VV. 
(Raymond-Martimbeau, 2009; Morrison and Neuhardt, 2009; Wright et al., 2010) A 
right-to-left shunt was detected in 59% VV patients in a recent study, although as 
transcranial Doppler (TCD) was used they were unable to differentiate between intra-
cardiac and intra-pulmonary shunts. (Wright et al., 2010) Both transthoracic 
echocardiography and TCD have been used extensively to detect emboli in the heart 
and middle cerebral artery respectively, and have found that while echogenic signals 
(foam microemboli) in untreated veins, heart chambers and the cerebral circulation 
are a common phenomenon during UGFS, neurological complications develop in 
relatively few patients with right-to-left shunts. (Ceulen et al., 2008; Rush and Wright, 
2008; Regan et al., 2008; Morrison et al., 2008, Morrison and Neuhardt, 2009)  
Various manoeuvres during foam injection have been suggested to decrease the 
amount of foam that enters the deep venous system and thus the systemic 
circulation, thereby improving the safety of UGFS. Leg elevation prior to injection is 
employed by 69% of surgeons using foam in a survey of the Vascular Society of 
Great Britain and Ireland, and 63% manually blocked the SFJ or SPJ before injection. 
(O’Hare and Earnshaw, 2007) In recently published guidelines, leg elevation is 
recommended but there is no consensus regarding compression at the SFJ or SPJ. 
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(Breu et al., 2008) Hill et al. found that the presence of echogenic phenomena in the 
right heart was significantly higher (100%) in patients injected without leg elevation 
but with SFJ compression applied, than in patients with their leg elevated and also 
with SFJ compression (84%). The lowest incidence was in patients injected with their 
leg elevated but with no SFJ compression (47%). Where SFJ compression was used 
a concentrated bolus of bubbles was frequently observed after release of digital 
pressure. (Hill et al., 2008) In contrast to this a small study of eight patients suggests 
that compression (or ligation) of the SFJ may reduce sclerosant foam entering the 
deep venous system. (Ceulen et al., 2010)  
Another variation on technique suggested to decrease the passage of foam into the 
deep veins is the use of multiple small injections rather than larger volumes. (Yamaki 
et al., 2009) However, the small injections were given directly into tributaries prior to 
direct injections of the saphenous trunk and their occlusion rate of 52% legs at six 
months was poor. (Yamaki et al., 2009) 
The final modification of technique is regarding the gas used to generate foam. Most 
studies have used air, however, there is some evidence that the side-effects are 
lower using either carbon dioxide or a 70/30 mixture of carbon dioxide and oxygen, 
(Morrison et al., 2008; Morrison et al., 2010) however the comparator group was 
historical and the incidence of side-effects was much higher than those previously 
reported (8% visual disturbance, 16% cough). The findings are not supported by 
others. (Cabrera et al., 2004; Wright et al., 2006b; Ceulen et al., 2008)  
Further studies are still required to determine the aetiology and significance of these 
neurological events. While visual disturbance is more common after UGFS, it is also 
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reported after liquid sclerotherapy suggesting that the mechanism cannot simply be 
related to bubbles persisting in the systemic circulation, but could be due to 
vasospasm induced by the sclerosant itself. (Guex et al., 2005; Hamel-Desnos and 
Allaert, 2009; Bradbury et al., 2010; O’Hare et al., 2010) There is further evidence 
that the visual disturbances correspond with migraine with aura, thus suggesting that 
they are not transient ichaemic events but possibly due to endothelin release from 
the damaged vein. (Gillet et al., 2010) 
In the UK, after two separate comprehensive reviews of the evidence, UGFS has 
been accepted as a safe treatment by the National Institute of Health and Clinical 
Excellence (NICE), and by the major private insurance companies and the majority of 
vascular surgeons. (Bradbury et al., 2010) 
A weakness of the study is that the two groups were not randomized. Two surgeons 
in our unit used UGFS as the preferred treatment for VV, whereas other colleagues 
continued to employ conventional SVS. All patients in the present study were 
referred from general practitioners through a common UK NHS referral pool. The 
hospital management system allocated patients to each vascular surgeon in 
accordance to their capacity to offer treatment. Therefore, there was little or no 
clinical or surgeon selection bias, which explains why, despite the lack of formal 
randomization, the UGFS and SVS groups were so similar.  
Another limitation of the present study was the discrepancy in size of the UGFS and 
SVS cohorts, although this was unlikely to have resulted in any systematic bias. 
Assessment of severity of bruising and pain were subjective, and decided by the 
patient. This could have been improved by objective assessment of bruising in a 
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follow-up clinic, and by using a validated pain score, but arguably the patient’s 
assessment of his or her post-operative recovery remains the most important 
outcome measure. 
In conclusion, this questionnaire study showed that, when compared with SVS, 
UGFS was associated with significantly less pain, bruising and analgesia use, and 
time off work and driving. The low incidence of complications in the UGFS group 
gives further evidence of its safety.  
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CHAPTER 4. PATIENT-REPORTED OUTCOMES 
FOLLOWING ULTRASOUND-GUIDED FOAM 
SCLEROTHERAPY 
Extended outcome measures, including patient-reported outcomes, are useful for 
measuring the success of any intervention for VV particularly when the clinical 
efficacy is similar. These outcomes give health providers more information about the 
patient’s experience of the disease and the effectiveness of any intervention.  
In this Chapter I will be looking at measures of functional status (HRQL) and also 
patient satisfaction by examining the patient’s expectations of treatment, and whether 
these expectations are met. 
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4.1  Changes in health-related quality of life following ultrasound-
guided foam sclerotherapy for great and small saphenous 
varicose veins 
The data contained within this Chapter were 
 presented at the International Surgical Congress of the Association of 
Surgeons of Great Britain and Ireland in Glasgow, UK in May 2009 
 published in the Journal of Vascular Surgery in April 2010 (Darvall et al., 
2010b).  
 
4.1.1 Introduction 
Measuring HRQL is a comprehensive way to assess the effect of VV on patients, and 
whether surgical interventions produce improvement. (Smith et al., 1999) Valuable 
information is gained on the patient-perceived burden of illness. The use of both 
generic and disease-specific measures is important when HRQL is assessed, and a 
variety of venous disease-specific measures have been developed and validated.  
CVD, including VV and CVU, is associated with a reduced HRQL. (Smith et al., 1999; 
Kaplan et al., 2003; Sam et al., 2004a; Kahn et al., 2004) Both disease-specific and 
generic HRQL improve following SVS for VV, (Baker et al., 1995; Smith et al., 1999; 
Durkin et al., 2001; MacKenzie et al., 2002a; MacKenzie et al., 2002b; Sam 2004b, 
Subramonia and Lees, 2005) and this is also the case with EVLA and RFA. (Rautio 
et al., 2002; Lurie et al., 2003) The effects of UGFS on HRQL are unknown.  
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The aim of this study, therefore, is to determine the effect of UGFS for VV on both 
generic and disease-specific HRQL.  
 
4.1.2 Methods 
4.1.2.1 Patients and follow-up 
Following local ethical committee approval and obtaining written informed consent, 
consecutive patients undergoing UGFS between April 2005 and May 2007 were 
invited to take part in the study (as per Section 2.1.2.1).  
To be considered suitable for UGFS patients had to have symptomatic, CEAP C2-6 
venous disease (i.e. treatment was not offered for cosmetic indications) and 
significant (>0.5s) reflux in the GSV or SSV. 
HRQL questionnaires were posted to all patients one week prior to treatment, and at 
one, six and 12 months after treatment. If patients were having bilateral treatments 
these were done at least four weeks apart, and the questionnaires were completed 
one, six and 12 months after the first treatment to the first leg. No reminders were 
sent. Patients who did not bring the completed questionnaires with them to their first 
treatment session were excluded from the study. 
 
4.1.2.2 HRQL questionnaires 
The HRQL questionnaires were a generic measure, the SF12 (Appendix 1) and a 
disease-specific measure, the AVSS (Appendix 2).  
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The SF12 consists of 12 questions about general health and provides two summary 
scores, the PCS which represents physical functioning, and the MCS which 
represents mental functioning. The mean PCS and MCS of the general population is 
50 with a standard deviation of 10: the higher the score, the better the HRQL.  
The AVSS comprises 13 questions about leg symptoms and provides a final score 
between 0 and 100; a higher score denotes a poorer disease-specific HRQL.  
 
4.1.2.3 UGFS treatment 
UGFS treatment was performed as described in Section 2.1.2.3. 
 
4.1.2.4 Statistical analysis 
SPSS version 17.0 was used for data analysis. Mann-Whitney U test (MWU, for 
numerical variables) and Χ2 test (categorical variables) were used as appropriate to 
determine any significant differences between responders and non-responders at 
each time-point. Wilcoxon signed ranks test (WSR) was used to assess the intra-
group change in PCS, MCS and AVSS following treatment, and MWU test was used 
to determine inter-group differences in HRQL scores between sub-groups. 
 
4.1.3 Results 
4.1.3.1 Patients 
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Questionnaires were sent to 351 consecutive patients between April 2005 and May 
2007, and 296 (84.3%) returned questionnaires and agreed to enrol in the study. 
Table 4.1 summarizes the baseline characteristics for each patient. Treatment was to 
the GSV alone in 221 patients (74.7%), to the SSV alone in 30 (10.1%), and to both 
the GSV and SSV in 45 (15.2%). Deep and superficial reflux was combined in 12 
patients. A second treatment was required in 72 legs (18%) before 12 months; two of 
these had three treatment sessions.  
 
Table 4.1  Demographic data of responders 
  
Pre-
treatment 
responders 
 
  
1 month 
responders 
 
  
6 month 
responders 
  
12 month 
responders 
 
No. of patients 
 
Age: in years† 
 
Sex: male‡ 
 
Recurrent disease‡ 
 
Bilateral disease‡ 
 
Pre-treatment: 
  CEAP C4-6, worst leg‡ 
   
  PCS† 
   
   
  MCS† 
   
 
  AVSS† 
 
 
296 
 
57 (45-67) 
 
102 (34) 
 
72 (24) 
 
99 (33) 
 
 
102 (34) 
 
  
242 
 
57 (46-67) 
 
82 (34) 
 
54 (22) 
 
79 (33) 
 
 
74 (32) 
 
 
47.1  
(39.9-53.2) 
 
52.6 
(43.5-57.3) 
 
19.0 
(12.7-26.2) 
 
  
216 
 
60 (49-69) 
 
76 (35) 
 
45 (21) 
 
69 (32) 
 
 
77 (36) 
 
 
46.5 
(38.2-52.6) 
 
52.4 
(42.3-57.5) 
 
19.6 
(12.7-27.1) 
  
204 
 
59 (48-69) 
 
66 (32) 
 
45 (22) 
 
69 (34) 
 
 
68 (33) 
 
 
47.0 
(39.9-53.1) 
 
53.6 
(44.8-57.9) 
 
18.5 
(12.6-25.7) 
 
Values in table are median (IQR)† or number (percentage)‡ 
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Of the 296 patients entered into the study, 242 returned questionnaires at one month 
(81.8%), 216 at six months (73.0%) and 204 at 12 months (68.9%). There were no 
significant differences between responders and non-responders both pre-treatment 
and at one month in terms of age, gender, previous SVS, bilateral disease and CEAP 
clinical grade. (Table 4.1) Patients who returned questionnaires six and 12 months 
after treatment were significantly older than non-responders with a median difference 
of 13 years at six months (P < .0005, MWU), and a median difference of seven years 
at 12 months (P < .0005, MWU). 
Pre-treatment median PCS was significantly worse (lower) in responders than non-
responders at six months (46.5 versus 48.4, P = .017, MWU); pre-treatment median 
MCS was significantly better (higher) in responders at 12 months (53.6 versus 49.8, 
P = .010, MWU). No other differences in pre-treatment scores between responders 
and non-responders were documented at each evaluation.  
 
4.1.3.2 Physical component summary score of SF12 (PCS) 
The PCS significantly improved during the first month after treatment, from a median 
at baseline of 47.6 to 49.4 (P = .008; WSR), and continued to 51.9 (P < .0005) at six 
months and to 52.9 (P < .0005) at 12 months (Figure 4.1). Further significant 
improvement was also seen between both one and six months (49.4 versus 51.9, P < 
.0005), and six and 12 months (51.9 versus 52.9, P < .0005) (Figure 4.1).  
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Figure 4.1 Box and whisker plot indicating SF12 PCS before and at 1, 6 and 12 
months after UGFS  
 
The horizontal line inside each box indicates the median; the box itself represents the IQR. 
Dots represent outliers which are observations lying more than 1.5 times the IQR from the first 
or third quartile. Asterisks represent extremes which are values more than 3 times the IQR 
above or below the third or first quartile respectively. Whiskers represent the largest and 
smallest values that are not outliers or extremes. The reference line is set at 50, the general 
population mean. 
 
 
4.1.3.3 Mental component summary score of SF12 (MCS) 
There was a significant improvement in MCS during the first month after treatment, 
from a median of 52.4 to 55.1 (P < .0005; WSR), but this was not sustained at six 
and 12 months post-treatment (Figure 4.2). 
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Figure 4.2 Box and whisker plot indicating SF12 MCS before and at 1, 6 and 12 
months after UGFS 
 
 
4.1.3.4 Aberdeen Varicose Vein Symptom Severity Score (AVSS) 
AVSS significantly improved after treatment from a median baseline of 19 to 16.5 at 
one month (P < .0005), which continued to improve to 8.7 at 6 months (P < .0005) 
and to 8.6 at 12 months (P < .0005) (Figure 4.3).  
There was also further significant improvement seen between one and six months 
(16.5 versus 8.7, P < .0005), but not after six months (8.7 versus 8.6, P = .702) 
(Figure 4.3). 
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Figure 4.3 Box and whisker plot indicating AVSS before and at 1, 6 and 12 months 
after UGFS 
  
 
 
4.1.3.6 Subgroup analyses 
There were no differences in PCS, MCS or AVSS according to whether the treated 
vein was GSV alone or SSV alone, and no differences in PCS or MCS according to 
whether the treated veins were primary or recurrent. 
AVSS was significantly higher (worse) at all measured intervals in patients treated for 
recurrent VV (Table 4.2, Figure 4.4). Both groups of patients showed similar 
improvement during the 12 months after treatment (Table 4.2, Figure 4.4). 
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Table 4.2 Changes in AVSS after UGFS in patients with primary and recurrent VV 
 
  
Primary 
 
Recurrent 
  
P† 
 
 
AVSS 
 
Pre-treatment 
 
1 month 
 
6 months 
 
12 months 
 
 
Change in AVSS‡ 
 
0-1 month 
 
0-6 months 
 
0-12 months 
 
 
 
18.0 (12.3-25.2) 
 
16.0 (11.0-21.8) 
 
7.5 (3.4-14.2) 
 
8.2 (2.4-14.6) 
 
 
 
 
P<.0005 
 
P<.0005 
 
P<.0005 
 
 
 
 
23.3 (16.6 -30.4) 
 
20.2 (13.1-26.5) 
 
12.0 (6.9-16.2) 
 
12.3 (6.4-20.2) 
 
 
 
 
P=.109 
 
P<.0005 
 
P<.0005 
  
 
 
.001 
 
.006 
 
.002 
 
.005 
Values are median (IQR); † = P value from MWU test; ‡ = P values from WSR test 
 
 
Figure 4.4 Changes in AVSS after UGFS in patients with primary and recurrent VV 
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There was no difference in MCS according to whether the treated veins were 
uncomplicated (CEAP C2-3) or complicated (CEAP C4-6). PCS was significantly lower 
(worse) at all measured intervals in patients treated for complicated VV (Table 4.3, 
Figure 4.5). PCS improved significantly during the 12 months after treatment in both 
uncomplicated and complicated VV compared with pre-treatment values (Table 4.3, 
Figure 4.5). The improvement in PCS was greater in those with uncomplicated VV.  
 
Table 4.3 Changes in SF12 PCS after UGFS in patients with uncomplicated 
(CEAP C2-3) and complicated (CEAP C4-6) VV 
 
  
Uncomplicated 
C2-3 
 
 
Complicated 
C4-6 
  
P† 
 
 
PCS 
 
Pre-treatment 
 
1 month 
 
6 months 
 
12 months 
 
 
Change in PCS‡ 
 
0-1 month 
 
0-6 months 
 
0-12 months 
 
 
 
 
49.1 (41.6-53.9) 
 
50.1 (43.8-55.3) 
 
53.9 45.8-55.9) 
 
53.7 (46.4-55.9) 
 
 
 
 
P=.085 
 
P<.0005 
 
P<.0005 
 
 
 
 
45.0 (32.9-51.5) 
 
47.6 (38.0-52.8) 
 
45.9 (36.1-53.5) 
 
47.3 (34.3-54.8) 
 
 
 
 
P=.044 
 
P=.014 
 
P=.327 
  
 
 
.001 
 
.022 
 
<.0005 
 
<.0005 
Values are median (IQR); † = P value from MWU test; ‡ = P values from WSR test 
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Figure 4.5 Changes in SF12 PCS after UGFS in patients with uncomplicated 
(CEAP C2-3) and complicated (CEAP C4-6) VV 
 
 
 
AVSS was significantly higher (worse) at all measured intervals in patients treated for 
complicated VV (Table 4.4, Figure 4.6). Both groups of patients showed similar 
improvement during the 12 months after treatment (Table 4.4, Figure 4.6). 
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least 12 months.  
Despite previously held beliefs that VV are simply a cosmetic issue for most patients, 
several studies have shown poorer generic HRQL (particularly in physical domains) 
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similar to those previously reported for patients with chronic obstructive pulmonary 
disease, osteoarthritis or angina. (Kahn et al., 2004)  
When outcomes of treatment are assessed, it is important to consider change in 
HRQL with disease-specific as well as generic measures. Generic HRQL measures 
allow the NHS to compare interventions to enable appropriate allocation of 
resources. Disease-specific measures for VV are useful for demonstrating non-
inferiority of the newer minimally invasive techniques compared with traditional SVS. 
 
Table 4.4 Changes in AVSS after UGFS in patients with uncomplicated (CEAP 
C2-3) and complicated (CEAP C4-6) VV 
 
  
Uncomplicated 
C2-3 
 
 
Complicated 
C4-6 
  
P† 
 
 
AVSS 
 
Pre-treatment 
 
1 month 
 
6 months 
 
12 months 
 
 
Change in AVSS‡ 
 
0-1 month 
 
0-6 months 
 
0-12 months 
 
 
 
 
17.3 (12.0-22.6) 
 
15.8 (10.9-21.0) 
 
7.3 (4.0-12.6) 
 
7.7 (3.3-13.3) 
 
 
 
 
P=.068 
 
P<.0005 
 
P<.0005 
 
 
 
 
26.6 (17.5-35.8) 
 
18.5 (13.7-27.6) 
 
11.5 (5.4-20.4) 
 
12.6 (5.0-18.8) 
 
 
 
 
P<.0005 
 
P<.0005 
 
P<.0005 
  
 
 
<.0005 
 
<.0005 
 
<.0005 
 
.006 
Values are median (IQR); † = P value from MWU test; ‡ = P values from WSR test 
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Figure 4.6 Changes in AVSS  after UGFS in patients with uncomplicated (CEAP 
C2-3) and complicated (CEAP C4-6) VV 
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one month after SVS in two studies, (Smith et al., 1999; Chetter et al., 2006) 
although no change was seen in mental health in the studies with longer follow-up. 
This is similar to the findings of the current study where physical functioning (PCS) 
showed sustained improvement as early as one month after UGFS, whereas mental 
health (MCS) showed an early, but short-lived, improvement. RCTs comparing 
improvement in generic HRQL after EVLA and SVS, found similar improvements in 
the physical domains of SF36 between three months and two years after treatment. 
(Rasmussen et al., 2007; Christenson et al., 2010; Rasmussen et al., 2010; 
Carradice et al., 2011) Only Carradice et al. looked at HRQL one week post-
treatment and found that patients undergoing EVLA had significantly less 
deterioration in generic physical HRQL after one week than those undergoing SVS. 
(Carradice et al., 2011) 
The SF12 is a fully-validated adaptation of the SF36 that is quicker to complete and 
has been shown to give results comparable to those of the SF36. (Jenkinson et al., 
1997; Hurst et al., 1998; Ware et al., 2002) Our group has previously looked at 
improvement in SF12 after SVS and found, as expected, similar significant 
improvements in physical HRQL at three, six and 12 months, but no improvement in 
mental HRQL. (Sam et al., 2004a; Sam et al., 2006) Shepherd et al. used the SF12 
in their RCT comparing EVLA and RFA and found similar improvements six weeks 
after treatment. (Shepherd et al., 2010a) 
 The AVSS has been the most widely used disease-specific measure in assessing 
VV treatment, including conventional SVS and EVLA. AVSS appears to worsen 
slightly one to two weeks after SVS before reaching pre-treatment levels or, more 
commonly, improving by four to six weeks. (Smith et al., 1999; MacKenzie et al., 
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2002a; MacKenzie et al., 2002b; Subramonia and Lees, 2005; Chetter et al., 2006; 
Rasmussen et al., 2007) Similar results were also found after EVLA and RFA, 
(Theivacumar et al., 2007; Darwood et al., 2008; Theivacumar et al., 2008; Carradice 
et al., 2009; Shepherd et al., 2010a; Subramonia and Lees, 2010) with one RCT 
documenting no difference in the improvement seen between EVLA or conventional 
SVS out to three months. (Rasmussen et al., 2007) One study compared SVS (SFJ 
ligation, stripping of the GSV, and multiple stab avulsions) with a combination of SVS 
(SFJ ligation alone) and UGFS. (Bountouroglou et al., 2006) Both groups showed 
similar improvement in AVSS with three months follow-up. In studies that have 
looked at improvement beyond three months, an RCT by Darwood et al. found 
similar sustained improvement in AVSS in SVS and EVLA groups at one year, 
(Darwood et al., 2008) and our group found sustained improvement in AVSS at 2 
years after SVS. (MacKenzie et al., 2002a; MacKenzie et al., 2002) 
Two studies used the Chronic Venous Insufficiency Questionnaire (CIVIQ), an 
alternative validated disease-specific HRQL measure, (Launois et al., 1996) to 
assess change after treatment. One multicentre RCT compared CIVIQ scores at 
three months after sclerotherapy with either 3% polidocanol foam or 3% polidocanol 
liquid. (Rabe et al., 2008) Patients in both treatment groups improved, but 
improvement was greater in the foam group. The other study, also an RCT, 
compared CIVIQ scores out to four months after SVS or RFA, and found similar 
improvements at four months, but a quicker improvement in HRQL, in the RFA group. 
(Lurie et al., 2003) 
The current study provides further evidence that VV treatment results in significantly 
improved generic and disease-specific HRQL. In particular, to our knowledge, this is 
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the first study of its kind to look specifically at UGFS, and thus allows UGFS to be 
compared with other treatments for VV and also interventions available for other 
conditions to aid allocation of healthcare resources. The other studies looking at 
HRQL after UGFS are limited because of short follow-up, by the use of only a 
disease-specific instrument, (Rabe et al., 2008) by looking at a combination of SVS 
and UGFS, (Bountouroglou et al., 2006) or by simply asking patients whether their 
quality of life had improved. (Barrett et al., 2004) 
Our previous studies have shown that recurrent VV are more symptomatic at 
baseline than primary VV, and that the improvement in HRQL (measured by AVSS) 
after SVS for recurrent VV is less than that achieved for primary disease. (MacKenzie 
et al., 2002b) The results from the current study after UGFS were very similar. The 
degree of improvement in AVSS after UGFS for recurrent VV paralleled that for 
primary VV, yet the HRQL was significantly worse in the recurrent VV group at all 
follow-up intervals.  One advantage of UGFS is that it is easy to treat recurrent VV 
when compared with redo SVS. 
As expected, AVSS in patients with complicated VV (CEAP C4-6) was worse at each 
follow-up interval than in those with uncomplicated VV (CEAP C2-3), as previously 
found in SVS patients. (MacKenzie et al., 2002b) Interestingly, the patients with 
uncomplicated VV had a much greater improvement in PCS during the 12 months 
after UGFS than those with complicated VV, suggesting that even though 
uncomplicated VV are considered a relatively minor problem, patients have as much, 
if not more, to gain from treatment than complicated VV. Indeed, two recent trials 
have shown that SVS for uncomplicated VV provides significant benefit over 
conservative treatment in terms of health status, HRQL and patient satisfaction at a 
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relatively small cost, (Michaels et al., 2006; Ratcliffe et al., 2006) yet rationing of 
treatment for uncomplicated symptomatic VV remains widespread. (Nasr et al., 2008) 
A limitation of the current study is the number of questionnaires available for follow-
up analysis. A 69% response rate at 12 months is not as good as we had hoped but 
is comparable with other questionnaire studies, and better than many involving VV 
patients. The response rate could likely have been improved if reminders had been 
sent to non-responders, or if the questionnaires were administered in a face-to-face 
interview, but this would have introduced interviewer bias. The initial sample size was 
also large enough that the power of the study was not compromised. 
Another limitation is the lack of a control group. We do not apologise for this as this is 
an observational study of our practice, and according to our experience in the last 
few years, over 90% of our patients prefer to have UGFS and would therefore not 
consent to be randomised to SVS or UGFS. In addition, we have already published 
HRQL results after conventional SVS. (MacKenzie et al., 2002a; MacKenzie et al., 
2002b; Sam et al., 2004a; Sam et al., 2006) 
Further study is of course required to ascertain the longevity of the HRQL 
improvement seen after UGFS, and indeed after EVLA and RFA, and we are 
continuing follow-up of our cohort. 
In conclusion, significant improvements are seen in both generic and disease-specific 
HRQL following UGFS and this is sustained to at least 12 months after treatment. 
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4.2 Patients’ expectations before and satisfaction after ultrasound 
guided foam sclerotherapy for varicose veins 
The data contained within this Chapter were 
 presented at the International Surgical Congress of the Association of 
Surgeons of Great Britain and Ireland in Glasgow, UK in May 2009 
 published in the European Journal of Vascular and Endovascular Surgery in 
November 2009 (Darvall et al., 2009d). 
 
4.2.1 Introduction 
Up to 20% of patients have reported dissatisfaction with SVS and such surgery 
remains the commonest cause of litigation against vascular surgeons in the UK. 
(Davies et al., 1995; Ray, 2005; Scurr and Scurr, 2005) It has been suggested that 
this is due to unrealistic expectations of surgery. (Davies et al., 1995; MacKenzie et 
al., 2002b; Ray, 2005; Scurr and Scurr, 2005) However, unless one knows what 
those expectations are and understands the limitations of the treatments one is 
offering, one cannot define what is unrealistic and what is not. When specifically 
asked, most patients admit to having a wide variety of expectations in relation to their 
VV treatment, many of them probably unanticipated by the clinician. It is perhaps not 
surprising, therefore, that the patient and the clinician can find themselves 
inadvertently talking at cross-purposes with resulting dissatisfaction and even 
recourse to medico-legal action. (Ray, 2005)  
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The aim of this study, therefore, is to examine patients’ expectations before and 
satisfaction after UGFS for VV in terms of relief of lower limb symptoms, 
improvement in appearance, and beneficial effect on lifestyle. 
 
4.2.2 Methods 
4.2.2.1 Patients 
Following local ethical committee approval and obtaining written informed consent, 
consecutive patients undergoing UGFS for symptomatic VV between April 2005 and 
May 2007 were invited to take part in the study (as per Section 2.1.2.1).   
Questionnaires were sent to 351 patients (464 treated legs) one week prior to 
(Appendix 5) and six months after (Appendix 6) treatment.  
To be considered suitable for UGFS patients had to have symptomatic, CEAP C2-6 
venous disease (i.e. treatment was not offered for cosmetic indications) and 
significant (>0.5s) reflux in the GSV or SSV on DUS.  
 
4.2.2.2 Pre-treatment assessment 
Patients were examined and the severity of venous disease according to the CEAP 
clinical classification was determined (Table 1.1). 
DUS was performed, as described in Section 2.1.2.2, at the initial clinic attendance 
in order to identify sites of superficial, deep and communicating venous reflux. 
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4.2.2.3 UGFS treatment 
UGFS treatment was performed as described in Section 2.1.2.3. 
 
4.2.2.4 Pre-treatment questionnaire 
Section 1 asked how much improvement was expected in lower limb symptoms (pain 
or aching, itching, tingling, cramps, restless legs, swelling and heaviness). The 
answers were sought separately for each leg to be treated. Section 2 asked about 
expected improvements in appearance, life-style (choice of clothes, work 
performance, social and leisure activities) and relationships. Possible responses 
were ‘an awful lot’, ‘a lot’, ‘quite a bit’, ‘a little’, and ‘not at all’ or ‘I do not have this 
symptom’. 
 
4.2.2.5 Post-treatment questionnaire  
Patients were asked to grade the improvement (if any) that they had experienced in 
terms of symptoms, appearance, life-style and relationship using the same menu of 
responses. Pre- and post-treatment questionnaires were compared to ascertain 
whether expectations had been met. 
 
4.2.2.6 Analysis 
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The responses ‘an awful lot’ and ‘a lot’ were grouped together to represent ‘a 
significant improvement’, and the responses ‘quite a bit’ and ‘a little’ were combined 
to signify ‘a moderate improvement’.  
Symptoms were analysed by the number of limbs treated; other outcomes by number 
of patients. Subgroup analysis was performed to determine the effects of age, 
gender, CEAP clinical grade, and previous SVS on the expectations and whether 
they were met using Chi-squared (χ2). SPSS version 17.0 was used for data 
analysis. 
 
4.2.3 Results 
4.2.3.1 Patient characteristics and response rates 
The pre-treatment questionnaire was returned by 282 (80.3%) patients, and 281 
(80.1%) returned the post-treatment questionnaire (Table 4.5); 209 patients (59.5%) 
completed both questionnaires. Patients who completed post-treatment 
questionnaires (median age 59 years, IQR 48-68 years for responders; median 49 
years, IQR 39-61 years for non-responders; P < .0005, MWU) and those who 
returned both questionnaires (median age 60 years, IQR 50-69 years for responders; 
median age 51 years, IQR 40-62 years for non-responders; P < .0005, MWU) were 
significantly older than the non-responders. Otherwise, there were no significant 
differences between responders and non-responders including gender, CEAP clinical 
grade, and the proportion being treated for recurrent disease after previous SVS 
. 
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Table 4.5 Demographic data of responders 
 
  
Pre-treatment 
responders 
 
 
Post-treatment 
responders 
 
 
No. of patients 
 
No. of legs 
 
Age: median (IQR) in years 
 
Male sex† 
 
Bilateral† 
 
Recurrent‡ 
 
CEAP C2 or C3‡ 
 
282 
 
373 
 
57 (45-67) 
 
100 (35.5) 
 
91 (32.3) 
 
107 (28.7) 
 
249 (66.8) 
 
281 
 
365 
 
60 (50-69) 
 
99 (35.2) 
 
84 (29.9) 
 
96 (26.3) 
 
258 (70.7) 
 
 
Values in parentheses are percentages of patients† or legs‡ 
 
 
Figure 4.7 Percentage of limbs in which a significant or moderate improvement in 
each lower limb symptom was expected prior to treatment 
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4.2.3.2 Lower limb symptoms 
These data were analysed by leg. Pre-treatment questionnaires were returned for 
373 legs (80.4%), post-treatment questionnaires for 365 legs (78.7%), and both 
questionnaires for 270 legs (58.2%). Pain or ache was the most common symptom 
being present in 84.7% of legs. Itching, restlessness, swelling, heaviness and cramp 
were less common occurring in 70.2%, 64.6%, 64.1%, 60.9% and 55.2% of the legs 
respectively; and tingling was the least common symptom occurring in only 37.5% of 
legs. A significant improvement in symptoms was expected in around one-third of 
legs, and a moderate improvement in the remaining two-thirds (Figure 4.7). Between 
48.8% and 63.2% of legs had a significant improvement in symptoms after UGFS, 
around 10% showed no improvement at all (Figure 4.8).  
 
Figure 4.8 Percentage of limbs with improvement in lower limb symptoms six 
months following treatment 
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Expectations in respect of lower limb symptoms were met or exceeded in around 
80% of legs (Figure 4.9). 
 
Figure 4.9 Percentage of limbs in which expectations of improvement in each 
lower limb symptom were exceeded, met or unmet 
 
 
Patients who had had previous SVS were less likely to have their expectations met 
than those with primary veins in terms of pain (71% versus 83.3%, P = .042), tingling 
(58% versus 91%, P = .002), and restless legs (66% versus 83%, P = .033).  
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These data are analysed by patient. Over 90% of patients expected an improvement 
in the appearance of their legs (Figure 4.10); 96.1% of patients experienced a 
significant cosmetic improvement (Figure 4.11); and 85.6% of patients had their pre-
intervention cosmetic expectations met (Figure 4.12). 
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Figure 4.10 Percentage of patients expecting an improvement in appearance, and 
social and leisure activities prior to treatment 
 
 
 
4.2.3.4 Life-style benefits 
Approximately two-thirds of patients expected to be able to wear different clothes as 
well as an improvement in their working performance and social and leisure activities 
clothes as a result of their treatment (Figure 4.10). Over 50% of patients experienced 
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(Figure 4.11).  However, over 80% who had hoped for such an improvement had 
their expectations met or in a quarter of cases exceeded (Figure 4.12). 
 
Figure 4.11 Percentage of patients who had an improvement in appearance, and 
social and leisure activities six months after treatment 
 
 
Figure 4.12 Percentage of patients in whom the expected improvements in 
appearance, social and leisure outcomes were exceeded, met or unmet 
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4.2.3.6 Factors affecting outcomes 
There was no difference in terms of cosmetic and social expectations according to 
whether the patient had had previous SVS or not. Younger patients (<55 versus ≥55 
yrs) were significantly more likely to be expecting an improvement in appearance of 
their legs (96.0% versus 89.2%, P = .034), and the same was true for C2 disease 
compared with C5/6 (97.5% versus 68%, P < .0001). Women (80.8% versus 49.0%, P 
< .0001), patients <55 yrs (77.6% versus 64.3%, P = .016) and C2 patients (versus 
C5/6; 77.5% versus 46%, P = .0001) were all more likely to expect improvements in 
their ability to wear different clothes after treatment. There were no observed 
differences in expectations of improvement in terms of work, relationships and social 
and leisure activities by gender, age, previous SVS or CEAP clinical grade.  
 
4.2.4 Discussion 
The main finding of this study is that UGFS for VV produces significant improvements 
in lower limb symptoms, cosmetic appearance, life-style and relationships in the 
majority of patients. Furthermore, the great majority who expect such benefits have 
their expectations met or exceeded. 
Virtually all patients were expecting treatment to improve their lower limb symptoms, 
and most did report such an improvement and had their expectations met or 
exceeded. In this regard, UGFS appears to be at least as effective as SVS, (Davies 
et al., 1995; Campbell et al., 2003; Barrett et al., 2004; Michaels et al., 2006) RFA 
and EVLA. (Subramonia and Lees, 2007; Gandhi et al., 2010) 
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The cosmetic aspects of VV treatment are well-recognised and in this series over 
90% patients were expecting an improvement in the appearance of their legs. (Baker 
et al., 1995; Michaels et al., 2006) As has been reported by others after UGFS, 
(Barrett et al., 2004) 96% of patients experienced such an improvement, and more 
than 85% of patients had their cosmetic expectations met or exceeded.  Again, these 
data suggest that UGFS is at least as effective as other treatments for VV. (Rautio et 
al., 2002; Gandhi et al., 2010) 
Perhaps not surprisingly, these favourable physical and cosmetic outcomes 
translated into a range of significant life-style benefits such as the ability to wear 
different clothes, improved work performance, and more satisfying social and leisure 
activities for those that wished them.  This supports a number of studies showing that 
CVD has a greater effect on physical (‘what a person can do’) rather than mental 
(‘how a person feels’) status. (Baker et al., 1995; Kurz et al., 2001; Kaplan et al., 
2003; Sam et al., 2004a) However, these parameters are obviously interconnected. 
Thus, UGFS also resulted in improvements in the quality of personal relationships in 
those patients who were seeking such benefits with the majority having their 
expectations met or exceeded. 
Several studies have demonstrated that conventional SVS, EVLA, RFA and UGFS 
for VV results in significant improvement in HRQL as determined by validated 
disease-specific and generic instruments (see Section 4.1.4).  However, such 
studies and instruments do not allow patients to express their individual expectations 
of treatment and to what extent these expectations were met. The present type of 
study therefore adds value to traditional HRQL research in this patient group by 
personalising the treatment aims and by reducing the risks of the patient and the 
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clinician talking at cross-purposes when discussing the risks and benefits of 
intervention. (Davies et al., 1995; Jackson and Kroenke, 2001; Kravitz, 2001; 
Campbell, 2006; Shepherd et al., 2010b) 
Although the primary purpose of this study was not to compare UGFS with other 
treatments for VV, it is worth noting that when overall patient satisfaction has been 
assessed after SVS  it has been found wanting, (Bradbury et al., 2000) with only 23% 
reporting ‘complete satisfaction’ and 26% reporting being ‘very dissatisfied’ up to ten 
years after SVS. (Davies et al., 1995) It seems likely that many medicolegal claims 
following SVS result from a lack of understanding, poor history taking and 
communication. (Davies et al., 1995; MacKenzie et al., 2002b; Campbell et al., 2002; 
Ray, 2005; Scurr and Scurr, 2005; Campbell et al., 2006; Michaels et al., 2006; 
Campbell et al., 2007)  
More recently three further RCTs have reported patient satisfaction rates. The first 
found only 27% (11/41) SVS patients and 57% (27/47) RFA patients to be completely 
satisfied five weeks after treatment. (Subramonia and Lees, 2010) Pronk et al. found 
79% and 77% of SVS and EVLA patients would have the treatment done on the 
other leg if necessary; (Pronk et al., 2010) and at two years patient satisfaction rates 
were 90% and 88% respectively in the SVS and EVLA groups in the final study. 
(Theivacumar et al., 2009b) A further questionnaire study by Gandhi et al. found that 
151/176 (85.8%) were satisfied with their treatment after endothermal ablation; they 
also found that patients being treated for recurrent VV were more likely to be 
dissatisfied (25% versus 8%). (Gandhi et al., 2010) 
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In this study the questionnaires were administered by post. The self-completion 
method was chosen, rather than a face-to-face or telephone interview to reduce the 
likelihood of introducing interviewer or social desirability bias. Self-administration, 
however, could also introduce bias due to respondents’ lack of comprehension or 
motivation. Response rates were good at each time-point (around 80%), and 
although both questionnaires were available for only 60% of the cohort, this is 
comparable to other questionnaire studies in VV patients of 59-85%. (Baker et al., 
1995; Smith et al., 1999; Durkin et al., 2001; Campbell et al., 2007; Gandhi et al., 
2010; Shepherd et al., 2010b) Systematic bias in the loss of respondents is unlikely 
as those who were unhappy with treatment may be more likely to respond. 
In conclusion, we have found that when specifically asked most patients admit to 
having a wide range of different expectations in relation to their VV treatment. Many 
of these expectations may be unanticipated by the clinician and thus remain 
unknown to them unless specifically sought during patient interview. Present data 
indicate that UGFS is usually able to meet, and often exceeds, these physical and 
psychosocial needs and expectations six months after treatment. UGFS is, therefore, 
a highly effective treatment for VV from the patients’ perspective. 
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CHAPTER 5. SUMMARY, CONCLUSIONS AND PROSPECTS FOR 
FUTURE RESEARCH 
5.1 Key findings of this thesis 
The aim of this Thesis was to investigate the role of UGFS in the management of 
CVD and began with two studies of the technical and clinical efficacy of UGFS in the 
treatment of GSVV (Chapter 2). I showed that UGFS was an effective treatment for 
both primary (Section 2.1) and recurrent GSVV (Section 2.2). Specifically, UGFS 
eradicated reflux in almost 100% of patients and left no visible VV in around 90% of 
legs, similar to EVLA and RFA as reported in meta-analysis. (Van den Bos et al., 
2009) Although recanalisation rates at 12 months, while superior to those often 
reported after SVS, were somewhat higher than many report following EVLA or RFA, 
recanalisation was easily and successfully treated in our patients with a single further 
treatment. Furthermore, in some studies, less than half of patients with recurrent 
GSVV were amenable to treatment with either of the catheter-based techniques. 
(Goode et al., 2009) UGFS also has the advantage of being able to eradicate, 
without any risk of nerve injury, BK-GSV reflux which is well recognised as an 
important source of recurrent disease. (Theivacumar et al., 2009a; van Neer et al., 
2009) 
In Section 2.3 I found that UGFS was also an effective treatment for primary and 
recurrent SSVV, eradicating reflux in 100% of cases and leaving no visible VV in over 
95% of legs. Recanalisation rates at 12 months were similar to those reported in the 
literature for SVS, (O’Hare et al., 2008b) but higher than that reported by some 
workers following EVLA. (Desmyttere et al., 2010) However, EVLA is only suitable for 
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around 70% of patients with SSV reflux. (Theivacumar et al., 2007) As with GSVV, if 
recanalisation requiring re-treatment occurs after UGFS, it is quick, safe, and both 
clinically and cost-effective. 
In the final section of Chapter 2 (Section 2.4) I examined the effect of UGFS on CVU 
healing and recurrence rates. In this small pilot study of 28 legs, I found that 96% of 
CVU were healed within three months, with only a 7% recurrence rate at 12 months. 
These results are superior to those reported in the literature for either compression 
alone or compression combined with SVS, (Barwell et al., 2004) and suggest that 
UGFS is a useful adjunct to compression. Two other small studies have recently 
reported similarly encouraging results using UGFS to treat SVS in association with 
CVU, (Hertzman and Owens, 2007; O’Hare et al., 2010) and we have recently 
published the results of a larger study with longer follow-up that reproduces these 
results. (Pang et al., 2010) We offer UGFS to our CVU patients as long as they are 
able to comply with the post-operative instructions for mobilisation. 
Having established the technical and clinical efficacy of UGFS, I went on to examine 
safety and morbidity (Chapter 3). In Section 3.1 I found that patients undergoing 
UGFS reported significantly less pain, bruising and analgesia usage, and also 
returned to normal activities faster than patients treated with SVS. UGFS was also 
safe with only one DVT and three episodes of blurred vision following 418 
treatments. Recovery from UGFS appears to be quicker and associated with less 
morbidity than SVS and also EVLA and RFA. (Darwood et al., 2009; Goode et al., 
2010; Subramonia and Lees, 2010; Shepherd et al., 2010a; Carradice et al., 2011) 
This study has allowed us to give more accurate information about post-treatment 
recovery to our patients. Taken together with our recently published prospective 
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series of 977 patients, these data indicate that UGFS is a safe and clinically effective 
treatment for SVR. (Bradbury et al.,2010)  
In Chapter 4 I utilised questionnaires to assess the patient’s experience of venous 
disease and its treatment (patient-reported outcomes). The first study (Section 4.1) 
was designed to examine the changes in HRQL following UGFS for symptomatic VV. 
I demonstrated that UGFS resulted in significant improvements in both generic 
(mainly in physical domains) and disease-specific HRQL, and that these 
improvements continued for at least 12 months after treatment and were comparable 
to those reported after SVS, EVLA and RFA. (Darwood et al., 2008; Theivacumar et 
al., 2008; Rasmussen et al., 2010; Christenson et al., 2010; Shepherd et al., 2010a; 
Subramonia and Lees, 2010; Carradice et al., 2011) To our knowledge, this was the 
first study to examine changes in HRQL after UGFS and will facilitate further work 
comparing the cost-effectiveness of different treatments. Interestingly, the 
improvement in generic HRQL was greater in those patients with symptomatic but 
uncomplicated VV (for whom treatment would currently not be funded by the NHS in 
many areas of the UK) than those with VV complicated by skin changes of CVI. (Nasr 
et al., 2008). 
In Section 4.2 I described a qualitative study of patient expectations prior to, and 
following, UGFS. I observed that the majority of patients, who had undergone 
standard assessment and counselling, had high expectations of UGFS in terms of its 
ability to produce symptomatic, cosmetic and lifestyle improvements. Fortunately, the 
data clearly indicate that UGFS is usually able to meet, and often exceed, these 
expectations, comparing favourably with SVS, EVLA and RFA. (Theivacumar et al., 
2009b; Gandhi et al., 2010; Subramonia and Lees, 2010; Pronk et al., 2010) 
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5.2 Future work 
The work I have presented in this Thesis raises a number of interesting questions 
worthy of future research: 
1. What are the longer-term outcomes of UGFS in terms of recanalisation and re-
treatment rates and how do they compare with SVS, EVLA and RFA?  
2. What is the optimum UGFS technique? There is much variation in UGFS 
technique between operators and it seems likely that the technique has not 
been optimised in terms of foam preparation, delivery and 
bandaging/compression. 
3. What will be the long term healing and recurrence rates for CVU following 
UGFS? 
4. In an era of increasing healthcare rationing within the UK NHS, what is the 
relative cost-effectiveness of conservative therapy with compression only, 
SVS, EVLA and RFA over the medium term (5 years)? 
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Appendix 1. SF-12 questionnaire (Ware et al., 2002) 
YOUR GENERAL HEALTH 
Instructions: This survey asks for your views about your health. The information will 
help keep track of how you well you are able to do your usual activities. 
Please answer each question by circling one response. If you are unsure about how 
to answer please give the best answer you can. 
1. In general would you say your health is: 
Excellent Very good Good Fair Poor 
The following items are about activities that you might do during a typical day. Does 
your health now limit you in these activities? If so, how much? 
2. Moderate activities such as moving a table pushing a vacuum cleaner or 
playing golf? 
Yes limited a lot Yes limited a little Not limited at all 
3. Climbing several flights of stairs? 
Yes limited a lot Yes limited a little Not limited at all 
During the past 4 weeks have you had any of the following problems with your work 
or other regular daily activities as a result of your physical health? 
4. Accomplished less than you would like    YES / NO 
5. Were limited in the kind of work or other activities  YES / NO 
During the past 4 weeks have you had any of the following problems with your work 
or other regular daily activities as a result of any emotional problems (such as feeling 
depressed or anxious)? 
6. Accomplished less than you would like    YES / NO 
7. Didn’t do work or other activities as carefully as usual  YES / NO 
8.  During the past 4 weeks how much did pain interfere with your normal work 
(including work outside the home and housework)? 
Not at all A little bit Moderately Quite a lot Extremely 
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These questions are about how you feel and how things have been you during the 
past 4 weeks. For each question please give the one answer that comes closest to 
the way you have been feeling.  
How much of the time during the past 4 weeks: 
9. Have you felt calm and peaceful? 
All of the 
time 
Most of the 
time 
A good bit 
of the time 
Some of 
the time 
A little of 
the time 
Never 
10. Did you have a lot of energy? 
All of the 
time 
Most of the 
time 
A good bit 
of the time 
Some of 
the time 
A little of 
the time 
Never 
11. Have you felt down or low? 
All of the 
time 
Most of the 
time 
A good bit 
of the time 
Some of 
the time 
A little of 
the time 
Never 
12. During the past 4 weeks how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with 
friends relatives etc.) 
All of the time Most of the 
time 
Some of the 
time 
A little of the 
time 
Never 
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Appendix 2. Aberdeen varicose vein symptom severity score 
(Garratt et al., 1996) 
YOUR VARICOSE VEINS 
 
1. Please draw in your varicose veins in the diagram(s) below 
 
 
 
 
2. In the last two weeks, for how many days did your varicose veins cause you pain or ache? 
(Please tick one box for each leg)  
 
  R leg  L leg 
     None at all     
     Between 1 and 5 days     
     Between 6 and 10 days     
     For more than 10 days     
 
 
 
Legs viewed from front Legs viewed from back 
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3. During the last two weeks, on how many days did you take painkilling tablets for your 
varicose veins? 
(Please tick one box) 
None at all   
   Between 1 and 5 days   
   Between 6 and 10 days   
   For more than 10 days   
 
 
 
 
4. In the last two weeks, how much ankle swelling have you had? 
(Please tick one box) 
None at all   
   Slight ankle swelling   
   Moderate ankle swelling   
   Severe ankle swelling   
 
 
5. In the last two weeks, have you worn support stockings or tights? 
(Please tick one box for each leg)  
  R leg  L leg 
     No     
     Yes, those I bought myself without a 
doctors prescription 
    
     Yes, those which my doctor prescribed for 
me which I wear occasionally 
    
     Yes, those which my doctor prescribed for 
me which I wear every day 
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6. In the last two weeks, have you had any itching in association with your varicose veins? 
(Please tick one box for each leg)  
  R leg  L leg 
     No     
     Yes, but only above the knee     
     Yes, but only below the knee     
     Both above and below the knee     
 
 
 
 
 
7. Do you have purple discolouration caused by tiny blood vessels in the skin, in association 
with your varicose veins? 
(Please tick one box for each leg)  
  R leg  L leg 
     No     
     Yes     
 
 
 
 
 
8. Do you have a rash or eczema in the area of your ankle? 
(Please tick one box for each leg)  
  R leg  L leg 
     No     
     Yes, but it does not require any treatment 
from a doctor or district nurse 
    
     Yes, and it requires treatment from my 
doctor or district nurse 
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9. Do you have a skin ulcer associated with your varicose veins? 
(Please tick one box for each leg)  
  R leg  L leg 
     No     
     Yes     
 
 
 
 
 
10. Does the appearance of your varicose veins cause you concern? 
(Please tick one box) 
No   
   Yes, their appearance causes me 
slight concern 
  
   Yes, their appearance causes me 
a great deal of concern 
  
 
 
 
 
11. Does the appearance of your varicose veins influence your choice of clothing including 
tights? 
(Please tick one box) 
No   
   Occasionally   
   Often   
   Always   
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12. During the last two weeks have your varicose veins interfered with your work / housework 
or other daily activities? 
(Please tick one box) 
No   
   I have been able to work, but my work has 
suffered to a slight extent 
  
   I have been able to work, but my work has 
suffered to a moderate extent 
  
   My veins have prevented me from working 
for one day or more 
  
 
 
 
13. During the past two weeks, have your varicose veins interfered with your leisure activities 
(including sport, hobbies and social life)? 
(Please tick one box) 
No   
   Yes, my enjoyment has suffered to a slight 
extent 
  
   Yes, my enjoyment has suffered to a 
moderate extent 
  
   Yes, my veins have prevented me from 
taking part in any leisure activities 
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Appendix 3. Foam Sclerotherapy Recovery Questionnaire 
Please answer the following questions about your recovery after your foam injections for varicose 
veins. Please circle one answer for each question. 
 
 
Did you have any 
bruising after your foam 
injections? 
 
None 
 
A little 
 
Quite a 
bit 
 
A lot 
 
An awful 
lot 
 
If yes, how long did the 
bruising last? 
 
 
Less than 
1 week 
 
1-2 
weeks 
 
2-4 
weeks 
 
More than 
4 weeks 
 
 
 
 
Did you have any pain in 
your leg after your foam 
injections? 
 
None 
 
A little 
 
Quite a 
bit 
 
A lot 
 
An awful 
lot  
 
If yes, how long did the 
pain last? 
 
 
First 1-2 
days only 
 
3-7 
days 
 
1-2 
weeks 
 
2-4 
weeks 
 
More than 
4 weeks 
 
Did you have any 
itching after your foam 
injections? 
 
None 
 
 
A little 
 
Quite a 
bit 
 
A lot 
 
An awful 
lot 
 
If yes, how long did the 
itching last? 
 
 
First 1-2 
days only 
 
3-7 
days 
 
1-2 
weeks 
 
2-4 
weeks 
 
More than 
4 weeks 
 
Did you notice any 
‘lumpiness’ in your legs 
following your foam 
injections? 
 
 
None 
 
 
 
A little 
 
 
Quite a 
bit 
 
 
A lot 
 
 
An awful 
lot 
 
If yes, how long did the 
‘lumpiness’ last? 
 
 
Less than 
1 week 
 
1-2 
weeks 
 
2-4 
weeks 
 
More than 
4 weeks 
 
 
 
 
Did you have any 
problems with your 
eyesight following your 
foam injections? 
 
 
Yes 
 
 
No 
   
 
If so, please write what 
problem you had, and 
how long it lasted for. 
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How long after 
your foam 
injections did you 
return to work? 
 
 
I don’t 
go out 
to work 
 
Same 
day 
 
Next 
day 
 
2-4 
days 
later 
 
5-7 
days 
later 
 
7-14 
days 
later 
 
More 
than 14 
days 
later 
 
 
What kind of work 
do you do? 
 
 
I don’t 
go out 
to work 
 
 
Mostly 
sitting 
 
Sitting 
and 
standing 
 
 
Mostly 
standing 
 
Very 
active 
(lifting 
etc.) 
 
  
 
When did you 
return to driving? 
 
 
I don’t 
drive 
 
Same 
day 
 
Next 
day 
 
2-4 
days 
later 
 
5-7 
days 
later 
 
7-14 
days 
later 
 
More 
than 14 
days 
later 
 
 
Did you take any 
painkillers for your 
leg following your 
foam injections? 
 
 
None 
at all 
 
Same 
day 
only 
 
For the 
first 2 
days only 
 
For 2-4 
days 
after 
 
For 5-7 
days 
after 
 
For 7-
14 
days 
after 
 
For 
more 
than 14 
days 
after 
 
 
 
If you have any further comments please write them below. Thank you 
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Appendix 4. Varicose Vein Surgery Recovery Questionnaire 
Please answer the following questions about your recovery after your recent surgery for varicose 
veins. Please circle one answer for each question. 
 
 
Did you have any 
bruising after your 
varicose vein surgery? 
 
None 
 
A little 
 
Quite a 
bit 
 
A lot 
 
An awful 
lot 
 
If yes, how long did the 
bruising last? 
 
 
Less than 
1 week 
 
1-2 
weeks 
 
2-4 
weeks 
 
More than 
4 weeks 
 
 
 
 
Did you have any pain in 
your leg after your 
varicose vein surgery? 
 
None 
 
A little 
 
Quite a 
bit 
 
A lot 
 
An awful 
lot  
 
If yes, how long did the 
pain last? 
 
 
First 1-2 
days only 
 
3-7 
days 
 
1-2 
weeks 
 
2-4 
weeks 
 
More than 
4 weeks 
 
Did you have any 
itching after your 
varicose vein surgery? 
 
None 
 
 
A little 
 
Quite a 
bit 
 
A lot 
 
An awful 
lot 
 
If yes, how long did the 
itching last? 
 
 
First 1-2 
days only 
 
3-7 
days 
 
1-2 
weeks 
 
2-4 
weeks 
 
More than 
4 weeks 
 
Did you notice any 
‘lumpiness’ in your legs 
after your varicose vein 
surgery? 
 
 
None 
 
 
 
A little 
 
 
Quite a 
bit 
 
 
A lot 
 
 
An awful 
lot 
 
If yes, how long did the 
‘lumpiness’ last? 
 
 
Less than 
1 week 
 
1-2 
weeks 
 
2-4 
weeks 
 
More than 
4 weeks 
 
 
 
 
Please turn over 
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How long after 
your varicose vein 
surgery did you 
return to work? 
 
 
I don’t 
go out 
to work 
 
Same 
day 
 
Next 
day 
 
2-4 
days 
later 
 
5-7 
days 
later 
 
7-14 
days 
later 
 
More 
than 14 
days 
later 
 
 
What kind of work 
do you do? 
 
 
I don’t 
go out 
to work 
 
 
Mostly 
sitting 
 
Sitting 
and 
standing 
 
 
Mostly 
standing 
 
Very 
active 
(lifting 
etc.) 
 
  
 
When did you 
return to driving? 
 
 
I don’t 
drive 
 
Same 
day 
 
Next 
day 
 
2-4 
days 
later 
 
5-7 
days 
later 
 
7-14 
days 
later 
 
More 
than 14 
days 
later 
 
 
Did you take any 
painkillers for your 
leg following your 
varicose vein 
surgery? 
 
 
None 
at all 
 
Same 
day 
only 
 
For the 
first 2 
days only 
 
For 2-4 
days 
after 
 
For 5-7 
days 
after 
 
For 7-
14 
days 
after 
 
For 
more 
than 14 
days 
after 
 
 
 
If you have any further comments please write them below. Thank you 
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Appendix 5. Pre-treatment expectations questionnaire 
 
About one in five patients has varicose veins in both legs so we are going to ask you about 
your symptoms in each leg separately.  
  
RIGHT LEG 
If you are going to have foam injections in your RIGHT leg (not necessarily at your first 
appointment) please answer all questions below by ticking the relevant boxes. 
 
I am expecting my foam injections to get rid of the following symptoms in my RIGHT leg:  
 
 I do not have 
this symptom 
A little Quite a bit A lot An awful lot 
Pain/Aching      
Itching       
Tingling      
Cramps      
Restless Legs      
Swelling      
Heaviness      
 
 
LEFT LEG 
If you are going to have foam injections in your LEFT leg (not necessarily at your first 
appointment) please answer all questions below by ticking the relevant boxes. 
 
I am expecting my foam injections to get rid of the following symptoms in my LEFT leg:   
 
 I do not have this 
symptom 
A little Quite a bit A lot An awful lot 
Pain/Aching      
Itching       
Tingling      
Cramps      
Restless legs      
Swelling      
Heaviness      
 
 
Please turn over page 
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Many people have foam injections to improve the appearance and function of their leg. 
Please answer all questions about your leg(s). 
 
 Not at all A little Quite a bit A lot An awful lot 
I am expecting my foam 
injections to improve the 
appearance of my varicose 
veins  
     
I am expecting my foam 
injections to allow me to wear 
different clothes 
     
I am expecting my foam 
injections to allow me to do my 
work better. 
     
I am expecting my foam 
injections to improve my 
relationships. 
     
I am expecting my foam 
injections to improve my social 
and leisure activities. 
     
 
 
Thank you for completing this questionnaire.  Please feel free to add any comments: 
…………………………………………………………………………………………………………... 
…………………………………………………………………………………………………………… 
…………………………………………………………………………………………………………… 
…………………………………………………………………………………………………………… 
Please bring this with you to your appointment for your foam injections    
Thank you 
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Appendix 6. Post-treatment expectations questionnaire 
 
Please answer the following questions about any improvement that you have had in your symptoms 
and activities since your foam injections for varicose veins. Please only consider the leg(s) which you 
had foam injections on. Please tick the box which most closely matches any improvement you have 
had. 
MY FOAM INJECTIONS HAVE IMPROVED THE FOLLOWING SYMPTOMS IN MY LEGS: (please 
tick one box for each symptom) 
 Completely 
(the 
symptom 
has gone) 
 
A lot 
 
Quite a 
bit 
 
A little 
 
Not at 
all 
The 
symptom 
has got 
worse 
I never 
had this 
symptom 
 
Pain or ache 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Itching        
Tingling        
Cramps        
Restless legs        
Swelling        
Heaviness        
 
MY FOAM INJECTIONS HAVE: (please tick one box for each statement) 
  
An awful 
lot 
 
A lot 
 
Quite a 
bit 
 
A little 
 
Not at all 
 
Improved the appearance of my 
varicose veins 
 
 
 
 
 
 
 
 
 
 
Allowed me to wear different clothes      
Allowed me to do my work better      
Improved my relationships      
Improved my social and leisure 
activities 
     
 
If you have any comments please feel free to add them overleaf. Thank you. 
159 
 
LIST OF REFERENCES 
Allegra, C., Antignani, P.L., Carlizza, A. (2007) Recurrent varicose veins following surgical 
treatment: our experience with five years follow-up. European Journal of Vascular and 
Endovascular Surgery, 33, 751-756. 
Baker, D., Turnbull, N., Pearson, J., Makin, G. (1995) How successful is varicose vein 
surgery? A patient outcome study following varicose vein surgery using the SF-36 health 
assessment questionnaire. European Journal of Vascular and Endovascular Surgery, 9, 299-
304. 
Barrett, J., Allen, B., Ockelford, A., Goldman, M. (2004) Microfoam ultrasound-guided 
sclerotherapy treatment for varicose veins in a subgroup with diameters at the junction of 
10mm or greater compared with a subgroup of less than 10mm. Dermatologic Surgery, 30, 
1386-1390. 
Barwell, J.R., Davies, C.E., Deacon, J., Harvey, K., Minor, J., Sassano, A., Taylor, M., Usher, 
J., Wakely, C., Earnshaw, J.J., Heather, B.P., Mitchell, D.C., Whyman, M.R., Poskitt, K.R. 
(2004) Comparison of surgery and compression with compression alone in chronic venous 
ulceration (ESCHAR study): randomised controlled trial. Lancet, 363, 1854-1859. 
Barwell, J.R., Taylor, M., Deacon, J., Ghauri, A.S., Wakely, C., Phillips, L.K., Whyman, M.R., 
Poskitt, K.R. (2000) Surgical correction of isolated superficial venous reflux reduces long-
term recurrence rate in chronic venous leg ulcers. European Journal of Vascular and 
Endovascular Surgery, 20, 363-368. 
Beale, R.J., Gough, M.J. (2005) Treatment options for primary varicose veins – a review. 
European Journal of Vascular and Endovascular Surgery, 30, 83–95. 
Bello, M., Scriven, M., Hartshorne, T., Bell, P.R., Naylor, A.R., London, N.J. (1999) Role of 
superficial venous surgery in the treatment of venous ulceration. British Journal of Surgery, 
86, 755-759. 
Bergan, J., Pascarella, L., Mekenas, L. (2006) Venous disorders: treatment with sclerosant 
foam. Journal of Cardiovascular Surgery, 47, 9-18. 
Bergan, J.J., Weiss, R.A., Goldman, M.P. (2001) Extensive tissue necrosis following high-
concentration sclerotherapy for varicose veins. Dermatologic Surgery, 26, 535-542.  
Biegeleisen, K., Neilsen, R.D., O’Shaughnessy, A. (1993) Inadvertent intra-arterial injection 
complicating ordinary and ultrasound-guided sclerotherapy. Journal of Dermatology and 
Surgical Oncology, 19, 953-958.  
Biswas, A., Clark, A., Shields, D.A. (2007) Randomised clinical trial of the duration of 
compression therapy after varicose vein surgery. European Journal of Vascular and 
Endovascular Surgery, 33, 631-637. 
Blaise, S., Bosson, J.L., Diamand, J.M. (2010) Ultrasound-guided sclerotherapy of the great 
saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomized 
trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery, 39, 779-
786.  
Blomgren, L., Johansson, G., Bergqvist, D. (2006) Quality of life after surgery for varicose 
veins and the impact of preoperative duplex: results based on a randomized trial. Annals of 
Vascular Surgery, 20, 30-34.  
160 
 
Blomgren, L., Johanson, G., Dahlberg-Akerman, A., Thermaenius, P., Bergqvist, D. (2005) 
Changes in superficial and perforating vein reflux after varicose vein surgery. Journal of 
Vascular Surgery, 42, 315-320. 
Bountouroglou, D., Azzam, M., Kakkos, S., Pathmarajah, M., Young, P., Geroulakos, G. 
(2006) Ultrasound-guided foam sclerotherapy combined with sapheno-femoral ligation 
compared to surgical treatment of varicose veins: early results of a randomised controlled 
trial. European Journal of Vascular and Endovascular Surgery, 31, 93-100. 
Bowling, A., Bond, M., Jenkinson, C., Lamping, D.L. (1999) Short Form 36 (SF-36) Health 
Survey questionnaire: which normative data should be used? Comparisons between norms 
provided by the Omnibus Survey in Britain, the Health Survey for England and the Oxford 
Health Life survey. Journal of Public Health Medicine, 21, 255-270. 
Bradbury, A.W., Bate, G., Pang, K., Darvall, K.A., Adam, D.J. (2010) Ultrasound-guided foam 
sclerotherapy is a safe and clinically effective treatment for superficial venous reflux. Journal 
of Vascular Surgery, 52, 939-945. 
Bradbury, A.W., Evans, C.J., Allan, P., Lee, A.J., Ruckley, C.V., Fowkes, F.G.R. (2000) The 
relationship between lower limb symptoms and superficial and deep venous reflux on duplex 
ultrasonography: The Edinburgh Vein Study. Journal of Vascular Surgery, 32, 921-931. 
Bradbury, A.W., Evans, C.J., Allan, P., Lee, A.J., Ruckley, C.V., Fowkes, F.G.R. (1999) What 
are the symptoms of varicose veins? Edinburgh vein study cross-sectional population survey. 
British Medical Journal, 318, 353-356. 
Bradbury, A.W., Stonebridge, P.A., Ruckley, C.V., Beggs, I. (1993) Recurrent varicose veins: 
correlation between pre-operative clinical and hand-held Doppler ultrasonographic 
examination and anatomical findings at surgery. British Journal of Surgery, 80, 849-851.  
Breu, F.X., Guggenbichler, S. (2004) European consensus meeting on foam sclerotherapy, 
April 4-6, 2003, Tegernsee, Germany. Dermatologic Surgery, 30, 709-717.  
Breu, F.X., Guggenbichler, S., Wollmann, J.C. (2008) 2nd European consensus meeting on 
foam sclerotherapy 2006, Tegernsee, Germany. Vasa, 37 (suppl 71), 1-29.  
Bush, R.G., Derrick, M., Manjoney, D. (2008) Major neurological events following foam 
sclerotherapy. Phlebology, 23, 189-192. 
Cabrera, J., Cabrera, J. Jr., Garcia-Olmedo, M.A. (2001) Sclerosants in microfoam: a new 
approach in angiology. International Angiology, 20, 322-329. 
Cabrera, J., Cabrera, J., Garcia-Olmedo, M.A. (2000) Treatment of varicose long saphenous 
veins with sclerosant in microfoam: long-term outcomes. Phlebology, 15, 19-23. 
Cabrera, J., Redondo, P., Becerra, A., Garrido, C., Cabrera, J. Jr., Garcia-Olmedo, M.A., 
Sierra, A., Lloret, P., Martinez-Gonzalez, M.A. (2004) Ultrasound-guided injection of 
polidocanol microfoam in the management of venous leg ulcers. Archives of Dermatology, 
140, 667-673. 
Caggiati, A., Franceschini, M. (2010) Stroke following endovenous laser treatment of 
varicose veins. Journal of Vascular Surgery, 51, 218-220. 
161 
 
Campbell, W.B., Decaluwe, H., Boecxstaens, V., MacIntyre, J.A., Walker, N., Thompson, 
J.F., Cowan, A.R. (2007) The symptoms of varicose veins: difficult to determine and difficult 
to study. European Journal of Vascular and Endovascular Surgery, 34, 741-744. 
Campbell, W.B., Decaluwe, H., MacIntyre, J.A., Thompson, J.F., Cowan, A.R. (2006) Most 
patients with varicose veins have fears or concerns about the future, in addition to their 
presenting symptoms. European Journal of Vascular and Endovascular Surgery, 31, 332-
334. 
Campbell, W.B., France, F. (2002) Medicolegal claims in vascular surgery. Annals of the 
Royal College of Surgeons of England, 84, 181-184. 
Campbell, W.B., Kumar, A., Collin, T., Allington, K., Michaels, J. (2003) The outcome of 
varicose vein surgery at 10 years: clinical findings, symptoms and patient satisfaction. Annals 
of the Royal College of Surgeons of England, 85, 52-57. 
Carradice, D., Mekako, A.I., Hatfield, J., Chetter, I.C. (2009) Randomised clinical trial of 
concomitant or sequential phlebectomy after endovenous laser therapy for varicose veins. 
British Journal of Surgery, 96, 369-375. 
Carradice, D., Mekako, A.I., Mazan, F.A.K., Samuel, N., Hatfield, J., Chetter, I.C. (2011) 
Randomized clinical trial of endovenous laser ablation compared with conventional surgery 
for great saphenous varicose veins. British Journal of Surgery, 98, 501-510. 
Cavezzi, A., Tessari, L. (2009) Foam sclerotherapy techniques: different gases and methods 
of preparation catheter versus direct injection. Phlebology, 24, 247-251. 
Ceulen, R.P.M., Jagtman, E.A., Sommer, A., Teule, G.J.J., Schurink, G.W.H., Kemerink, G.J. 
(2010) Blocking the saphenofemoral junction during ultrasound-guided foam sclerotherapy – 
assessment of a presumed safety-measure procedure. European Journal of Vascular and 
Endovascular Surgery, 40, 772-776. 
Ceulen, R.P.M., Sommer, A., Vernooy, K. (2008) Microembolism during foam sclerotherapy 
of varicose veins (letter). New England Journal of Medicine, 358, 1525. 
Chetter, I.C., Mylankal, K.J., Hughes, H., Fitridge, R. (2006) Randomized clinical trial 
comparing multiple stab incision phlebectomy and transilluminated powered phlebectomy for 
varicose veins. British Journal of Surgery, 93, 169-174. 
Christenson, J.T., Gueddi, S., Gemayel, G., Bounameaux, H. (2010) Prospective randomized 
trial comparing endovenous laser ablation and surgery for treatment of primary great 
saphenous varicose veins with a 2-year follow-up. Journal of Vascular Surgery, 52, 1234-
1241. 
Coleridge Smith, P. (2006) Chronic venous disease treated by ultrasound guided foam 
sclerotherapy. European Journal of Vascular and Endovascular Surgery, 32, 577-583. 
Coleridge Smith, P. (2009) Sclerotherapy and foam sclerotherapy for varicose veins. 
Phlebology, 24, 260-269. 
Corder, A.P., Schache, D.J., Farquharson, S.M., Tristram, S. (1991) Wound infection 
following high saphenous ligation. A trial comparing two skin closure techniques: subcuticular 
polyglycolic acid and interrupted monofilament nylon mattress sutures. Journal of the Royal 
College of Surgeons of Edinburgh, 28, 11-15.  
162 
 
Cullum, N., Nelson, E.A., Fletcher, A.W., Sheldon, T.A. (2001) Compression for venous leg 
ulcers. The Cochrane Database of Systematic Reviews, Issue 2, Art. No. CD000265. 
DOI:10.1002/14651858. 
Darke, S.G., Baker, S.J.A. (2006) Ultrasound-guided foam sclerotherapy for the treatment of 
varicose veins. British Journal of Surgery, 93, 969-974. 
Darvall, K.A.L., Bate, G.R., Adam, D.J., Bradbury, A.W. (2009a) Recovery, analgesia use, 
and return to normal activities after ultrasound-guided foam sclerotherapy compared with 
conventional surgery for varicose veins. British Journal of Surgery, 96, 1262-1267. 
Darvall, K.A.L., Bate, G.R., Adam, D.J., Silverman, S.H., Bradbury, A.W. (2010a) Duplex 
ultrasound outcomes following ultrasound-guided foam sclerotherapy of symptomatic primary 
great saphenous varicose veins. European Journal of Vascular and Endovascular Surgery, 
40, 534-539.  
Darvall, K.A.L., Bate, G.R., Adam, D.J., Silverman, S.H., Bradbury, A.W. (2011). Duplex 
ultrasound outcomes following ultrasound-guided foam sclerotherapy of symptomatic 
recurrent great saphenous varicose veins. European Journal of Vascular and Endovascular 
Surgery, 42, 107-114. 
Darvall, K.A.L., Bate, G.R., Adam, D.J., Silverman, S.H., Bradbury, A.W. (2009b) Medium-
term results of ultrasound guided foam sclerotherapy of small saphenous varicose veins. 
British Journal of Surgery, 96, 1268-1273. 
Darvall, K.A.L., Bate, G.R., Adam, D.J., Silverman, S.H., Bradbury, A.W. (2009c) Ultrasound-
guided foam sclerotherapy for the treatment of chronic venous ulceration: a preliminary 
study. European Journal of Vascular and Endovascular Surgery, 38, 764-769. 
Darvall, K.A.L., Bate, G.R., Sam, R.C., Adam, D.J., Silverman, S.H., Bradbury, A.W. (2009d) 
Patients’ expectations before and satisfaction after ultrasound-guided foam sclerotherapy for 
varicose veins. European Journal of Vascular and Endovascular Surgery, 38, 642-647. 
Darvall, K.A.L., Sam, R.C., Bate, G.R., Silverman, S.H., Adam, D.J., Bradbury, A.W. (2010b) 
Changes in health-related quality of life following ultrasound guided foam sclerotherapy for 
great and small saphenous varicose veins. Journal of Vascular Surgery, 51, 913-920. 
Darwood, R.J., Theivacumar, N., Dellagrammaticas, D., Mavor, A.I.D., Gough, M.J. (2008) 
Randomized clinical trial comparing endovenous laser ablation with surgery for the treatment 
of primary great saphenous varicose veins. British Journal of Surgery, 95, 294-301. 
Darwood, R.J., Walker, N., Bracey, M., Cowan, A.R., Thomson, J.F., Campbell, W.B. (2009) 
Return to work, driving and other activities after varicose vein surgery is very variable and is 
influenced little by advice from specialists. European Journal of Vascular and Endovascular 
Surgery, 38, 213-219. 
Davies, A.H., Steffen, C., Cosgrove, C., Wilkins, D.C. (1995) Varicose vein surgery: patient 
satisfaction. Journal of the Royal College of Surgeons of Edinburgh, 40, 298-299. 
Desmyttere, J., Grard, C., Stalnikiewicz, G., Wassmer, B., Mordon, S. (2010) Endovenous 
laser ablation (980nm) of the small saphenous vein in a series of 147 limbs with a 3-year 
follow-up. European Journal of Vascular and Endovascular Surgery, 39, 99-103. 
Disselhoff, B.C.V.M., Buskens, E., Kelder, J.C., der Kinderen, D.J., Moll, F.L. (2009) 
Randomised comparison of costs and cost-effectiveness of cryostripping and endovenous 
163 
 
laser ablation for varicose veins: 2-year results. European Journal of Vascular and 
Endovascular Surgery, 37, 357-363. 
Doganci, S., Yildirim, V., Demirkilic, U. (2011) Does puncture site affect the rate of nerve 
injuries following endovenous laser ablation of the small saphenous veins? European Journal 
of Vascular and Endovascular Surgery, 41, 400-405. 
Durkin, M., Turton, E., Wijesinghe, L., Scott, D., Berridge, D. (2001) Long saphenous vein 
stripping and quality of life - a randomised trial. European Journal of Vascular and 
Endovascular Surgery, 21, 545-549. 
Dwerryhouse, S., Davies, B., Harradine, K., Earnshaw, J.J. (1999) Stripping the long 
saphenous vein reduces the rate of reoperation for recurrent varicose veins: five-year results 
of a randomized trial. Journal of Vascular Surgery, 29, 589-592. 
Eklof, B., Rutherford, R.B., Bergan, J.J., Carpentier, P.H., Gloviczki, P., Kistner, R.L., 
Meissner, M.H., Moneta, G.L., Myers, K., Padberg, F.T., Perrin, M., Ruckley, C.V., Smith, 
P.C., Wakefield, T.W. (2004) American Venous Forum International Ad Hoc Committee for 
the Revision of the CEAP Classification. Revision of the CEAP classification for chronic 
venous disorders: consensus statement. Journal of Vascular Surgery, 40, 1248-52. 
Engelhorn, C.A., Englehorn, A.L., Cassou, M.F., Salles-Cunha, S.X. (2005) Patterns of 
saphenous reflux in women with varicose veins. Journal of Vascular Surgery, 41, 645-651. 
Enzler, M.A., van den Bos., R.R. (2010) A new gold standard for varicose vein treatment. 
European Journal of Vascular and Endovascular Surgery, 39, 97-98. 
Fassiadis, N., Kianifard, B., Holdstock, J.M., Whiteley, M.S. (2002) A novel approach to the 
treatment of recurrent varicose veins. International Angiology, 21, 275-276. 
Fletcher, A., Cullum, N., Sheldon, T.A. (1997) A systematic review of compression treatment 
for venous leg ulcers. British Medical Journal, 315, 576-580. 
Forlee, M.V., Grouden, M., Moore, D.J., Shanik, G. Stroke after varicose veins foam injection 
sclerotherapy. Journal of Vascular Surgery, 43, 162-164. 
Frullini, A., Cavezzi, A. (2002) Sclerosing foam in the treatment of varicose veins and 
telangiectases: history and analysis of safety and complications. Dermatologic Surgery, 28, 
11-15.  
Galland, R.B., Magee, T.R., Lewis, M.H. (1998) A survey of current attitudes of British and 
Irish vascular surgeons to venous sclerotherapy. European Journal of Vascular and 
Endovascular Surgery, 16, 43-46. 
Gandhi, A., Froghi, F., Shepherd, A.C., Shalhoub, J., Lim, C.S., Gohel, M.S., Davies, A.H. 
(2010) A study of patient satisfaction following endothermal ablation for varicose veins. 
Vascular and Endovascular Surgery, 44, 274-278. 
Garratt, A.M., Macdonald, L.M., Ruta, D.A., Russell, I.T., Buckingham, J.K., Krukowski, Z.H. 
(1993) Towards measurement of outcome for patients with varicose veins. Quality Health 
Care, 2, 5-10. 
Garratt, A.M., Ruta, D.A., Abdalla, M.I., Russell, I.T.. Responsiveness of the SF-36 and a 
condition specific measure of health outcome for patients with varicose veins. Quality of Life 
Research, 5, 1-12.  
164 
 
Ghauri, A.S.K., Taylor, M., Deacon, J.E., Whyman, M.R., Earnshaw, J.J., Heather, B.P., 
Poskitt, K.R. (2000) Influence of a specialized leg ulcer service on management and 
outcome. British Journal of Surgery, 87, 1048-1056. 
Gibbs, P.J., Foy, D.M., Darke, S.G. (1999) Reoperation for recurrent saphenofemoral 
incompetence: a prospective randomised trial using a reflected flap of pectineus fascia. 
European Journal of Vascular and Endovascular Surgery, 18, 494-498. 
Gibson, K.D., Ferris, B.L., Polissar, N., Neradilek, B., Pepper, D. (2007) Endovenous laser 
treatment of the short saphenous vein: efficacy and complications. Journal of Vascular 
Surgery, 45, 795-803. 
Gillet, J.L., Donnet, A., Lausecker, M., Guedes, J.M., Guex, J.J., Lehmann, P. (2010) 
Pathophysiology of visual disturbances occurring after foam sclerotherapy. Phlebology, 25, 
261-266. 
Gillet, J.L., Guedes, J.M., Guex, J.J., Hamel-Desnos, C., Schadeck, M., Lausecker, M., 
Allaert, F.A. (2009) Side-effects and complications of foam sclerotherapy of the great and 
small saphenous veins: a controlled multicentre prospective study including 1025 patients. 
Phlebology, 24, 131-138. 
Gohel, M.S., Barwell, J.R., Taylor, M., Chant, T., Foy, C., Earnshaw, J.J., Heather, B.P., 
Mitchell, D.C., Whyman, M.R., Poskitt, K.R. (2007) Long term results of compression therapy 
alone versus compression plus surgery in chronic venous ulceration (ESCHAR): randomised 
controlled trial. British Medical Journal, 335, 83-88. 
Gohel, M.S., Epstein, D.M., Davies, A.H. (2010) Cost-effectiveness of traditional and 
endovenous treatments for varicose veins. British Journal of Surgery, 97, 1815-1823. 
Goode, S.D., Chowdhury, A., Crockett, M., Beech, A., Simpson, R., Richards, T., Braithwaite, 
B.D. (2010) Laser and radiofrequency ablation study (LARA study): A randomised study 
comparing radiofrequency ablation and endovenous laser ablation (810nm). European 
Journal of Vascular and Endovascular Surgery, 40, 246-253. 
Goode, S.D., Kuhan, G., Altaf, N., Simpson, R., Beech, A., Richards, T., MacSweeney, S.T., 
Braithwaite, B.D. (2009) Suitability of varicose veins for endovascular treatments. 
Cardiovascular Interventional Radiology, 32, 988-991. 
Guex, J.J. (2009) Complications and side-effects of foam sclerotherapy. Phlebology, 24, 270-
274. 
Guex, J.J., Allaert, F.A., Gillet, J.L., Chleir, F. (2005) Immediate and mid-term complications 
of sclerotherapy: report of a prospective multicenter registry of 12,173 sclerotherapy 
sessions. Dermatologic Surgery, 31, 123-128. 
Hahn, M., Schulz, T., Junger, M. (2010) Late stroke after foam sclerotherapy. Vasa, 39, 108-
110. 
Hamel-Desnos, C., Allaert, F.A. (2009) Liquid versus foam sclerotherapy. Phlebology, 24, 
240-246. 
Hamel-Desnos, C., Desnos, P., Wollmann, J-C., Ouvry, P., Mako, S., Allaert, F-A. (2003) 
Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in 
sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery, 29, 1170-
1175.  
165 
 
Hamel-Desnos, C.M., Gillet, J.L., Desnos, P.R., Allaert, F.A. (2009) Sclerotherapy of 
varicose veins in patients with documented thrombophilia: a prospective controlled 
randomized study of 105 cases. Phlebology, 24, 176-182. 
Hamel-Desnos, C.M., Guias, B.J., Desnos, P.R., Mesgard, A. (2010) Foam sclerotherapy of 
the saphenous veins: randomised controlled trial with or without compression. European 
Journal of Vascular and Endovascular Surgery, 39, 500-507.  
Hamel-Desnos, C., Ouvry, P., Benigni, J-P., Boitelle, G., Schadeck, M., Desnos, P., Allaert, 
F-A. (2007) Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy 
of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. “The 3/1 
study”. European Journal of Vascular and Endovascular Surgery, 34, 723-729.  
Hanisch, F., Muller, T., Krivokuca, M., Winterholler, M. (2004) Stroke following variceal 
sclerotherapy. European Journal of Medical Research, 9, 282-284. 
Hartmann, K., Harms, L., Simon, M. (2009) Reversible neurological deficit after foam 
sclerotherapy. European Journal of Vascular and Endovascular Surgery, 38, 648-649. 
Harzheim, M., Becher, H., Klockgether, T. (2000) Brain infarct from a paradoxical embolism 
following a varices operation. Dtsch Med Wochenschr, 125, 794-796. 
Hayden, A., Holdsworth, J. (2001) Complications following re-exploration of the groin for 
recurrent varicose veins. Annals of the Royal College of Surgeons of England, 83, 272-273. 
Hertzman, P.A., Owens, R. (2007) Rapid healing of chronic venous ulcers following 
ultrasound-guided foam sclerotherapy. Phlebology, 22, 34-39. 
Hill, D., Hamilton, R., Fung, T. (2008) Assessment of techniques to reduce sclerosant foam 
migration during ultrasound-guided sclerotherapy of the great saphenous vein. Journal of 
Vascular Surgery, 48, 934-939.  
Hinchcliffe, R.J., Ubhi, J., Beech, A., Ellison, J., Braithwaite, B.D. (2006) A prospective 
randomized controlled trial of VNUS Closure versus surgery for the treatment of recurrent 
long saphenous varicose veins. European Journal of Vascular and Endovascular Surgery, 
31, 212-218. 
Hobbs, J. (1974) Surgery and sclerotherapy in the treatment of varicose veins. A random 
trial. Archives of Surgery, 109, 793-796. 
Homma, S., Sacco, R.L. (2005) Patent foramen ovale and stroke. Circulation, 112, 1063-
1072.  
Howard, D.P.J., Howard, A., Kothari, A., Wales, L., Guest, M., Davies, A.H. (2008) The role 
of superficial venous surgery in the management of venous ulcers: a systematic review. 
European Journal of Vascular and Endovascular Surgery, 36, 458-465. 
Huisman, L.C., Bruins, R.M.G., van den Berg, M., Hissink, R.J. (2009) Endovenous laser 
ablation of the small saphenous vein: prospective analysis of 150 patients, a cohort study. 
European Journal of Vascular and Endovascular Surgery, 38, 199-202. 
Hurst, N.P., Ruta, D.A., Kind, P. (1998) Comparison of the MOS short form-12 (SF12) health 
status questionnaire with the SF36 in patients with rheumatoid arthritis. British Journal of 
Rheumatology, 37, 862-869. 
166 
 
Ikponmwosa, A., Bhasin, N., Weston, M.J., Berridge, D.C., Scott, D.J. (2010) Outcome 
following sapheno-popliteal surgery: a prospective observational study. Phlebology, 25, 174-
178. 
Jackson, J.L., Kroenke, K.A. (2001) The effect of unmet expectations among adults 
presenting with physical symptoms. Annals of Internal Medicine, 134, 889-897. 
Jenkinson, C., Layte, R., Jenkinson, D., Lawrence, K., Petersen, S., Paice, C., Stradling, J. 
(1997) A shorter form health survey: can the SF-12 replicate results from the SF-36 in 
longitudinal studies? Journal of Public Health Medicine, 19, 179-186. 
Jia, X., Mowatt, G., Burr, J.M., Cassar, K., Cook, J., Fraser, C. (2007) Systematic review of 
foam sclerotherapy for varicose veins. British Journal of Surgery, 94, 925-936. 
Jones, L., Braithwaite, B.D., Selwyn, D., Cooke, S., Earnshaw, J.J. (1996) 
Neovascularisation is the principal cause of varicose vein recurrence: results of a 
randomised trial of stripping the long saphenous vein. European Journal of Vascular and 
Endovascular Surgery, 12, 442-445. 
Kahn, S.R., M’Lan, C.E., Lamping, D.L., Kurz, X., Berard, A., Abenhaim, L.A., for the 
VEINES Study Group. (2004) Relationship between clinical classification of chronic venous 
disease and patient-reported quality of life: Results from an international cohort study. 
Journal of Vascular Surgery, 39, 823-828. 
Kakkos, S.K., Bountouroglou, D.G., Azzam, M., Kalodiki, E., Daskalopoulos, M., Geroulakos, 
G. Effectiveness and safety of ultrasound-guided foam sclerotherapy for recurrent varicose 
veins: immediate results. Journal of Endovascular Therapy, 13, 357-364.  
Kaplan, R., Criqui, M., Denenberg, J., Bergan, J., Fronek, A. (2003) Quality of life in patients 
with chronic venous disease: San Diego population study. Journal of Vascular Surgery, 37, 
1047-1053. 
Kontothanassis, D., Dimitri, R., Ferrari Ruffino, S., Zambrini, E., Camporese, G., Gerard, J., 
Labropoulos, N. (2009) Endovenous laser treatment of the small saphenous vein. Journal of 
Vascular Surgery, 49, 973-979. 
Kravitz, R.L. (2001) Measuring patients’ expectations and requests. Annals of Internal 
Medicine, 134, 881-888. 
Kulkarni, S.R., Barwell, J.R., Gohel, M.S., Bulbulia, R.A., Whyman, M.R., Poskitt, K.R. (2007) 
Residual venous reflux after superficial venous surgery does not predict ulcer recurrence. 
European Journal of Vascular and Endovascular Surgery, 34, 107-111. 
Kurz, X., Kahn, S.R., Abenhaim, L., Clement, D., Norgren, L., Baccaglini, U., Berard, A., 
Cooke, J.P., Cornu-Thenard, A., Depairon, M., Dormandy, J.A., Durand-Zaleski, I., Fowkes, 
G.R., Lamping, D.L., Partsch, H., Scurr, J.H., Zuccarelli, F. (1999) Chronic venous disorders 
of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-
based report of the VEINES task force. Venous Insufficiency Epidemiologic and Economic 
Studies. International Angiology, 18, 83-102.  
Kurz, X., Lamping, D.L., Kahn, S.R., Baccaglini, U., Zuccarelli, F., Spreafico, G., Abenhaim, 
L. (2001) Do varicose veins affect quality of life? Results of an international population-based 
study. Journal of Vascular Surgery, 34, 641-648. 
167 
 
Lamping, D.L., Schroter, S., Kurz, X., Kahn, S.R., Abenhaim, L. (2003) Evaluation of 
outcomes in chronic venous disorders of the leg: development of a scientifically rigorous, 
patient-reported measure of symptoms and quality of life. Journal of Vascular Surgery, 37, 
410-419.  
Launois, R., Reboul-Marty, J., Henry, B. (1996) Construction and validation of a quality of life 
questionnaire in chronic lower limb venous insufficiency (CIVIQ). Quality of Life Research, 5, 
539-554. 
Luebke, T., Brunkwall, J. (2008) Systematic review and meta-analysis of endovenous 
radiofrequency obliteration, endovenous laser therapy, and foam sclerotherapy for primary 
varicosis. Journal of Cardiovascular Surgery, 49, 213-233. 
Lurie, F., Creton, D., Eklof, B., Kabnick, L.S., Kistner, R.L., Pichot, O., Sessa, C., Schuller-
Petrovic, S. (2005) Prospective randomized study of endovenous radiofrequency ablation 
(closure) versus ligation and vein stripping (EVOLVeS): two-year follow-up. European 
Journal of Vascular and Endovascular Surgery, 29, 67-73.  
Lurie, F., Creton, D., Eklof, B., Kabnick, L., Kistner, R., Pichot, O., Schuller-Petrovic, S., 
Sessa, C. (2003) Prospective randomized study of endovenous radiofrequency obliteration 
(Closure procedure) versus ligation and stripping in a selected patient population (EVOLVeS 
Study). Journal of Vascular Surgery, 38, 207-214. 
MacKenzie, R.K., Allan, P.L., Ruckley, C.V., Bradbury, A.W. (2004) The effect of long 
saphenous vein stripping on deep venous reflux. European Journal of Vascular and 
Endovascular Surgery, 28, 104-107. 
MacKenzie, R.K., Lee, A.J., Paisley, A., Burns, P., Allan, P.L., Ruckley, C.V., Bradbury, A.W. 
(2002a) Patient, operative, and surgeon factors that influence the effect of superficial venous 
surgery on disease-specific quality of life. Journal of Vascular Surgery, 36, 896-902. 
MacKenzie, R.K., Paisley, A., Allan, P.L., Lee, A.J., Ruckley, C.V., Bradbury, A.W. (2002b) 
The effect of long saphenous vein stripping on quality of life. Journal of Vascular Surgery, 35, 
1197-1203. 
Margolis, D.J., Bilker, W., Santarina, J., Baumgarten, M. (2002) Venous leg ulcer: incidence 
and prevalence in the elderly. Journal of the American Academy of Dermatology, 46, 381-
386. 
McDaniel, M.D., Nehler, M.R., Santilli, S.M., Hiatt, W.R., Regensteiner, J.G., Goldstone, J., 
McCarthy, W.J., White, JV. Extended outcome assessment in the care of vascular diseases: 
revising the paradigm for the 21st century. Journal of Vascular Surgery, 32, 1239-1250. 
Meier, B., Lock, J.E. (2003) Contemporary management of patent foramen ovale. Circulation, 
107, 5-9.  
Merchant, R.F., DePalma, R.G., Kabnick, L.S. (2002) Endovascular obliteration of 
saphenous reflux: a multicenter study. Journal of Vascular Surgery, 35, 1190-1196.  
Merchant, R.F., Pichot, O., for the Closure Group (2005). Long-term outcomes of 
endovenous radiofrequency obliteration of saphenous reflux as a treatment for superficial 
venous insufficiency. Journal of Vascular Surgery, 42, 502-509. 
168 
 
Michaels, J., Brazier, J., Campbell, W., MacIntyre, J., Palfreyman, S., Ratcliffe. J. (2006) 
Randomized clinical trial comparing surgery with conservative treatment for uncomplicated 
varicose veins. British Journal of Surgery, 93, 175-181. 
Min, R.J., Khilnani, N., Zimmet, S.E. (2003) Endovenous laser treatment of saphenous vein 
reflux: long-term results. Journal of Vascular and Interventional Radiology, 14, 991-996.  
Morrison, C., Dalsing, M.C. (2003) Signs and symptoms of saphenous nerve injury after 
greater saphenous vein stripping: prevalence, severity, and relevance for modern practice. 
Journal of Vascular Surgery, 38, 886-890. 
Morrison, N., Neuhardt, D.L. (2009) Foam sclerotherapy: Cardiac and cerebral monitoring. 
Phlebology, 24, 252-259. 
Morrison, N., Neuhardt, D.L., Rogers, C.R., McEown, J., Morrison, T., Johnson, E., Salles-
Cunha, S.X. (2008) Comparisons of side-effects using air and carbon dioxide foam for 
endovenous chemical ablation. Journal of Vascular Surgery, 47, 830-836.  
Morrison, N., Neuhardt, D.L., Rogers, C.R., McEown, J., Morrison, T., Johnson, E., Salles-
Cunha, S.X. (2010) Incidence of side-effects using carbon dioxide-oxygen foam for chemical 
ablation of superficial veins of the lower extremity. European Journal of Vascular and 
Endovascular Surgery, 40, 407-413.  
Mundy, L., Merlin, T.L., Fitridge, R.A., Hiller, J.E. (2005) Systematic review of endovenous 
laser treatment for varicose veins. British Journal of Surgery, 92, 1189-1194. 
Myers, K.A., Jolley, D., Clough, A., Kirwan, J. (2007) Outcome of ultrasound-guided 
sclerotherapy for varicose veins: medium-term results assessed by ultrasound surveillance. 
European Journal of Vascular and Endovascular Surgery, 33, 116-121. 
Myers, K.A., Jolley, D. (2008) Factors affecting the risk of deep venous occlusion after 
ultrasound-guided sclerotherapy for varicose veins. European Journal of Vascular and 
Endovascular Surgery, 36, 602-605. 
Myers, K.A., Roberts, S. (2009) Evaluation of published reports of foam sclerotherapy: what 
do we know conclusively? Phlebology, 24, 275-280. 
Nasr, M.K., Budd, J.S., Horrocks, M. (2008) Uncomplicated varicose vein surgery in the UK – 
a postcode lottery. Annals of the Royal College of Surgeons of England, 90, 474-476. 
Navarro, L., Min, R.J., Bone, C. (2001) Endovenous laser: a new minimally invasive method 
of treatment for varicose veins – preliminary observations using an 810 nm diode laser. 
Dermatologic Surgery, 27, 117-122.  
Negus D. (1993) Recurrent varicose veins: a national problem. British Journal of Surgery, 80, 
823-824. 
Nelzen, O., Bergqvist, D., Lindhagen, A. (1996) The prevalence of lower limb ulceration has 
been underestimated: results of a validated population questionnaire. British Journal of 
Surgery, 83, 255-258. 
Nelzen, O. (2000) Prospective study of safety, patient satisfaction and leg ulcer healing 
following saphenous and subfascial endoscopic perforator surgery. British Journal of 
Surgery, 87, 86-91. 
169 
 
Nicolini, P., Closure Group. (2005) Treatment of primary varicose veins by endovenous 
obliteration with the VNUS closure system: results of a prospective multicentre study. 
European Journal of Vascular and Endovascular Surgery, 29, 433-439. 
O’Donnell, T.F., Iafrati, M.D. (2007) The small saphenous vein and other ‘neglected’ veins of 
the popliteal fossa. Phlebology, 22, 148-155. 
O’Hare, J.L., Earnshaw, J.J. (2007) The use of foam sclerotherapy for varicose veins: a 
survey of the members of the Vascular Society of Great Britain and Ireland. European 
Journal of Vascular and Endovascular Surgery, 34, 232-235. 
O’Hare, J.L., Earnshaw, J.J. (2010) Randomised clinical trial of foam sclerotherapy for 
patients with a venous leg ulcer. European Journal of Vascular and Endovascular Surgery, 
39, 495-499. 
O’Hare, J.L., Parkin, D., Vandenbroeck, C.P., Earnshaw, J.J. (2008a) Mid term results of 
ultrasound guided foam sclerotherapy for complicated and uncomplicated varicose veins. 
European Journal of Vascular and Endovascular Surgery, 36, 109-113.  
O’Hare, J.L., Stephens, J., Parkin, D., Earnshaw, J.J. (2010) Randomized clinical trial of 
different bandage regimens after foam sclerotherapy. British Journal of Surgery, 97, 650-656. 
O’Hare, J.L., Vandenbroeck, C.P., Whitman, B., Campbell, B., Heather, B.P., Earnshaw, J.J., 
on behalf of the Joint Vascular Research Group (2008b). A prospective evaluation of the 
outcome after small saphenous varicose vein surgery with one-year follow-up. Journal of 
Vascular Surgery, 48, 669-674. 
O’Shaughnessy, M., Rahall, E., Walsh, T.N., Given, H.F. (1989) Surgery in the treatment of 
varicose veins. Irish Medical Journal, 82, 54-55. 
Ouvry, P., Allaert, F.A., Desnos, P., Hamel-Desnos, C. (2008) Efficacy of polidocanol foam 
versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised 
controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular 
Surgery, 36, 366-370. 
Palfreyman, S.J., Lochiel, R., Michaels, J.A. (1998) A systematic review of compression 
therapy for venous leg ulcers. Vascular Medicine, 3, 301-313. 
Pang, K.H., Bate, G.R., Darvall, K.A.L., Adam, D.J., Bradbury, A.W. (2010) Healing and 
recurrence rates following ultrasound-guided foam sclerotherapy of superficial venous reflux 
in patients with chronic venous ulceration. European Journal of Vascular and Endovascular 
Surgery, 40, 790-795.   
Pannier, F., Rabe, E. (2006) Endovenous laser therapy and radiofrequency ablation of 
saphenous varicose veins. Journal of Cardiovascular Surgery, 47, 3-8. 
Park, S.W., Hwang, J.J., Yun, I.J., Lee, S.A., Kim, J.S., Chang, S.H., Chee, H.K., Hong, S.J., 
Cha, I.H., Kim, H.C. (2008) Endovenous laser ablation of the incompetent small saphenous 
vein with a 980-nm diode laser: our experience with 3 years follow-up. European Journal of 
Vascular and Endovascular Surgery, 36, 738-742. 
Pascarella, L., Bergan, J.J., Mekenas, L.V. (2006) Severe chronic venous insufficiency 
treated by foamed sclerosant. Annals of Vascular Surgery, 20, 83-91. 
170 
 
Phillips, T., Stanton, B., Provan, A., Lew, R. (1994) A study of the impact of leg ulcers on 
quality of life: financial, social and psychological implications. Journal of the American 
Academy of Dermatology, 31, 49-53. 
Picard, C., Deltombe, B., Duni, C., Godefroy, O., Bugnicourt, J-M. (2010) Foam 
sclerotherapy: a possible cause of ischaemic stroke. Journal of Neurology Neurosurgery and 
Psychiatry, 81, 582-583. 
Pichot, O.K.L., Creton, D., Merchant, R.F., Schuller-Petrovic, S., Chandler, J.G. (2004) 
Duplex ultrasound scan findings two years after great saphenous vein radiofrequency 
endovenous obliteration. Journal of Vascular Surgery, 39, 189-195. 
Proebstle, T.M., Gul, D., Kargl, A., Knop, J. (2003a) Endovenous laser treatment of the 
lesser saphenous vein with a 940-nm diode laser: early results. Dermatologic Surgery, 29, 
357-361. 
Proebstle, T.M., Gul, D., Lehr, H.A., Kargl, A., Knop, J. (2003b) Infrequent early 
recanalisation of greater saphenous vein after endovenous laser treatment. Journal of 
Vascular Surgery, 38, 511-516.  
Proebstle, T.M., Lehr, H.A., Kargl, A., Espinola-Klein, C., Rother, W., Bethge, S., Knop, J. 
(2002) Endovenous treatment of the greater saphenous vein with a 940-nm diode laser: 
thrombotic occlusion after endoluminal thermal damage by laser-generated steam bubbles. 
Journal of Vascular Surgery, 35, 729-736. 
Pronk, P., Gauw, S.A., Mooij, M.C., Gaastra, M.T.W., Lawson, J.A., van Goethem, A.R., van 
Vlijmen-van Keulen, C.J. (2010) Randomised controlled trial comparing sapheno-femoral 
ligation and stripping of the great saphenous vein with endovenous laser ablation (980nm) 
using local tumescent anaesthesia: one year results. European Journal of Vascular and 
Endovascular Surgery, 40, 649-656. 
Rabe, E., Otto, J., Schliephake, D., Pannier, F. (2008) Efficacy and safety of great 
saphenous vein sclerotherapy using standardized polidocanol foam (ESAF): a randomized 
controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery, 
35, 238-245. 
Rashid, H.I., Ajeel, A., Tyrrell, M.R. (2002) Persistent popliteal fossa reflux following 
saphenopopliteal disconnection. British Journal of Surgery, 89, 748-751. 
Rasmussen, L., Bjoern, L., Lawaetz, M., Blemings, A., Lawaetz, B., Eklof, B. (2007) 
Randomized trial comparing endovenous laser ablation of the great saphenous vein with 
high ligation and stripping in patients with varicose veins: short-term results. Journal of 
Vascular Surgery, 46, 308-315. 
Rasmussen, L.H., Bjoern, L., Lawaetz, M., Lawaetz, B., Blemings, A., Eklof, B. (2010) 
Randomized clinical trial comparing endovenous laser ablation with stripping of the great 
saphenous vein: clinical outcome and recurrence after 2 years. European Journal of 
Vascular and Endovascular Surgery, 39, 630-635. 
Ratcliffe, J., Brazier, J.E., Campbell, W.B., Palfreyman, S., MacIntyre, J.B., Michaels, J.A. 
(2006) Cost-effectiveness analysis of surgery versus conservative treatment for 
uncomplicated varicose veins in a randomized clinical trial. British Journal of Surgery, 93, 
182-186. 
171 
 
Rautio, T., Ohinmaa, A., Perala, J., Ohtonen, P., Heikkinen, T., Wiik, H., Karjalainen, P., 
Haukipuro, K., Juvonen, T. (2002) Endovenous obliteration versus conventional stripping 
operation in the treatment of primary varicose veins: A randomized controlled trial with 
comparison of the costs. Journal of Vascular Surgery, 35, 958-965. 
Ravi, R., Rodriguez-Lopez, J.A., Trayler, E.A., Barrett, D.A., Ramaiah, V., Diethrich, E.B. 
(2006) Endovenous ablation of incompetent saphenous veins: a large single-center 
experience. Journal of Endovascular Therapy, 13, 244-248. 
Raymond-Martimbeau, P. (2009) Transient adverse events positively associated with patent 
foramen ovale after ultrasound-guided foam sclerotherapy. Phlebology, 24, 114-119. 
Ray, S. (2005) Complaints and litigation following varicose veins surgery. Clinical Risk, 11, 
221-224. 
Regan, J.D., Gibson, K.D., Ferris, B., Rush, J.E., Rowe, V.L., Kouri, B., Weaver, F.A., 
Wright, D.D.I. (2008) Safety of proprietary sclerosant microfoam for saphenous 
incompetence in patients with R-to-L shunt: interim report. Journal of Vascular Interventional 
Radiology, 19 (Suppl), S35. (Abstract) 
Ruckley, C.V., Evans, C.J., Allan, P.L., Lee, A.J., Fowkes, F.G.R. (2002) Chronic venous 
insufficiency: clinical and duplex correlations. The Edinburgh Vein Study of venous disorders 
in the general population. Journal of Vascular Surgery, 36, 520-525. 
Ruckley, C.V. (1997) Socioeconomic impact of chronic venous insufficiency and leg ulcers. 
Angiology, 48, 67-69. 
Rush, J.E., Wright, D.D.I. (2008) More on microembolism and foam sclerotherapy (letter). 
New England Journal of Medicine, 359, 656-657.  
Sadick, N.S. (2000) Choosing the right sclerosing agent. In: Manual of sclerotherapy. Sadick 
NS, Ed. Philadelphia: Lippincott Williams and Wilkins: 115-132. 
Sam, R.C., Darvall, K.A.L., Adam, D.J., Silverman, S.H., Bradbury, A.W. (2006) A 
comparison of the changes in generic quality of life after superficial venous surgery with 
those after laparoscopic cholecystectomy. Journal of Vascular Surgery, 44, 606-610. 
Sam, R.C., MacKenzie, R.K., Paisley, A.M., Ruckley, C.V., Bradbury, A.W. (2004a) The 
effect of superficial venous surgery on generic health-related quality of life. European Journal 
of Vascular and Endovascular Surgery, 28, 253-256. 
Sam, R.C., Silverman, S.H., Bradbury, A.W. (2004b) Nerve injuries and varicose vein 
surgery. European Journal of Vascular and Endovascular Surgery, 27, 113-120. 
Scriven, J.M., Hartshorne, T., Thrush, A.J., Bell, P.R., Naylor, A.R., London, N.J. (1998) Role 
of saphenous vein surgery in the treatment of venous ulceration. British Journal of Surgery, 
85, 781-784. 
Scurr, J.R.H., Scurr, J.H. (2005) Varicose veins: a review of 200 consecutive medicolegal 
claims. Clinical Risk, 11, 225-230. 
Shamiyeh, A., Schrenk, P., Huber, E., Danis, J., Wayand, W. (2003) Transilluminated 
Powered Phlebectomy: advantages and disadvantages of a new technique. Dermatologic 
Surgery, 29, 616-619. 
172 
 
Shepherd, A.C., Gohel, M.S., Brown, L.C., Metcalfe, M.J., Hamish, M., Davies, A.H. (2010a) 
Randomised clinical trial of VNUS® ClosureFAST™ radiofrequency ablation versus laser for 
varicose veins. British Journal of Surgery, 97, 810-818. 
Shepherd, A.C., Gohel, M.S., Lim, C.S., Hamish, M., Davies, A.H. (2010b) The treatment of 
varicose veins: an investigation of patient preferences and expectations. Phlebology, 25, 54-
65. 
Skevington, S.M., Tucker, C. (1999) Designing response scales for cross-cultural use in 
health care: Data from the development of the UK WHOQOL. British Journal of Medical 
Psychology, 72, 51-61. 
Smith, J.J., Garratt, A.M., Guest, M., Greenhalgh, R.M., Davies, A.H. (1999) Evaluating and 
improving health-related quality of life in patients with varicose veins. Journal of Vascular 
Surgery, 30, 710-719. 
Subramonia, S., Lees, T. (2005) Sensory abnormalities and bruising after long saphenous 
vein stripping: impact on short-term quality of life. Journal of Vascular Surgery, 42, 510-514. 
Subramonia, S., Lees, T. (2007) The treatment of varicose veins. Annals of the Royal 
College of Surgeons of England, 89, 96-100. 
Subramonia, S., Lees, T. (2010) Randomized clinical trial of radiofrequency ablation or 
conventional high ligation and stripping for great saphenous varicose veins. British Journal of 
Surgery, 97, 328-336.  
Tennant, W.G., Ruckley, C.V. (1997) Causes of legal action following treatment for varicose 
veins. Clinical Risk, 3, 52-54.  
Tessari, L., Cavezzi, A., Frullini, A. (2001) Preliminary experience with a new sclerosing foam 
in the treatment of varicose veins. Dermatologic Surgery, 27, 58-60. 
Theivacumar, N.S., Beale, R.J., Mavor, A.I.D., Gough, M.J. (2007) Initial experience in 
endovenous laser ablation (EVLA) of varicose veins due to small saphenous vein reflux. 
European Journal of Vascular and Endovascular Surgery, 33, 614-618. 
Theivacumar, N.S., Darwood, R.J., Dellegrammaticas, D., Mavor, A.I., Gough, M.J. (2009a) 
The clinical significance of below-knee great saphenous vein reflux following endovenous 
laser ablation of above-knee great saphenous vein. Phlebology, 24, 17-20. 
Theivacumar, N.S., Darwood, R., Gough, M.J. (2009b) Neovascularisation and recurrence 2 
years after varicose vein treatment for sapheno-femoral and great saphenous vein reflux: A 
comparison of surgery and endovenous laser ablation. European Journal of Vascular and 
Endovascular Surgery, 38, 203-207.  
Theivacumar, N.S., Dellagrammaticas, D., Mavor, A.I.D., Gough, M.J. (2008) Endovenous 
laser ablation: Does standard above-knee great saphenous vein ablation provide optimum 
results in patients with both above- and below-knee reflux? A randomized controlled trial. 
Journal of Vascular Surgery, 48, 173-178. 
Tisi, P.V., Beverley, C.A. (2004) Injection sclerotherapy for varicose veins (Cochrane 
Review). In: The Cochrane Library, Issue 3. Chichester, UK: John Wiley and Sons, Ltd. 
Tong, Y., Royle, J. (1996) Recurrent varicose veins after short saphenous vein surgery: a 
duplex ultrasound study. Cardiovascular Surgery, 4, 364-367. 
173 
 
Turton, E.P., Scott, D.J., Richards, S.P., Weston, M.J., Berridge, D.C., Kent, P.J., Kester, 
R.C. (1999) Duplex-derived evidence of reflux after varicose vein surgery: neoreflux or 
neovascularisation? European Journal of Vascular and Endovascular Surgery, 17, 230-233. 
Van den Bos, R., Arends, L., Kockaert, M., Neumann, M., Nijsten, T. (2009)  Endovenous 
therapies of lower extremity varicosities: a meta-analysis. Journal of Vascular Surgery, 49, 
230-239. 
Van Groenendael, L., van der Vliet, J.A., Flinkenflogel, L., Roovers, E.A., van Sterkenburg, 
S.M.M., Reijnen, M.M.P.J. (2009) Treatment of recurrent varicose veins of the great 
saphenous vein by conventional surgery and endovenous laser ablation. Journal of Vascular 
Surgery, 50, 1106-1113. 
Van Neer, P., Kessels, F.G., Estourgie, R.J., de Haan, E.F., Neumann, M.A., Veraart, J.C. 
(2009) Persistent reflux below the knee after stripping of the great saphenous vein. Journal 
of Vascular Surgery, 50, 831-834. 
Van Rij, A.M., Chai, J., Hill, G.B., Christie, R.A. (2004) Incidence of deep vein thrombosis 
after varicose vein surgery. British Journal of Surgery, 91, 1582-1585.   
Van Rij, A.M., Jiang, P., Solomon, C., Christie, R.A., Hill, G.B. (2003) Recurrence after 
varicose vein surgery: a prospective long-term clinical study with duplex ultrasound scanning 
and air plethysmography. Journal of Vascular Surgery, 38, 935-943. 
Vasquez, M.A., Wang, J., Mahathanaruk, M., Buczkowski, G., Sprehe, E., Dosluoglu, H.H. 
(2007) The utility of the venous clinical severity score in 682 limbs treated by radiofrequency 
saphenous vein ablation. Journal of Vascular Surgery, 45, 1008-1015. 
Ware, J.E., Kosinski, M., Keller, S.D. (2002) How to score the SF-12 physical and mental 
health summary scales. 4th ed. Lincoln (RI): Qualitymetric Inc. 
Weiss, R.A., Weiss, M.A. (2002) Controlled radiofrequency endovenous occlusion using a 
unique radiofrequency catheter under duplex guidance to eliminate saphenous varicose vein 
reflux: a 2-year follow-up. Dermatologic Surgery, 28, 38-42.  
Winterborn, R.J., Campbell, W.B., Heather, B.P., Earnshaw, J.J. (2004) The management of 
short saphenous varicose  veins: a survey of the members of the Vascular Surgical Society 
of Great Britain and Ireland. European Journal of Vascular and Endovascular Surgery, 28, 
400-403. 
Winterborn, R.J., Corbett, C.R.R. (2008) Treatment of varicose veins: the present and the 
future – a questionnaire survey. Annals of the Royal College of Surgeons of England, 90, 
561-564. 
Wollman, J.G.R. (2004) The history of sclerosing foams. Dermatologic Surgery, 30, 694-703. 
Wood, J.J., Chant, H., Laugharne, M., Chant, T., Mitchell, D.C. (2005) A prospective study of 
cutaneous nerve injury following long saphenous varicose vein surgery. European Journal of 
Vascular and Endovascular Surgery, 30, 654-658.  
Wright, A.P., Berridge, D.C., Scott, D.J.A. (2006a) Return to work following varicose vein 
surgery: influence of type of operation, employment and social status. European Journal of 
Vascular and Endovascular Surgery, 31, 553-557. 
174 
 
Wright, D.D., Gibson, K.D., Barclay, J., Razumovsky, A., Rush, J., McCollum, C.N. (2010) 
High prevalence of right-to-left shunt in patients with symptomatic great saphenous 
incompetence and varicose veins. Journal of Vascular Surgery, 51, 104-107.  
Wright, D., Gobin, J.P., Bradbury, A.W., Coleridge-Smith, P., Spoelstra, H., Berridge, D., 
Wittens, C.H.A., Sommer, A., Nelzen, O., Chanter, D. (2006b) Varisolve polidocanol 
microfoam compared with surgery or sclerotherapy in the management of varicose veins in 
the presence of trunk vein incompetence: European randomized controlled trial. Phlebology, 
21, 180-190. 
Yamaki, T., Nozaki, M., Iwasaka, S. (2004) Comparative study of duplex-guided foam 
sclerotherapy and duplex-guided liquid sclerotherapy for the treatment of superficial venous 
insufficiency. Dermatologic Surgery, 30, 718-722.  
Yamaki, T., Nozaki, M., Sakurai, H., Takeuchi, M., Soejima, K., Kono, T. (2009) Multiple 
small-dose injections can reduce the passage of sclerosant foam into deep veins during 
foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular 
Surgery, 37, 343-348. 
 
